Difference between revisions of "Timeline of biotechnology companies"

From Timelines
Jump to: navigation, search
 
(101 intermediate revisions by the same user not shown)
Line 1: Line 1:
−
This is a '''timeline of biotechnology companies'''.
+
This is a '''timeline of biotechnology companies''', attempting to describe mostly the launch in recent decades of a variety of organizations in the field.
  
 
== Sample questions ==
 
== Sample questions ==
Line 5: Line 5:
 
The following are some interesting questions that can be answered by reading this timeline:  
 
The following are some interesting questions that can be answered by reading this timeline:  
  
−
* What are some notable or sample biotechnology companies having been launched in the last decades?
+
* What are the diverse industries and specialties where biotechnology  is conducted?
 +
** Sort the full timeline by Industry/specialty.
 +
** You will see a large variety of subfields of biotechnology, but mostly related to healthcare.
 +
* What are some milestones in the history of biotechnology?
 +
** Sort the full timeline by Event type and look for the rows with value "Background".
 +
** You will see important scientific developments shaping the field and giving path to business development.
 +
* What are some notable or sample biotechnology companies having been launched over the last decades?
 
** Sort the full timeline by Event type and look for the rows with value "Company launch".
 
** Sort the full timeline by Event type and look for the rows with value "Company launch".
−
** You will see the establishment of a number of companies in different industries, all related or within the realm lf biotechnology.
+
** You will see the establishment of a number of companies in different industries, all related to biotechnology.
 +
* What are some notable Initial public offerings?
 +
** Sort the full timeline by Event type and look for the rows with value "Notable {{w|IPO}}".
 +
** You will see some notable IPOs by very important companies in the field.
 +
* What are some notable accelerators and incubators in the biotechnology sector?
 +
** Sort the full timeline by Event type and look for the rows with value "Accelerator/incubator launch".
 +
** You will mostly see a number of these organizations launched in the United States.
 +
* What are some notable or illustrative biotechnology funds?
 +
** Sort the full timeline by Event type and look for the rows with value "Fund launch".
 +
** You will see a number of funds launched in the United States.
 
* What are some notable studies related to the business of biotechnology?
 
* What are some notable studies related to the business of biotechnology?
 
** Sort the full timeline by Event type and look for the rows with value "Research".
 
** Sort the full timeline by Event type and look for the rows with value "Research".
Line 18: Line 33:
 
* What are some other notable events in the history of biotrchnology companies?
 
* What are some other notable events in the history of biotrchnology companies?
 
** Sort the full timeline by Event type and look for the rows with value "Notable case".
 
** Sort the full timeline by Event type and look for the rows with value "Notable case".
 +
* Other events are described under the following types: "Concept development", "Industry size", "Legal", "Market size", and "Statistics".
  
 
==Big picture==
 
==Big picture==
Line 38: Line 54:
 
|}
 
|}
  
−
== Numerical and visual data ==
 
−
 
−
=== Google trends ===
 
−
The chart shows {{w|Google Trends}} data for Biotechnology, from January 2004 to May 2022, when the screenshot was taken. Data is also ranked by country and displayed on world map.<ref>{{cite web |title=Google Trends |url=https://trends.google.com/trends/explore?date=all&q=%2Fm%2F01ftz |website=Google Trends |access-date=30 May 2022}}</ref>
 
−
[[File:Biotechnology google trends.png|thumb|center|800px]]
 
−
 
−
=== Google Ngram viewer ===
 
−
The chart shows Google Ngram Viewer data for biotechnology from 1900 to 2019.<ref>{{cite web |title=Google Books Ngram Viewer |url=https://books.google.com/ngrams/graph?content=biotechnology&year_start=1900&year_end=2019&corpus=26&smoothing=3&direct_url=t1%3B%2Cbiotechnology%3B%2Cc0 |website=books.google.com |access-date=30 May 2022 |language=en}}</ref>
 
−
 
−
[[File:Biotechnology ngram.PNG|thumb|center|800px]]
 
  
−
=== Google Scholar ===
 
−
 
−
The table and graph below show the evolution of mentions of Biotechnology on Google Scholar as of May 29, 2022
 
−
 
−
{| class="sortable wikitable"
 
−
! Year
 
−
! N° of mentions
 
−
|-
 
−
| 1970 || 30,900
 
−
|-
 
−
| 1975 || 7,120
 
−
|-
 
−
| 1980 || 27,800
 
−
|-
 
−
| 1985 || 16,300
 
−
|-
 
−
| 1990 || 70,500
 
−
|-
 
−
| 1995 || 99,700
 
−
|-
 
−
| 2000 || 319,000
 
−
|-
 
−
| 2005 || 707,000
 
−
|-
 
−
| 2010 || 1,070,000
 
−
|-
 
−
| 2015 || 915,000
 
−
|-
 
−
| 2020 || 248,000
 
−
|-
 
−
|}
 
−
 
−
[[File:Biotechnology google scholar.PNG|thumb|center|600px]]
 
−
 
−
=== Wikipedia views ===
 
−
 
−
The chart below shows pageviews of the English Wikipedia article Biotechnology, from July 2015 to April 2022.<ref>{{cite web |title=Wikipedia Views: results |url=https://wikipediaviews.org/displayviewsformultiplemonths.php?page=Biotechnology&allmonths=allmonths-api&language=en&drilldown=all |website=wikipediaviews.org |access-date=30 May 2022}}</ref>
 
−
 
−
[[File:Biotechnology WV.png|thumb|center|600px]]
 
  
 
==Full timeline==
 
==Full timeline==
Line 121: Line 88:
 
|-
 
|-
 
| 1985 || || Background || The first DNA marker is found linked to {{w|cystic fibrosis}}. The anonymous marker is known as CRI-917.<ref name=dhShimasaki/><ref>{{cite journal |last1=Tsui |first1=Lap-Chee |last2=Dorfman |first2=Ruslan |title=The Cystic Fibrosis Gene: A Molecular Genetic Perspective |journal=Cold Spring Harbor Perspectives in Medicine |date=1 February 2013 |volume=3 |issue=2 |pages=a009472 |doi=10.1101/cshperspect.a009472}}</ref> ||
 
| 1985 || || Background || The first DNA marker is found linked to {{w|cystic fibrosis}}. The anonymous marker is known as CRI-917.<ref name=dhShimasaki/><ref>{{cite journal |last1=Tsui |first1=Lap-Chee |last2=Dorfman |first2=Ruslan |title=The Cystic Fibrosis Gene: A Molecular Genetic Perspective |journal=Cold Spring Harbor Perspectives in Medicine |date=1 February 2013 |volume=3 |issue=2 |pages=a009472 |doi=10.1101/cshperspect.a009472}}</ref> ||
 +
|-
 +
| 1985 (December 16) || Health || Fund launch || Fidelity Select Biotechnology Portfolio (FBIOX) is launched in the {{w|United States}}.<ref>{{cite web |title=Fidelity® Select Biotechnology Portfolio, FBIOX summary - FT.com |url=https://markets.ft.com/data/funds/tearsheet/summary?s=fbiox |website=markets.ft.com |access-date=1 July 2022}}</ref> It mostly invests in companies researching, developing, manufacturing, and distributing various biotechnological products, services, and processes and companies that benefit significantly from advances in biotechnology.<ref>{{cite web |title=FBIOX - Fidelity ® Select Biotechnology Portfolio {{!}} Fidelity Investments |url=https://fundresearch.fidelity.com/mutual-funds/summary/316390772 |website=fundresearch.fidelity.com |access-date=7 July 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1986 || Recombinant DNA technology || Background || {{w|Recombivax HB}} is licensed in the United States. It is the first recombinant vaccine for humans, a vaccine for {{w|hepatitis B}}.<ref>{{cite web |title=Pinkbook: Hepatitis B {{!}} CDC |url=https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html#:~:text=and%20Recombivax%20HB)-,Hepatitis%20B%20Vaccine,both%20pediatric%20and%20adult%20formulations. |website=www.cdc.gov |access-date=20 May 2022 |language=en-us |date=17 August 2021}}</ref><ref name=dhShimasaki/> || {{w|United States}}
 
| 1986 || Recombinant DNA technology || Background || {{w|Recombivax HB}} is licensed in the United States. It is the first recombinant vaccine for humans, a vaccine for {{w|hepatitis B}}.<ref>{{cite web |title=Pinkbook: Hepatitis B {{!}} CDC |url=https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html#:~:text=and%20Recombivax%20HB)-,Hepatitis%20B%20Vaccine,both%20pediatric%20and%20adult%20formulations. |website=www.cdc.gov |access-date=20 May 2022 |language=en-us |date=17 August 2021}}</ref><ref name=dhShimasaki/> || {{w|United States}}
Line 147: Line 116:
 
|-
 
|-
 
| 1991 || {{w|Aquaculture}} || Company launch || {{w|AquaBounty Technologies}} is founded. <ref>{{cite web |title=Cascadia Capital Provides Intrexon Corporation with Fairness Opinion of AquaBounty Technologies, LLC |url=https://www.cascadiacapital.com/story/cascadia-capital-provides-intrexon-corporation-with-fairness-opinion-of-aquabounty-technologies-llc/ |website=Cascadia Capital |access-date=9 February 2022}}</ref> Its land-based fish farms produce genetically engineered salmon.<ref>{{cite web |title=AquaBounty |url=https://www.linkedin.com/company/aquabounty |website=linkedin.com |access-date=23 January 2022}}</ref><ref>{{cite web |title=AquaBounty Technologies |url=https://www.crunchbase.com/organization/aquabounty-technologies |website=crunchbase.com |access-date=23 January 2022}}</ref> || {{w|United States}} ({{w|Maynard, Massachusetts}})  
 
| 1991 || {{w|Aquaculture}} || Company launch || {{w|AquaBounty Technologies}} is founded. <ref>{{cite web |title=Cascadia Capital Provides Intrexon Corporation with Fairness Opinion of AquaBounty Technologies, LLC |url=https://www.cascadiacapital.com/story/cascadia-capital-provides-intrexon-corporation-with-fairness-opinion-of-aquabounty-technologies-llc/ |website=Cascadia Capital |access-date=9 February 2022}}</ref> Its land-based fish farms produce genetically engineered salmon.<ref>{{cite web |title=AquaBounty |url=https://www.linkedin.com/company/aquabounty |website=linkedin.com |access-date=23 January 2022}}</ref><ref>{{cite web |title=AquaBounty Technologies |url=https://www.crunchbase.com/organization/aquabounty-technologies |website=crunchbase.com |access-date=23 January 2022}}</ref> || {{w|United States}} ({{w|Maynard, Massachusetts}})  
 +
|-
 +
| 1991 || {{w|Pharmaceutical}}, {{w|biotherapeutics}} || Notable {{w|IPO}} || {{w|Vertex Pharmaceuticals}} completes its IPO, trading as VRTX on {{w|Nasdaq}}.<ref>{{cite web |title=Vertex Pharmaceuticals Incorporated {{!}} Encyclopedia.com |url=https://www.encyclopedia.com/books/politics-and-business-magazines/vertex-pharmaceuticals-incorporated#:~:text=1991%3A,offering%20of%20stock%20is%20conducted. |website=www.encyclopedia.com |access-date=2 June 2022}}</ref> Based in {{w|Boston}}, it one of the world's biggest biopharma businesses.<ref>{{cite web |title=Where will Vertex Pharmaceuticals be in 5 years? |url=https://www.healthleadersmedia.com/pharma/where-will-vertex-pharmaceuticals-be-5-years#:~:text=With%20a%20market%20capitalization%20of,the%20world's%20biggest%20biopharma%20businesses. |website=www.healthleadersmedia.com |access-date=29 June 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1991 || {{w|Oncology}}, {{w|health diagnostics}} || Company launch || {{w|ARIAD Pharmaceuticals}} is founded. <ref>{{cite web |title=ARIAD Pharmaceuticals |url=https://artsandculture.google.com/entity/m03p1j62?hl=es |website=Google Arts & Culture |access-date=9 February 2022 |language=es}}</ref> An oncology company focused on the discovery, development and commercialization of medicines for the cancer patients, it would be acquired by Takeda for US$5.2 billion on January, 2017.<ref>{{cite web |title=ARIAD Pharmaceuticals |url=https://www.crunchbase.com/organization/ariad-pharmaceuticals |website=crunchbase.com |access-date=23 January 2022}}</ref> || {{w|United States}} ({{w|Cambridge, Massachusetts}})  
 
| 1991 || {{w|Oncology}}, {{w|health diagnostics}} || Company launch || {{w|ARIAD Pharmaceuticals}} is founded. <ref>{{cite web |title=ARIAD Pharmaceuticals |url=https://artsandculture.google.com/entity/m03p1j62?hl=es |website=Google Arts & Culture |access-date=9 February 2022 |language=es}}</ref> An oncology company focused on the discovery, development and commercialization of medicines for the cancer patients, it would be acquired by Takeda for US$5.2 billion on January, 2017.<ref>{{cite web |title=ARIAD Pharmaceuticals |url=https://www.crunchbase.com/organization/ariad-pharmaceuticals |website=crunchbase.com |access-date=23 January 2022}}</ref> || {{w|United States}} ({{w|Cambridge, Massachusetts}})  
Line 158: Line 129:
 
| 1991 || {{w|Healthcare}}, {{w|molecular diagnostics}}, {{w|biotechnology}}, {{w|precision medicine}} || Company launch || {{w|Myriad Genetics}} is founded.<ref>{{cite web |title=Myriad Genetics Company History Starting in May 1991 |url=https://myriad.com/about-myriad/inside-myriad/history/ |website=Myriad Genetics, Inc. |access-date=9 February 2022}}</ref> It is a  molecular diagnostic focused on the discovery and commercialization of diagnostic tests for several major diseases, including cancer, rheumatoid arthritis, and diabetes, among others.<ref>{{cite web |title=Disease Info |url=https://myriad.com/patients-families/disease-info/#:~:text=Myriad%20Genetics%20is%20a%20leading,rheumatoid%20arthritis%2C%20diabetes%20and%20more. |website=Myriad Genetics |access-date=23 March 2022}}</ref>
 
| 1991 || {{w|Healthcare}}, {{w|molecular diagnostics}}, {{w|biotechnology}}, {{w|precision medicine}} || Company launch || {{w|Myriad Genetics}} is founded.<ref>{{cite web |title=Myriad Genetics Company History Starting in May 1991 |url=https://myriad.com/about-myriad/inside-myriad/history/ |website=Myriad Genetics, Inc. |access-date=9 February 2022}}</ref> It is a  molecular diagnostic focused on the discovery and commercialization of diagnostic tests for several major diseases, including cancer, rheumatoid arthritis, and diabetes, among others.<ref>{{cite web |title=Disease Info |url=https://myriad.com/patients-families/disease-info/#:~:text=Myriad%20Genetics%20is%20a%20leading,rheumatoid%20arthritis%2C%20diabetes%20and%20more. |website=Myriad Genetics |access-date=23 March 2022}}</ref>
 
|-
 
|-
−
| 1991 || {{w|Biotechnology}}, {{w|genetics}} || Company launch || {{w|Santa Cruz Biotechnology}} is founded by Dr. John Stephenson and his wife Brenda Stephenson in {{w|Santa Cruz, California}}.<ref>{{cite web|url=http://archives.mtexpress.com/index2.php?ID=2005123867#.WA6AbvkrJhE|title=Idaho Mountain Express: Biotechnology firm sets up shop in Ketchum - December 3, 2008|publisher=}}</ref>.<ref>{{cite web |title=Versatile Alternatives to Santa Cruz Biotechnology Polyclonal Antibodies - MyBioSource |url=https://www.mybiosource.com/santa-cruz-antibody-replacements/F |website=www.mybiosource.com |access-date=29 January 2022}}</ref> A developer of biological products for {{w|medical research}},<ref>{{cite web|url=http://www.santacruzsentinel.com/article/ZZ/20081211/NEWS/812119851|title=Santa Cruz Biotechnology opens office in Idaho|publisher=}}</ref><ref>{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=50230932|title=Santa Cruz Biotechnology, Inc.: Private Company Information - Bloomberg|publisher=}}</ref> it is one of the world’s largest suppliers of {{w|antibodies}}.<ref>{{cite web|url=http://www.sanluisobispo.com/news/business/article39464694.html|title=Economic growth pushes SLO County higher in national ranking|publisher=}}</ref> || {{w|United States}} ({{w|Santa Cruz, California}})
+
| 1991 || {{w|Antibodies}}, {{w|genetics}} || Company launch || {{w|Santa Cruz Biotechnology}} is founded by Dr. John Stephenson and his wife Brenda Stephenson in {{w|Santa Cruz, California}}.<ref>{{cite web|url=http://archives.mtexpress.com/index2.php?ID=2005123867#.WA6AbvkrJhE|title=Idaho Mountain Express: Biotechnology firm sets up shop in Ketchum - December 3, 2008|publisher=}}</ref>.<ref>{{cite web |title=Versatile Alternatives to Santa Cruz Biotechnology Polyclonal Antibodies - MyBioSource |url=https://www.mybiosource.com/santa-cruz-antibody-replacements/F |website=www.mybiosource.com |access-date=29 January 2022}}</ref> A developer of biological products for {{w|medical research}},<ref>{{cite web|url=http://www.santacruzsentinel.com/article/ZZ/20081211/NEWS/812119851|title=Santa Cruz Biotechnology opens office in Idaho|publisher=}}</ref><ref>{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=50230932|title=Santa Cruz Biotechnology, Inc.: Private Company Information - Bloomberg|publisher=}}</ref> it is one of the world’s largest suppliers of {{w|antibodies}}.<ref>{{cite web|url=http://www.sanluisobispo.com/news/business/article39464694.html|title=Economic growth pushes SLO County higher in national ranking|publisher=}}</ref> || {{w|United States}} ({{w|Santa Cruz, California}})
 
|-
 
|-
 
| 1991 || || Research || Philip Kotler suggests that a continuous flow of ideas provides the antecedents for the development of new products.<ref>Kotler, P. (1991), ''Marketing Management: Analysis, Planning, Implementation and Control'', 7th edn, Englewood Cliffs, NJ: Prentice-Hall.</ref>
 
| 1991 || || Research || Philip Kotler suggests that a continuous flow of ideas provides the antecedents for the development of new products.<ref>Kotler, P. (1991), ''Marketing Management: Analysis, Planning, Implementation and Control'', 7th edn, Englewood Cliffs, NJ: Prentice-Hall.</ref>
 
|-
 
|-
−
| 1992 || {{w|Biotechnology}}, {{w|genetics}}, medical<ref>{{cite web |title=Affymetrix |url=https://www.crunchbase.com/organization/affymetrix |website=crunchbase.com |access-date=24 January 2022}}</ref> || Company launch || {{w|Affymetrix}} is founded as a spin-off from Affymax Research Institute by {{w|Stephen Fodor}}. <ref>{{cite web |title=Affymetrix |url=https://www.bionity.com/en/encyclopedia/Affymetrix.html |website=www.bionity.com |access-date=9 February 2022}}</ref> The company would introduce its first product in 1994, an {{w|HIV}} [[w:genotype|genotyping]] chip.<ref>{{cite web|title=Affymetrix and bioMérieux Extend Their Agreement on GeneChip® Technology to Breast Cancer Diagnostics|url=https://www.biomerieux.com/en/affymetrix-and-biomerieux-extend-their-agreement-genechip-technology-breast-cancer-diagnostics|website=biomerieux.com|access-date=2022-01-12}}</ref> Affymetrix is based in {{w|Santa Clara, California}}. || {{w|United States}}
+
| 1991 (July 16) || {{w|Biopharmaceutical}} || Notable {{w|IPO}} || [[w:Alkermes (company)|Alkermes]] completes its IPO, trading with ticker name ALKS on {{w|Nasdaq}}.<ref>{{cite web |title=Alkermes PLC (ALKS) Stock Price, Quote & News |url=https://stockanalysis.com/stocks/alks/ |website=Stock Analysis |access-date=2 June 2022 |language=en}}</ref> Founded in 1987, it is a biopharmaceutical company that focuses on {{w|central nervous system}}.<ref>{{cite web |title=ALKERMES PUBLIC LIMITED COMPANY |url=https://investor.alkermes.com/static-files/b5b1daee-663e-4193-82ef-0ece863e323e |website=investor.alkermes |access-date=29 June 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 1992 || {{w|Genetics}}, medical<ref>{{cite web |title=Affymetrix |url=https://www.crunchbase.com/organization/affymetrix |website=crunchbase.com |access-date=24 January 2022}}</ref> || Company launch || {{w|Affymetrix}} is founded as a spin-off from Affymax Research Institute by {{w|Stephen Fodor}}. <ref>{{cite web |title=Affymetrix |url=https://www.bionity.com/en/encyclopedia/Affymetrix.html |website=www.bionity.com |access-date=9 February 2022}}</ref> The company would introduce its first product in 1994, an {{w|HIV}} [[w:genotype|genotyping]] chip.<ref>{{cite web|title=Affymetrix and bioMérieux Extend Their Agreement on GeneChip® Technology to Breast Cancer Diagnostics|url=https://www.biomerieux.com/en/affymetrix-and-biomerieux-extend-their-agreement-genechip-technology-breast-cancer-diagnostics|website=biomerieux.com|access-date=2022-01-12}}</ref> Affymetrix is based in {{w|Santa Clara, California}}. || {{w|United States}}
 
|-
 
|-
 
| 1992 || {{w|Healthcare}}, pharmaceutical<ref>{{cite web |title=Angiotech Pharmaceuticals |url=https://www.crunchbase.com/organization/angiotech-pharmaceuticals |website=crunchbase.com |access-date=24 January 2022}}</ref> || Company launch || {{w|Angiotech Pharmaceuticals}} is founded. <ref>{{cite web |title=Surgical Specialties Corporation (formerly Angiotech) Profile on T-Net |url=https://www.bctechnology.com/companies/Surgical-Specialties-Corporation-(formerly-Angiotech).cfm |website=T-Net British Columbia |access-date=9 February 2022}}</ref> In 2017, Angiotech would be acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital.<ref>{{cite web |last1=Falconer |first1=Kirk |title=Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group |url=https://www.pehub.com/3425572/ |website=PE Hub |access-date=25 January 2022 |date=19 December 2016}}</ref><ref>{{cite web |title=Angiotech closes acquisition of certain product candidates and technology assets of Haemacure Corporation |url=https://www.newswire.ca/news-releases/angiotech-closes-acquisition-of-certain-product-candidates-and-technologyassets-of-haemacure-corporation-539696251.html |website=newswire.ca |access-date=25 January 2022}}</ref> || {{w|Canada}}
 
| 1992 || {{w|Healthcare}}, pharmaceutical<ref>{{cite web |title=Angiotech Pharmaceuticals |url=https://www.crunchbase.com/organization/angiotech-pharmaceuticals |website=crunchbase.com |access-date=24 January 2022}}</ref> || Company launch || {{w|Angiotech Pharmaceuticals}} is founded. <ref>{{cite web |title=Surgical Specialties Corporation (formerly Angiotech) Profile on T-Net |url=https://www.bctechnology.com/companies/Surgical-Specialties-Corporation-(formerly-Angiotech).cfm |website=T-Net British Columbia |access-date=9 February 2022}}</ref> In 2017, Angiotech would be acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital.<ref>{{cite web |last1=Falconer |first1=Kirk |title=Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group |url=https://www.pehub.com/3425572/ |website=PE Hub |access-date=25 January 2022 |date=19 December 2016}}</ref><ref>{{cite web |title=Angiotech closes acquisition of certain product candidates and technology assets of Haemacure Corporation |url=https://www.newswire.ca/news-releases/angiotech-closes-acquisition-of-certain-product-candidates-and-technologyassets-of-haemacure-corporation-539696251.html |website=newswire.ca |access-date=25 January 2022}}</ref> || {{w|Canada}}
 
|-  
 
|-  
−
| 1992 || {{w|Bioinformatics}}, {{w|biotechnology}} || Company launch || {{w|Applied Maths}} is founded in Belgium as a {{w|bioinformatics}} company developing software for the biosciences.<ref>{{cite web |title=Applied Maths - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/applied-maths |website=Crunchbase |access-date=24 January 2022 |language=en}}</ref> It would gain worldwide recognition with the software GelCompar, used as a standard tool for the normalization and comparative analysis of {{w|electrophoresis}} patterns ({{w|PFGE}}, [[w:Amplified fragment length polymorphism|AFLP]], [[w:Random amplification of polymorphic DNA|RAPD]], REP-PCR and variants, etc).<ref>{{cite book |last1=Dijkshoorn |first1=L. |last2=Towner |first2=K. J. |last3=Struelens |first3=M. |title=New Approaches for the Generation and Analysis of Microbial Typing Data |date=10 July 2001 |publisher=Elsevier |isbn=978-0-08-053748-1 |url=https://books.google.com.ar/books/about/New_Approaches_for_the_Generation_and_An.html?id=YsP7fH3utXYC&source=kp_book_description&redir_esc=y |language=en}}</ref> || {{w|Belgium}}
+
| 1992 || {{w|Bioinformatics}} || Company launch || {{w|Applied Maths}} is founded in Belgium as a {{w|bioinformatics}} company developing software for the biosciences.<ref>{{cite web |title=Applied Maths - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/applied-maths |website=Crunchbase |access-date=24 January 2022 |language=en}}</ref> It would gain worldwide recognition with the software GelCompar, used as a standard tool for the normalization and comparative analysis of {{w|electrophoresis}} patterns ({{w|PFGE}}, [[w:Amplified fragment length polymorphism|AFLP]], [[w:Random amplification of polymorphic DNA|RAPD]], REP-PCR and variants, etc).<ref>{{cite book |last1=Dijkshoorn |first1=L. |last2=Towner |first2=K. J. |last3=Struelens |first3=M. |title=New Approaches for the Generation and Analysis of Microbial Typing Data |date=10 July 2001 |publisher=Elsevier |isbn=978-0-08-053748-1 |url=https://books.google.com.ar/books/about/New_Approaches_for_the_Generation_and_An.html?id=YsP7fH3utXYC&source=kp_book_description&redir_esc=y |language=en}}</ref> || {{w|Belgium}}
 
|-
 
|-
 
| 1992 (May) || Biopharmaceuticals, biotherapeutics || Company launch || {{w|Cubist Pharmaceuticals}} is founded. <ref>{{cite web |title=Working At Cubist Pharmaceuticals: Employee Reviews and Culture |url=https://www.zippia.com/cubist-pharmaceuticals-careers-20687/ |website=www.zippia.com |access-date=9 February 2022 |date=18 May 2020}}</ref> On 8 December 2014, {{w|Merck & Co.}} would acquire Cubist for US$102 per share in cash ($8.4 billion).<ref>{{cite web |title=Merck to take on superbugs with Cubist Pharma buy |url=https://www.reuters.com/article/us-cubist-pharma-m-a-merck-idUSKBN0JM19X20141209 |website=Reuters |access-date=24 January 2022 |language=en |date=9 December 2014}}</ref>
 
| 1992 (May) || Biopharmaceuticals, biotherapeutics || Company launch || {{w|Cubist Pharmaceuticals}} is founded. <ref>{{cite web |title=Working At Cubist Pharmaceuticals: Employee Reviews and Culture |url=https://www.zippia.com/cubist-pharmaceuticals-careers-20687/ |website=www.zippia.com |access-date=9 February 2022 |date=18 May 2020}}</ref> On 8 December 2014, {{w|Merck & Co.}} would acquire Cubist for US$102 per share in cash ($8.4 billion).<ref>{{cite web |title=Merck to take on superbugs with Cubist Pharma buy |url=https://www.reuters.com/article/us-cubist-pharma-m-a-merck-idUSKBN0JM19X20141209 |website=Reuters |access-date=24 January 2022 |language=en |date=9 December 2014}}</ref>
 
|-
 
|-
−
| 1992 || {{w|Biomedicine}}  || Conpany launch || {{w|Dendreon}} is founded.<ref>{{cite web |last1=Timmerman |first1=Luke |title=Short-sellers are betting Dendreon won’t win FDA’s OK |url=https://www.seattletimes.com/business/short-sellers-are-betting-dendreon-wont-win-fdas-ok/ |website=The Seattle Times |access-date=29 January 2022 |date=28 April 2007}}</ref> Its lead product, {{w|Provenge}} (known generically as sipuleucel-T), is an {{w|immunotherapy}} for {{w|prostate cancer}}.<ref>{{Cite web|url=http://files.shareholder.com/downloads/DNDN/579103823x0x290327/0d56dd47-8426-46dd-ab31-705983b009ca/DNDN_42809_IMPACT_Webcast_Slides_FINAL.pdf|title=AUA IMPACT Trial Presentation Summary }}</ref> || {{w|United States}}
+
| 1992 || {{w|Biomedicine}}  || Company launch || {{w|Dendreon}} is founded.<ref>{{cite web |last1=Timmerman |first1=Luke |title=Short-sellers are betting Dendreon won’t win FDA’s OK |url=https://www.seattletimes.com/business/short-sellers-are-betting-dendreon-wont-win-fdas-ok/ |website=The Seattle Times |access-date=29 January 2022 |date=28 April 2007}}</ref> Its lead product, {{w|Provenge}} (known generically as sipuleucel-T), is an {{w|immunotherapy}} for {{w|prostate cancer}}.<ref>{{Cite web|url=http://files.shareholder.com/downloads/DNDN/579103823x0x290327/0d56dd47-8426-46dd-ab31-705983b009ca/DNDN_42809_IMPACT_Webcast_Slides_FINAL.pdf|title=AUA IMPACT Trial Presentation Summary }}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1992 || Biotechnology, healthcare, health diagnostics, medical<ref>{{cite web |title=MorphoSys - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/morphosys |website=Crunchbase |access-date=5 May 2022 |language=en}}</ref> || Company launch || {{w|MorphoSys}} is founded.<ref>{{cite web |title=Our History {{!}} Morphosys de |url=https://www.morphosys.com/en/about-us/our-history |website=www.morphosys.com |access-date=9 February 2022}}</ref> Based in {{w|Planegg}}, {{w|Germany}}, it focuses on the research and development of fully human antibodies.<ref>{{cite web |title=MorphoSys - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/morphosys |website=Crunchbase |access-date=25 January 2022 |language=en}}</ref> || {{w|Germany}}
 
| 1992 || Biotechnology, healthcare, health diagnostics, medical<ref>{{cite web |title=MorphoSys - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/morphosys |website=Crunchbase |access-date=5 May 2022 |language=en}}</ref> || Company launch || {{w|MorphoSys}} is founded.<ref>{{cite web |title=Our History {{!}} Morphosys de |url=https://www.morphosys.com/en/about-us/our-history |website=www.morphosys.com |access-date=9 February 2022}}</ref> Based in {{w|Planegg}}, {{w|Germany}}, it focuses on the research and development of fully human antibodies.<ref>{{cite web |title=MorphoSys - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/morphosys |website=Crunchbase |access-date=25 January 2022 |language=en}}</ref> || {{w|Germany}}
Line 180: Line 153:
 
| 1992 (September 8) || Biopharmaceutical || Company launch || {{w|Shenzhen Kangtai Biological Products}} is founded. <ref>{{cite web |title=Shenzhen Kangtai Biological Products Co., Ltd Company Profile - China {{!}} Financials & Key Executives {{!}} EMIS |url=https://www.emis.com/php/company-profile/CN/Shenzhen_Kangtai_Biological_Products_Co_Ltd__%E6%B7%B1%E5%9C%B3%E5%BA%B7%E6%B3%B0%E7%94%9F%E7%89%A9%E5%88%B6%E5%93%81%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8__en_4392001.html |website=www.emis.com |access-date=9 February 2022}}</ref> It is a Chinese company that makes vaccines for diseases such as {{w|hepatitis B}} and {{w|measles}}.<ref>{{cite web |last1=Zimmer |first1=Carl |last2=Corum |first2=Jonathan |last3=Wee |first3=Sui-Lee |last4=Kristoffersen |first4=Matthew |title=Coronavirus Vaccine Tracker |url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html |website=The New York Times |access-date=17 May 2022 |date=10 June 2020}}</ref> || {{w|China}}
 
| 1992 (September 8) || Biopharmaceutical || Company launch || {{w|Shenzhen Kangtai Biological Products}} is founded. <ref>{{cite web |title=Shenzhen Kangtai Biological Products Co., Ltd Company Profile - China {{!}} Financials & Key Executives {{!}} EMIS |url=https://www.emis.com/php/company-profile/CN/Shenzhen_Kangtai_Biological_Products_Co_Ltd__%E6%B7%B1%E5%9C%B3%E5%BA%B7%E6%B3%B0%E7%94%9F%E7%89%A9%E5%88%B6%E5%93%81%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8__en_4392001.html |website=www.emis.com |access-date=9 February 2022}}</ref> It is a Chinese company that makes vaccines for diseases such as {{w|hepatitis B}} and {{w|measles}}.<ref>{{cite web |last1=Zimmer |first1=Carl |last2=Corum |first2=Jonathan |last3=Wee |first3=Sui-Lee |last4=Kristoffersen |first4=Matthew |title=Coronavirus Vaccine Tracker |url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html |website=The New York Times |access-date=17 May 2022 |date=10 June 2020}}</ref> || {{w|China}}
 
|-
 
|-
−
| 1993 (January 2) || {{w|Biotechnology}}, {{w|healthcare}} || Company launch || {{w|Bionor Pharma}} is founded. <ref>{{cite web |title=Bionor Pharma |url=https://www.crunchbase.com/organization/bionor-pharma |website=www.crunchbase.com |access-date=9 February 2022}}</ref> It is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure.<ref>{{cite web |title=Bloomberg - Are you a robot? |url=https://www.bloomberg.com/press-releases/2016-06-09/bionor-pharma-asa-the-peer-reviewed-and-highly-recognized-journal-the-lancet-hiv-has-accepted-the-results-of-the-reduc-part-b |website=www.bloomberg.com |access-date=21 March 2022}}</ref> || {{w|Norway}}
+
| 1993 (January 2) || {{w|Vaccine}}s, {{w|soy protein}}, {{w|healthcare}} || Company launch || {{w|Bionor Pharma}} is founded. <ref>{{cite web |title=Bionor Pharma |url=https://www.crunchbase.com/organization/bionor-pharma |website=www.crunchbase.com |access-date=9 February 2022}}</ref> It is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure.<ref>{{cite web |title=Bloomberg - Are you a robot? |url=https://www.bloomberg.com/press-releases/2016-06-09/bionor-pharma-asa-the-peer-reviewed-and-highly-recognized-journal-the-lancet-hiv-has-accepted-the-results-of-the-reduc-part-b |website=www.bloomberg.com |access-date=21 March 2022}}</ref> || {{w|Norway}}
 
|-
 
|-
 
| 1993 || {{w|Biomedicine}} || Company launch || {{w|Applied Spectral Imaging}} is founded.<ref>{{cite web |title=Diagnostics tools for pathology, cytogenetic and research laboratories |url=https://spectral-imaging.com/about-asi/ |website=ASI |access-date=9 February 2022}}</ref> It is a multinational biomedical company that develops and manufactures microscopy imaging and digital analysis tools for hospitals, service laboratories and research centers.<ref>{{cite web |title=Working At Applied Spectral Imaging: Employee Reviews and Culture |url=https://www.zippia.com/applied-spectral-imaging-careers-673782/ |website=www.zippia.com |access-date=21 March 2022 |date=18 May 2020}}</ref> || {{w|United States}}
 
| 1993 || {{w|Biomedicine}} || Company launch || {{w|Applied Spectral Imaging}} is founded.<ref>{{cite web |title=Diagnostics tools for pathology, cytogenetic and research laboratories |url=https://spectral-imaging.com/about-asi/ |website=ASI |access-date=9 February 2022}}</ref> It is a multinational biomedical company that develops and manufactures microscopy imaging and digital analysis tools for hospitals, service laboratories and research centers.<ref>{{cite web |title=Working At Applied Spectral Imaging: Employee Reviews and Culture |url=https://www.zippia.com/applied-spectral-imaging-careers-673782/ |website=www.zippia.com |access-date=21 March 2022 |date=18 May 2020}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 1993 || {{w|Biotechnology}} || Company launch || {{w|Biosearch Technologies}} is founded.<ref>{{cite web |title=Biosearch Technologies Licenses Access to New CDC "PDM" H1N1 Signatures |url=https://www.biosearchtech.com/about-us/news/biosearch-technologies-licenses-access-to-new-cdc-pdm-h1n1-signatures |website=LGC Biosearch Technologies |access-date=9 February 2022 |language=en}}</ref> It designs, develops, and manufactures custom oligonucleotides and associated reagents for the molecular diagnostics, research and applied markets.<ref>{{cite web |title=Biosearch Technologies- Chemistry for Genomics and Proteomics |url=https://www.gene-quantification.de/biosearchtech/#:~:text=Short%20company%20profile,diagnostics%2C%20research%20and%20applied%20markets. |website=www.gene-quantification.de |access-date=23 March 2022}}</ref> || {{w|United Kingdom}}
+
| 1993 || Oligonucleotide-based tools || Company launch || {{w|Biosearch Technologies}} is founded.<ref>{{cite web |title=Biosearch Technologies Licenses Access to New CDC "PDM" H1N1 Signatures |url=https://www.biosearchtech.com/about-us/news/biosearch-technologies-licenses-access-to-new-cdc-pdm-h1n1-signatures |website=LGC Biosearch Technologies |access-date=9 February 2022 |language=en}}</ref> It designs, develops, and manufactures custom oligonucleotides and associated reagents for the molecular diagnostics, research and applied markets.<ref>{{cite web |title=Biosearch Technologies- Chemistry for Genomics and Proteomics |url=https://www.gene-quantification.de/biosearchtech/#:~:text=Short%20company%20profile,diagnostics%2C%20research%20and%20applied%20markets. |website=www.gene-quantification.de |access-date=23 March 2022}}</ref> || {{w|United Kingdom}}
 
|-
 
|-
 
| 1993 || Immunostimulants || Background || The United States {{w|FDA}} approves {{w|Betaseron}}, the first of several biotech products that have had a major impact on {{w|multiple sclerosis}} treatment.<ref name=dhShimasaki/>
 
| 1993 || Immunostimulants || Background || The United States {{w|FDA}} approves {{w|Betaseron}}, the first of several biotech products that have had a major impact on {{w|multiple sclerosis}} treatment.<ref name=dhShimasaki/>
 
|-
 
|-
−
| 1993 || {{w|Biotechnology}} || Company launch || {{w|Shantha Biotechnics}} is founded.<ref>{{cite web |title=(PDF) Indian vaccine innovation: The case of Shantha Biotechnics |url=https://www.researchgate.net/publication/51064759_Indian_vaccine_innovation_The_case_of_Shantha_Biotechnics |website=ResearchGate |access-date=9 February 2022 |language=en}}</ref> It is one of the first Indian biotechnology companies to create a recombinant product, obtaining World Health Organization (WHO) prequalification for its {{w|Hepatitis B vaccine}} in 2002.<ref>{{cite journal |last1=Chakma |first1=Justin |last2=Masum |first2=Hassan |last3=Perampaladas |first3=Kumar |last4=Heys |first4=Jennifer |last5=Singer |first5=Peter A |title=Indian vaccine innovation: the case of Shantha Biotechnics |journal=Globalization and Health |date=December 2011 |volume=7 |issue=1 |pages=9 |doi=10.1186/1744-8603-7-9}}</ref> By 2013, {{w|Sanofi}} would complete the acquisition of 100% of the company.<ref>{{cite web |title=Sanofi infusing $122M to complete buy-out of Shantha Biotech and further expansion |url=http://www.vccircle.com/news/health-care/2013/11/01/sanofi-infusing-122m-complete-buy-out-shantha-biotech-and-further |access-date=25 January 2022}}</ref> || {{w|India}}
+
| 1993 || {{w|Vaccine}}s || Company launch || {{w|Shantha Biotechnics}} is founded.<ref>{{cite web |title=(PDF) Indian vaccine innovation: The case of Shantha Biotechnics |url=https://www.researchgate.net/publication/51064759_Indian_vaccine_innovation_The_case_of_Shantha_Biotechnics |website=ResearchGate |access-date=9 February 2022 |language=en}}</ref> It is one of the first Indian biotechnology companies to create a recombinant product, obtaining World Health Organization (WHO) prequalification for its {{w|Hepatitis B vaccine}} in 2002.<ref>{{cite journal |last1=Chakma |first1=Justin |last2=Masum |first2=Hassan |last3=Perampaladas |first3=Kumar |last4=Heys |first4=Jennifer |last5=Singer |first5=Peter A |title=Indian vaccine innovation: the case of Shantha Biotechnics |journal=Globalization and Health |date=December 2011 |volume=7 |issue=1 |pages=9 |doi=10.1186/1744-8603-7-9}}</ref> By 2013, {{w|Sanofi}} would complete the acquisition of 100% of the company.<ref>{{cite web |title=Sanofi infusing $122M to complete buy-out of Shantha Biotech and further expansion |url=http://www.vccircle.com/news/health-care/2013/11/01/sanofi-infusing-122m-complete-buy-out-shantha-biotech-and-further |access-date=25 January 2022}}</ref> || {{w|India}}
 
|-
 
|-
 
| 1993 || {{w|Biopharma}}, {{w|biotechnology}}, medical pharmaceutical || Company launch || [[w:Takeda Oncology|Millennium Pharmaceuticals]] is founded <ref>{{cite web |title=History of Millennium Pharmaceuticals, Inc. – FundingUniverse |url=http://www.fundinguniverse.com/company-histories/millennium-pharmaceuticals-inc-history/ |website=www.fundinguniverse.com |access-date=9 February 2022}}</ref>. On May 14, 2008, Japanese company Takeda Pharmaceutical would complete its acquisition of Millennium for a deal worth US$8.8 billion. The new subsidiary would finally be renamed Takeda Oncology. || {{w|United States}}
 
| 1993 || {{w|Biopharma}}, {{w|biotechnology}}, medical pharmaceutical || Company launch || [[w:Takeda Oncology|Millennium Pharmaceuticals]] is founded <ref>{{cite web |title=History of Millennium Pharmaceuticals, Inc. – FundingUniverse |url=http://www.fundinguniverse.com/company-histories/millennium-pharmaceuticals-inc-history/ |website=www.fundinguniverse.com |access-date=9 February 2022}}</ref>. On May 14, 2008, Japanese company Takeda Pharmaceutical would complete its acquisition of Millennium for a deal worth US$8.8 billion. The new subsidiary would finally be renamed Takeda Oncology. || {{w|United States}}
 
|-
 
|-
−
| 1993 || {{w|Biotechnology}} || Company launch || {{w|Ventria Bioscience}} is founded.<ref>{{cite web |title=Ventria Bioscience |url=https://www.crunchbase.com/organization/ventria-bioscience |website=www.crunchbase.com |access-date=9 February 2022}}</ref> It is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system.<ref>{{cite web |title=Ventria Bioscience |url=https://www.linkedin.com/company/ventria-bioscience/ |website=linkedin |access-date=6 April 2022}}</ref> || {{w|United States}}
+
| 1993 || [[w:Pharming (genetics)|Pharming]] || Company launch || {{w|Ventria Bioscience}} is founded.<ref>{{cite web |title=Ventria Bioscience |url=https://www.crunchbase.com/organization/ventria-bioscience |website=www.crunchbase.com |access-date=9 February 2022}}</ref> It is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system.<ref>{{cite web |title=Ventria Bioscience |url=https://www.linkedin.com/company/ventria-bioscience/ |website=linkedin |access-date=6 April 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 1993 (November 12) || {{w|Medical}}, {{w|medical device}}, {{w|pharmaceutical}} || Notable {{w|IPO}} || {{w|Incyte Corporation}} completes its IPO, trading under ticker INCY on {{w|Nasdaq}}·<ref>{{cite web |title=Incyte |url=https://www.crunchbase.com/organization/incyte/company_financials |website=crunchbase |access-date=2 June 2022}}</ref> It is a hlobal biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics.<ref>{{cite web |title=ShieldSquare Captcha |url=https://www.globaldata.com/company-profile/Incyte-Corp/ |website=www.globaldata.com |access-date=7 July 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 1994 (January 1) || {{w|Biotechnology}} || Company launch || {{w|Fermentek}} is founded.<ref>{{cite web |title=Fermentek Biotechnology |url=https://il.linkedin.com/company/fermentek-biotechnology |website=il.linkedin.com |access-date=18 February 2022}}</ref><ref>{{cite web |title=Fermentek - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/fermentek |website=Crunchbase |access-date=18 February 2022 |language=en}}</ref> It specializes in the research, development, and manufacture of biologically active natural products isolated from microorganisms and other natural sources such as plants and algae.<ref>{{cite web |title=Community for Businesses in Latin America and the Caribbean {{!}} ConnectAmericas |url=https://connectamericas.com/company/fermentek#:~:text=Fermentek%20is%20a%20biotechnology%20company,Pharmaceuticals |website=connectamericas.com |access-date=24 March 2022 |language=en}}</ref> || {{w|Israel}}
+
| 1994 (January 1) || {{w|Biopharmaceutical}}s || Company launch || {{w|Fermentek}} is founded.<ref>{{cite web |title=Fermentek Biotechnology |url=https://il.linkedin.com/company/fermentek-biotechnology |website=il.linkedin.com |access-date=18 February 2022}}</ref><ref>{{cite web |title=Fermentek - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/fermentek |website=Crunchbase |access-date=18 February 2022 |language=en}}</ref> Based on {{w|Jerusalem}}, it specializes in the research, development, and manufacture of biologically active natural products isolated from microorganisms and other natural sources such as plants and algae.<ref>{{cite web |title=Community for Businesses in Latin America and the Caribbean {{!}} ConnectAmericas |url=https://connectamericas.com/company/fermentek#:~:text=Fermentek%20is%20a%20biotechnology%20company,Pharmaceuticals |website=connectamericas.com |access-date=24 March 2022 |language=en}}</ref> || {{w|Israel}}
 
|-
 
|-
 
| 1994 (February 16) || || Literature || American journalist {{w|Barry Werth}} publishes ''{{w|The Billion-Dollar Molecule}}'', which recounts the founding and early research efforts of the American biotechnology company {{w|Vertex Pharmaceuticals}}. The book is notable as an inside look at a biotechnology company, and the stresses and marketing pressures on funding research into drug design.<ref>{{cite web |title=The Billion-Dollar Molecule |url=https://en.wikipedia.org/wiki/The_Billion-Dollar_Molecule |website=Wikipedia |access-date=18 May 2022 |language=en |date=28 November 2020}}</ref> || {{w|United States}}
 
| 1994 (February 16) || || Literature || American journalist {{w|Barry Werth}} publishes ''{{w|The Billion-Dollar Molecule}}'', which recounts the founding and early research efforts of the American biotechnology company {{w|Vertex Pharmaceuticals}}. The book is notable as an inside look at a biotechnology company, and the stresses and marketing pressures on funding research into drug design.<ref>{{cite web |title=The Billion-Dollar Molecule |url=https://en.wikipedia.org/wiki/The_Billion-Dollar_Molecule |website=Wikipedia |access-date=18 May 2022 |language=en |date=28 November 2020}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 1994 || {{w|Biotechnology}}, pharmaceutical || Company launch || {{w|Agenus}} is founded <ref>{{cite web |title=Agenus |url=https://www.bizjournals.com/boston/news/2017/02/22/lexingtons-agenus-quietly-discloses-failure-of.html |website=www.bizjournals.com |access-date=9 February 2022}}</ref>. It develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.<ref>{{cite web |title=Agenus - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/agenus |website=Crunchbase |access-date=25 January 2022 |language=en}}</ref> || {{w|United States}}
+
| 1994 || {{w|Oncology}}, {{w|immunotherapy}}, {{w|vaccine}}s || Company launch || {{w|Agenus}} is founded <ref>{{cite web |title=Agenus |url=https://www.bizjournals.com/boston/news/2017/02/22/lexingtons-agenus-quietly-discloses-failure-of.html |website=www.bizjournals.com |access-date=9 February 2022}}</ref>. It develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.<ref>{{cite web |title=Agenus - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/agenus |website=Crunchbase |access-date=25 January 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 1994 || {{w|Biotechnology}} || Company launch || {{w|Astellas Institute for Regenerative Medicine}} is founded as Advanced Cell Technology, Incorporated (ACT). It would be renamed to Ocata Therapeutics in November 2014.<ref>{{cite web |title=Press Releases :: Ocata Therapeutics, Inc. (OCAT) |url=https://web.archive.org/web/20150402112607/http://ir.ocata.com/press-releases/detail/2644/advanced-cell-technology-changes-name-to-ocata-therapeutics |website=web.archive.org |access-date=25 January 2022 |date=2 April 2015}}</ref> In February 2016 Ocata would be acquired by Astellas for US$379 million.<ref>{{cite web |last1=Writer |first1=GEN Staff |title=Astellas to acquire Ocata Therapeutics for $379M |url=https://www.genengnews.com/topics/drug-discovery/astellas-to-acquire-ocata-therapeutics-for-379m/ |website=GEN - Genetic Engineering and Biotechnology News |access-date=25 January 2022 |date=10 November 2015}}</ref> || {{w|United States}}
+
| 1994 || {{w|Stem-cell therapy}} || Company launch || Advanced Cell Technology, Incorporated (ACT) is founded. Renamed to Ocata Therapeutics in November 2014<ref>{{cite web |title=Press Releases :: Ocata Therapeutics, Inc. (OCAT) |url=https://web.archive.org/web/20150402112607/http://ir.ocata.com/press-releases/detail/2644/advanced-cell-technology-changes-name-to-ocata-therapeutics |website=web.archive.org |access-date=25 January 2022 |date=2 April 2015}}</ref>, in February 2016 it would be acquired by Astellas for US$379 million.<ref>{{cite web |last1=Writer |first1=GEN Staff |title=Astellas to acquire Ocata Therapeutics for $379M |url=https://www.genengnews.com/topics/drug-discovery/astellas-to-acquire-ocata-therapeutics-for-379m/ |website=GEN - Genetic Engineering and Biotechnology News |access-date=25 January 2022 |date=10 November 2015}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1994 || Pharmaceutical || Company launch || {{w|Cinnagen}} is founded. <ref>{{cite web |title=CinnaGen: Our History |url=https://www.cinnagen.com/Timeline.aspx?l=1#:~:text=CinnaGen%20Co.,biotech%20exporter%20in%20the%20region. |website=www.cinnagen.com |access-date=5 February 2022}}</ref> Based in {{w|Tehran}}, it is a manufacturing company of biotechnology and biopharmaceutical products.<ref>{{cite web |title=CinnaGen - Headquarter Locations, Competitors, Financials, Employees |url=https://www.cbinsights.com/company/cinnagen |website=www.cbinsights.com |access-date=24 March 2022}}</ref> || {{w|Iran}}
 
| 1994 || Pharmaceutical || Company launch || {{w|Cinnagen}} is founded. <ref>{{cite web |title=CinnaGen: Our History |url=https://www.cinnagen.com/Timeline.aspx?l=1#:~:text=CinnaGen%20Co.,biotech%20exporter%20in%20the%20region. |website=www.cinnagen.com |access-date=5 February 2022}}</ref> Based in {{w|Tehran}}, it is a manufacturing company of biotechnology and biopharmaceutical products.<ref>{{cite web |title=CinnaGen - Headquarter Locations, Competitors, Financials, Employees |url=https://www.cbinsights.com/company/cinnagen |website=www.cbinsights.com |access-date=24 March 2022}}</ref> || {{w|Iran}}
Line 206: Line 181:
 
| 1994 || Biotechnology, pharmaceutical || Company launch || [[w:Corixa (company)|Corixa]] is founded in {{w|Seattle, Washington}}. <ref>{{cite web |title=Corixa Corporation - company |url=https://www.coulterpharm.com/default.asp?pid=company |website=www.coulterpharm.com |access-date=9 February 2022}}</ref> Acquired by {{w|GlaxoSmithKline}} in 2005, the company would close in 2016. || {{w|United States}} ({{w|Seattle, Washington}})
 
| 1994 || Biotechnology, pharmaceutical || Company launch || [[w:Corixa (company)|Corixa]] is founded in {{w|Seattle, Washington}}. <ref>{{cite web |title=Corixa Corporation - company |url=https://www.coulterpharm.com/default.asp?pid=company |website=www.coulterpharm.com |access-date=9 February 2022}}</ref> Acquired by {{w|GlaxoSmithKline}} in 2005, the company would close in 2016. || {{w|United States}} ({{w|Seattle, Washington}})
 
|-
 
|-
−
| 1994 || {{w|Biotechnology}}, {{w|healthcare}}, pharmaceutical || Company launch || {{w|ViroPharma}} is founded. <ref>{{cite web |title=ViroPharma's |url=https://www.bizjournals.com/philadelphia/blog/health-care/2013/11/viropharmas-42b-deal-is-nothing-to.html |website=www.bizjournals.com |access-date=9 February 2022}}</ref> A company focused on product development activities on [[w:Virus#Role in human disease|viruses and human disease]], including those caused by {{w|cytomegalovirus}} (CMV) and {{w|hepatitis C}} virus (HCV) infections, it would be purchased by Irish drug manufacturer [[w:Shire (pharmaceutical company)|Shire]] in 2013, with Shire paying around US$4.2 billion.<ref>{{cite web |title=Shire acquires ViroPharma for $4.2bn |url=https://www.financierworldwide.com/shire-acquires-viropharma-for-42bn |website=Financier Worldwide |access-date=29 January 2022}}</ref> || {{w|United States}}
+
| 1994 || {{w|biopharmaceutical}} || Company launch || {{w|ViroPharma}} is founded. <ref>{{cite web |title=ViroPharma's |url=https://www.bizjournals.com/philadelphia/blog/health-care/2013/11/viropharmas-42b-deal-is-nothing-to.html |website=www.bizjournals.com |access-date=9 February 2022}}</ref> A company focused on product development activities on [[w:Virus#Role in human disease|viruses and human disease]], including those caused by {{w|cytomegalovirus}} (CMV) and {{w|hepatitis C}} virus (HCV) infections, it would be purchased by Irish drug manufacturer [[w:Shire (pharmaceutical company)|Shire]] in 2013, with Shire paying around US$4.2 billion.<ref>{{cite web |title=Shire acquires ViroPharma for $4.2bn |url=https://www.financierworldwide.com/shire-acquires-viropharma-for-42bn |website=Financier Worldwide |access-date=29 January 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1994 || {{w|Genetics}}, {{w|Oncology}} || Background || The first {{w|breast cancer}} gene is discovered.<ref name=dhShimasaki/>
 
| 1994 || {{w|Genetics}}, {{w|Oncology}} || Background || The first {{w|breast cancer}} gene is discovered.<ref name=dhShimasaki/>
Line 214: Line 189:
 
| 1994 || {{w|Immunotherapy}}, {{w|oncology}} || Company launch || {{w|MediGene}} is founded.<ref>{{cite web |title=Medigene |url=https://www.medigene.com/company/company-profile |website=medigene.com |access-date=29 January 2022}}</ref> Based in {{w|Martinsried}}, {{w|German}}, this company works on the development of immunotherapies to enhance {{w|T cell}} activity against solid cancers.<ref>{{cite web |title=Medigene |url=https://www.medigene.com/technologies |website=medigene.com |access-date=29 January 2022}}</ref> || {{w|Germany}}   
 
| 1994 || {{w|Immunotherapy}}, {{w|oncology}} || Company launch || {{w|MediGene}} is founded.<ref>{{cite web |title=Medigene |url=https://www.medigene.com/company/company-profile |website=medigene.com |access-date=29 January 2022}}</ref> Based in {{w|Martinsried}}, {{w|German}}, this company works on the development of immunotherapies to enhance {{w|T cell}} activity against solid cancers.<ref>{{cite web |title=Medigene |url=https://www.medigene.com/technologies |website=medigene.com |access-date=29 January 2022}}</ref> || {{w|Germany}}   
 
|-
 
|-
−
| 1994 || {{w|Biotechnology}} || Company launch || {{w|HyTest Ltd}} is founded.<ref>{{cite web |title=HyTest |url=https://fi.linkedin.com/company/hytest-ltd- |website=fi.linkedin.com |access-date=25 January 2022}}</ref> Based in {{w|Turku}}, {{w|Finland}}, it is a producer of {{w|monoclonal antibodies}} and {{w|antigen}}s for the {{w|diagnostic}} industry.<ref>{{cite web |title=Antibody Manufacturing and Cardiac Marker Production {{!}} HyTest Ltd. |url=https://hytest.fi/home#:~:text=At%20HyTest%2C%20we%20manufacture%20monoclonal,suppliers%20for%20the%20IVD%20industry. |website=hytest.fi |access-date=29 January 2022 |language=en}}</ref> || {{w|Finland}}
+
| 1994 || {{w|Monoclonal antibodies}}, {{w|antigen}}s  || Company launch || {{w|HyTest Ltd}} is founded.<ref>{{cite web |title=HyTest |url=https://fi.linkedin.com/company/hytest-ltd- |website=fi.linkedin.com |access-date=25 January 2022}}</ref> Based in {{w|Turku}}, {{w|Finland}}, it is a producer of {{w|monoclonal antibodies}} and {{w|antigen}}s for the {{w|diagnostic}} industry.<ref>{{cite web |title=Antibody Manufacturing and Cardiac Marker Production {{!}} HyTest Ltd. |url=https://hytest.fi/home#:~:text=At%20HyTest%2C%20we%20manufacture%20monoclonal,suppliers%20for%20the%20IVD%20industry. |website=hytest.fi |access-date=29 January 2022 |language=en}}</ref> || {{w|Finland}}
 
|-
 
|-
 
| 1994 (November) || {{w|Genomics}}, {{w|oncology}} || Company launch || {{w|Exelixis}} is founded. <ref>{{cite web |title=Exelixis is On a Mission to Help Cancer Patients Recover Stronger and Live Longer |url=https://www.exelixis.com/mission/ |website=Exelixis |access-date=9 February 2022}}</ref> Based in [[w:Alameda County, California|Alameda]], California, it is a {{w|genomics}}-based drug discovery company, and the producer of {{w|Cometriq}}, a treatment approved by the U.S. {{w|Food and Drug Administration}} (FDA) for {{w|medullary thyroid cancer}} with clinical activity in several other types of metastatic cancer. || {{w|United States}}
 
| 1994 (November) || {{w|Genomics}}, {{w|oncology}} || Company launch || {{w|Exelixis}} is founded. <ref>{{cite web |title=Exelixis is On a Mission to Help Cancer Patients Recover Stronger and Live Longer |url=https://www.exelixis.com/mission/ |website=Exelixis |access-date=9 February 2022}}</ref> Based in [[w:Alameda County, California|Alameda]], California, it is a {{w|genomics}}-based drug discovery company, and the producer of {{w|Cometriq}}, a treatment approved by the U.S. {{w|Food and Drug Administration}} (FDA) for {{w|medullary thyroid cancer}} with clinical activity in several other types of metastatic cancer. || {{w|United States}}
 
|-
 
|-
−
| 1995 || {{w|Biotechnology}} || Company launch || {{w|Sangamo Therapeutics}} is founded. <ref>{{cite web |last1=Hanel |first1=Meredith |last2=Sewell |first2=Dawson |last3=Faraguna |first3=Carla |last4=Scherfner |first4=Erin |last5=Mariappan |first5=Lax |last6=Gomila |first6=Jude |last7=Otieno |first7=Wyckliffe |last8=Bedia |first8=Marie Gabrielle Laguna- |last9=Mešanović |first9=Mevludin |last10=Jhaveri |first10=Neelam |title=Sangamo Therapeutics - Wiki |url=https://golden.com/wiki/Sangamo_Therapeutics-5K96JKM |website=Golden |access-date=9 February 2022 |language=en}}</ref> It is a genomic medicine company focused on leveraging novel platforms to advance clinical programs.<ref>{{cite web |title=Overview {{!}} Sangamo Therapeutics, Inc. |url=https://investor.sangamo.com/ |website=investor.sangamo.com |access-date=25 March 2022 |language=en}}</ref> || {{w|Australia}}
+
| 1995 || {{w|Genomics}} || Company launch || {{w|Sangamo Therapeutics}} is founded.<ref>{{cite web |last1=Hanel |first1=Meredith |last2=Sewell |first2=Dawson |last3=Faraguna |first3=Carla |last4=Scherfner |first4=Erin |last5=Mariappan |first5=Lax |last6=Gomila |first6=Jude |last7=Otieno |first7=Wyckliffe |last8=Bedia |first8=Marie Gabrielle Laguna- |last9=Mešanović |first9=Mevludin |last10=Jhaveri |first10=Neelam |title=Sangamo Therapeutics - Wiki |url=https://golden.com/wiki/Sangamo_Therapeutics-5K96JKM |website=Golden |access-date=9 February 2022 |language=en}}</ref> It is a genomic medicine company focused on leveraging novel platforms to advance clinical programs.<ref>{{cite web |title=Overview {{!}} Sangamo Therapeutics, Inc. |url=https://investor.sangamo.com/ |website=investor.sangamo.com |access-date=25 March 2022 |language=en}}</ref> || {{w|Australia}}
 
|-
 
|-
 
| 1995 (May 5) || {{w|Medical technology}} || Company launch || {{w|Aclara Biosciences}} is founded.<ref>{{cite web |title=Aclara Biosciences Company Profile: Acquisition & Investors {{!}} PitchBook |url=https://pitchbook.com/profiles/company/13129-03 |website=pitchbook.com |access-date=9 February 2022 |language=en}}</ref> It develops microfluidic lab-on-a-chip technology.<ref>{{cite web |title=Companies Granted $3 Million to Develop New Microfluidic System |url=https://www.bioprocessonline.com/doc/companies-granted-3-million-to-develop-new-mi-0001 |website=www.bioprocessonline.com |access-date=25 March 2022}}</ref> || {{w|United States}}
 
| 1995 (May 5) || {{w|Medical technology}} || Company launch || {{w|Aclara Biosciences}} is founded.<ref>{{cite web |title=Aclara Biosciences Company Profile: Acquisition & Investors {{!}} PitchBook |url=https://pitchbook.com/profiles/company/13129-03 |website=pitchbook.com |access-date=9 February 2022 |language=en}}</ref> It develops microfluidic lab-on-a-chip technology.<ref>{{cite web |title=Companies Granted $3 Million to Develop New Microfluidic System |url=https://www.bioprocessonline.com/doc/companies-granted-3-million-to-develop-new-mi-0001 |website=www.bioprocessonline.com |access-date=25 March 2022}}</ref> || {{w|United States}}
Line 224: Line 199:
 
| 1995 || {{w|Healthcare}}, {{w|biotechnology}} || Company launch || {{w|Acorda Therapeutics}} is founded.<ref>{{cite web |title=Acorda Therapeutics Inc - Investors - Corporate Governance |url=https://ir.acorda.com/investors/corporate-governance/default.aspx |website=ir.acorda.com |access-date=9 February 2022}}</ref> Based in {{w|Ardsley, New York}}, it is a biotechnology company that develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. This company manufactures and markets {{w|Zanaflex}}, {{w|Ampyra}} and {{w|Qutenza}} in the United States.<ref>{{cite web |title=Acorda Therapeutics, Inc. – Cruelty Free Investing |url=http://crueltyfreeinvesting.org/companies/acorda-therapeutics-inc/ |website=crueltyfreeinvesting.org |access-date=6 April 2022}}</ref> || {{w|United States}}
 
| 1995 || {{w|Healthcare}}, {{w|biotechnology}} || Company launch || {{w|Acorda Therapeutics}} is founded.<ref>{{cite web |title=Acorda Therapeutics Inc - Investors - Corporate Governance |url=https://ir.acorda.com/investors/corporate-governance/default.aspx |website=ir.acorda.com |access-date=9 February 2022}}</ref> Based in {{w|Ardsley, New York}}, it is a biotechnology company that develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. This company manufactures and markets {{w|Zanaflex}}, {{w|Ampyra}} and {{w|Qutenza}} in the United States.<ref>{{cite web |title=Acorda Therapeutics, Inc. – Cruelty Free Investing |url=http://crueltyfreeinvesting.org/companies/acorda-therapeutics-inc/ |website=crueltyfreeinvesting.org |access-date=6 April 2022}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 1995 || {{w|Biotechnology}}, {{w|pharmaceuticals}}, {{w|life sciences}} || Company launch || {{w|Caliper Life Sciences}} is founded. <ref>{{cite web |title=History of Caliper Life Sciences, Inc. – FundingUniverse |url=http://www.fundinguniverse.com/company-histories/caliper-life-sciences-inc-history/ |website=www.fundinguniverse.com |access-date=9 February 2022}}</ref> It is a provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.<ref>{{cite web |title=Caliper Life Sciences to Acquire Cambridge Research & Instrumentation |url=https://www.fiercebiotech.com/biotech/caliper-life-sciences-to-acquire-cambridge-research-instrumentation-0#:~:text=About%20Caliper%20Life%20Sciences,tests%20more%20quickly%20and%20efficiently. |website=Fierce Biotech |access-date=6 April 2022 |language=en |date=9 December 2010}}</ref> || {{w|United States}}
+
| 1995 || {{w|Pharmaceuticals}}, {{w|life sciences}} || Company launch || {{w|Caliper Life Sciences}} is founded. <ref>{{cite web |title=History of Caliper Life Sciences, Inc. – FundingUniverse |url=http://www.fundinguniverse.com/company-histories/caliper-life-sciences-inc-history/ |website=www.fundinguniverse.com |access-date=9 February 2022}}</ref> It is a provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.<ref>{{cite web |title=Caliper Life Sciences to Acquire Cambridge Research & Instrumentation |url=https://www.fiercebiotech.com/biotech/caliper-life-sciences-to-acquire-cambridge-research-instrumentation-0#:~:text=About%20Caliper%20Life%20Sciences,tests%20more%20quickly%20and%20efficiently. |website=Fierce Biotech |access-date=6 April 2022 |language=en |date=9 December 2010}}</ref> || {{w|United States}}
 +
|-
 +
| 1995 || || Accelerator/incubator launch || {{w|University of Florida}}'s Sid Martin Biotechnology Incubator opens. It is one of the first bio-business incubators in the United States.<ref>{{cite web |title=LinkedIn Login, Sign in |url=https://www.linkedin.com/company/uf-innovate-sid-martin-biotech/about/ |website=LinkedIn |access-date=29 June 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 1995 || {{w|Molecular medicine}} || Accelerator/incubator launch || The Molecular Medicine Research Institute is founded.<ref>{{cite web |last1=Colombo |first1=Sharon |title=About |url=https://www.mmrx.org/about/#:~:text=MMRI%20is%20an%20independent%2C%20501,Valley%2C%20in%20Sunnyvale%2C%20CA. |website=Molecular Medicine Research Institute |access-date=29 June 2022 |language=english}}</ref> Based in the {{w|Silicon Valley}}, MMRI is a sovereign, non-profit medical research institute including facilities that are proficient in supporting their efforts in molecular biology, immunology, cell biology.<ref name="Top 15 biotech incubators and accelerators in the US"/> || {{w|United States}}
 
|-
 
|-
 
| 1995 || || Research || According to Brown and Eisenhardt, new product development is critical to the success, survival, growth and renewal of organizations. New products provide a potential source of competitive advantage and allow organizations to diversify, adapt and even re-engineer to match involving markets and technical conditions.<ref>Brown, S.L. and K.M. Eisenhardt (1995), ‘Product development: past research, present findings and future directions’, Academy of Management Review, 20 (2), 343–78</ref>
 
| 1995 || || Research || According to Brown and Eisenhardt, new product development is critical to the success, survival, growth and renewal of organizations. New products provide a potential source of competitive advantage and allow organizations to diversify, adapt and even re-engineer to match involving markets and technical conditions.<ref>Brown, S.L. and K.M. Eisenhardt (1995), ‘Product development: past research, present findings and future directions’, Academy of Management Review, 20 (2), 343–78</ref>
Line 230: Line 209:
 
| 1995 || {{w|Immunotherapy}}, {{w|Oncology}} || Background || Gene therapy, immune-system modulation, and recombinantly produced antibodies enter the clinic for the treatment of cancer.<ref name=dhShimasaki/> ||
 
| 1995 || {{w|Immunotherapy}}, {{w|Oncology}} || Background || Gene therapy, immune-system modulation, and recombinantly produced antibodies enter the clinic for the treatment of cancer.<ref name=dhShimasaki/> ||
 
|-
 
|-
−
| 1995 || {{w|Biotechnology}} || Company launch || {{w|Monogram Biosciences}} is founded.<ref>{{cite web |title=Monogram Biosciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/monogram-biosciences |website=Crunchbase |access-date=25 February 2022 |language=en}}</ref> Based in {{w|San Francisco}}, it focuses on the development and commercialization of novel diagnostic technologies to enable individualized patient treatment decisions, and support the discovery and development of new drug and vaccine candidates.<ref>{{cite web |title=Monogram Biosciences |url=https://www.linkedin.com/in/christos-j-petropoulos-a6a295b#:~:text=Monogram%20Biosciences%20is%20a%20LabCorp,new%20drug%20and%20vaccine%20candidates. |website=linkedin |access-date=19 May 2022}}</ref> || {{w|United States}}
+
| 1995 || {{w|Diagnostic}}s || Company launch || {{w|Monogram Biosciences}} is founded.<ref>{{cite web |title=Monogram Biosciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/monogram-biosciences |website=Crunchbase |access-date=25 February 2022 |language=en}}</ref> Based in {{w|San Francisco}}, it focuses on the development and commercialization of novel diagnostic technologies to enable individualized patient treatment decisions, and support the discovery and development of new drug and vaccine candidates.<ref>{{cite web |title=Monogram Biosciences |url=https://www.linkedin.com/in/christos-j-petropoulos-a6a295b#:~:text=Monogram%20Biosciences%20is%20a%20LabCorp,new%20drug%20and%20vaccine%20candidates. |website=linkedin |access-date=19 May 2022}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 1995 || {{w|Biotechnology}} || Company launch || {{w|Dharmacon}} is founded by Stephen Scaringe to develop and commercialize a new technology for {{w|RNA}} {{w|oligonucleotide synthesis}}. <ref>{{cite web |title=Dharmacon |url=https://dbpedia.org/page/Dharmacon |website=dbpedia.org |access-date=9 February 2022}}</ref> || {{w|United States}}
+
| 1995 || {{w|Gene editing}} || Company launch || {{w|Dharmacon}} is founded by Stephen Scaringe to develop and commercialize a new technology for {{w|RNA}} {{w|oligonucleotide synthesis}}. <ref>{{cite web |title=Dharmacon |url=https://dbpedia.org/page/Dharmacon |website=dbpedia.org |access-date=9 February 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 1995 (December 29) || || Fund launch || T. Rowe Price Health Sciences Fund ({{w|ticker symbol}} PRHSX) is launched in the United States.<ref>{{cite web |title=T. Rowe Price Health Sciences Fund, PRHSX summary - FT.com |url=https://markets.ft.com/data/funds/tearsheet/summary?s=PRHSX |website=markets.ft.com |access-date=1 July 2022}}</ref> It invests in companies that research, develop, produce, or distribute of health-related products and services.<ref>{{cite web |title=PRHSX {{!}} T Rowe Price Health Sciences Fund Overview |url=https://www.marketwatch.com/investing/fund/prhsx |website=MarketWatch |access-date=8 July 2022 |language=en}}</ref> ||{{w|United States}}
 
|-
 
|-
 
| 1996 || {{w|Genealogy}}, {{w|Genetic genealogy}}, {{w|Online publishing}}, {{w|Software publishing}} || Company launch || {{w|Ancestry.com}} is launched.<ref>{{cite web |title=Ancestry celebrates 25 years! |url=https://www.ancestry.com/corporate/blog/ancestry-celebrates-25-years |website=www.ancestry.com |access-date=20 February 2022 |language=en}}</ref> Based in {{w|Lehi, Utah}}, it is the world's largest provider of DNA services.<ref>{{cite web |title=Blackstone to acquire Ancestry.com for $4.7 billion |url=https://www.reuters.com/article/us-ancestry-m-a-blackstonegroup-idCAKBN25K0R4 |website=Reuters |access-date=17 May 2022 |language=en |date=24 August 2020}}</ref> || {{w|United States}}
 
| 1996 || {{w|Genealogy}}, {{w|Genetic genealogy}}, {{w|Online publishing}}, {{w|Software publishing}} || Company launch || {{w|Ancestry.com}} is launched.<ref>{{cite web |title=Ancestry celebrates 25 years! |url=https://www.ancestry.com/corporate/blog/ancestry-celebrates-25-years |website=www.ancestry.com |access-date=20 February 2022 |language=en}}</ref> Based in {{w|Lehi, Utah}}, it is the world's largest provider of DNA services.<ref>{{cite web |title=Blackstone to acquire Ancestry.com for $4.7 billion |url=https://www.reuters.com/article/us-ancestry-m-a-blackstonegroup-idCAKBN25K0R4 |website=Reuters |access-date=17 May 2022 |language=en |date=24 August 2020}}</ref> || {{w|United States}}
Line 238: Line 219:
 
| 1996 || || Concept development || Persidis describes bioentrepreneurship as the wealth creation derived from the application of the biosciences to the business context. "Bioentrepreneurs look for commercial value in every aspect of technology that they utilize. Innovativeness is vital to the creation of a biotechnology venture while credibility remains the backbone of the bioentrepreneur’s character."<ref name="Kapeleris">{{cite book |last1=Hine |first1=Damian |last2=Kapeleris |first2=John |title=Innovation and Entrepreneurship in Biotechnology, an International Perspective: Concepts, Theories and Cases |date=1 January 2006 |publisher=Edward Elgar Publishing |isbn=978-1-84542-885-3 |url=https://books.google.com.ar/books/about/Innovation_and_Entrepreneurship_in_Biote.html?id=uFi9yzdcHpsC&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
| 1996 || || Concept development || Persidis describes bioentrepreneurship as the wealth creation derived from the application of the biosciences to the business context. "Bioentrepreneurs look for commercial value in every aspect of technology that they utilize. Innovativeness is vital to the creation of a biotechnology venture while credibility remains the backbone of the bioentrepreneur’s character."<ref name="Kapeleris">{{cite book |last1=Hine |first1=Damian |last2=Kapeleris |first2=John |title=Innovation and Entrepreneurship in Biotechnology, an International Perspective: Concepts, Theories and Cases |date=1 January 2006 |publisher=Edward Elgar Publishing |isbn=978-1-84542-885-3 |url=https://books.google.com.ar/books/about/Innovation_and_Entrepreneurship_in_Biote.html?id=uFi9yzdcHpsC&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
−
| 1996 || {{w|Biotechnology}} || Company launch || {{w|Bharat Biotech}} is founded.<ref>{{cite web |title=History & Milestones - Bharat Biotech - A Leading Biotech Company |url=https://www.bharatbiotech.com/history_milestones.html |website=www.bharatbiotech.com |access-date=21 February 2022}}</ref> Based in {{w|Hyderabad}}, it has one of the largest pharmaceutical manufacturing plants of its kind in Asia-Pacific. Bharat Biotech specializes in product-oriented research and development leading to the manufacture of vaccines and biotherapeutics with global IPR’s associated to its products.<ref>{{cite web |title=Bharat Biotech |url=https://www.devex.com/organizations/bharat-biotech-29493 |website=devex |access-date=6 April 2022}}</ref> || {{w|India}}
+
| 1996 || {{w|Vaccine}}s, {{w|biopharmaceutical}} || Company launch || {{w|Bharat Biotech}} is founded.<ref>{{cite web |title=History & Milestones - Bharat Biotech - A Leading Biotech Company |url=https://www.bharatbiotech.com/history_milestones.html |website=www.bharatbiotech.com |access-date=21 February 2022}}</ref> Based in {{w|Hyderabad}}, it has one of the largest pharmaceutical manufacturing plants of its kind in Asia-Pacific. Bharat Biotech specializes in product-oriented research and development leading to the manufacture of vaccines and biotherapeutics with global IPR’s associated to its products.<ref>{{cite web |title=Bharat Biotech |url=https://www.devex.com/organizations/bharat-biotech-29493 |website=devex |access-date=6 April 2022}}</ref> || {{w|India}}
 
|-
 
|-
 
| 1996 || {{w|Genetic engineering}} || Background || The first genetically engineered crop is launched to the market.<ref name=dhShimasaki/> ||
 
| 1996 || {{w|Genetic engineering}} || Background || The first genetically engineered crop is launched to the market.<ref name=dhShimasaki/> ||
 +
|-
 +
| 1996 || {{w|Healthcare}}, {{w|medical}}, {{w|therapeutics}} || Notable {{w|IPO}} || {{w|Alexion Pharmaceuticals}} completes an initial public offering of 2,530,000 shares of common stock, trading as ALXN on {{w|Nasdaq}}.<ref>{{cite web |title=Alexion Pharmaceuticals |url=https://ir.alexion.com/node/11696/html |website=alexion |access-date=2 June 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1996 || {{w|Genetics}} || Background || A gene associated with {{w|Parkinson’s disease}} is discovered by {{w|National Institutes of Health}} scientists, in collaboration with researchers from the UMDNJ-{{w|Robert Wood Johnson Medical School}} and the Istituto de Scienze Neurologiche in Naples, Italy.<ref>{{cite web |title=Scientists Locate Parkinson's Gene |url=https://www.genome.gov/10000485/1996-release-parkinsons-disease-gene#:~:text=November%201996,capable%20of%20causing%20the%20disease. |website=Genome.gov |access-date=19 May 2022 |language=en}}</ref><ref name=dhShimasaki/> || {{w|United States}}, {{w|Italy}}
 
| 1996 || {{w|Genetics}} || Background || A gene associated with {{w|Parkinson’s disease}} is discovered by {{w|National Institutes of Health}} scientists, in collaboration with researchers from the UMDNJ-{{w|Robert Wood Johnson Medical School}} and the Istituto de Scienze Neurologiche in Naples, Italy.<ref>{{cite web |title=Scientists Locate Parkinson's Gene |url=https://www.genome.gov/10000485/1996-release-parkinsons-disease-gene#:~:text=November%201996,capable%20of%20causing%20the%20disease. |website=Genome.gov |access-date=19 May 2022 |language=en}}</ref><ref name=dhShimasaki/> || {{w|United States}}, {{w|Italy}}
Line 246: Line 229:
 
| 1996 || {{w|Genetics}} || Company launch || {{w|deCODE genetics}} is founded.<ref>{{cite web |title=Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics |url=https://www.decode.com/amgen-to-acquire-decode-genetics-a-global-leader-in-human-genetics/ |website=deCODE genetics |access-date=22 February 2022 |date=12 December 2012}}</ref> by {{w|Kári Stefánsson}} and colleagues with the aim of using population genetics studies to identify variations in the human genome associated with common diseases, and to apply these discoveries "to develop novel methods to identify, treat and prevent diseases."<ref>{{cite web |title=Icelandic Genomics Company Identifies Location of Gene for Essential Tremor |url=https://www.decode.com/icelandic-genomics-company-identifies-location-of-gene-for-essential-tremor/ |website=deCODE genetics |access-date=14 March 2022 |date=25 August 1997}}</ref> || {{w|Iceland}}
 
| 1996 || {{w|Genetics}} || Company launch || {{w|deCODE genetics}} is founded.<ref>{{cite web |title=Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics |url=https://www.decode.com/amgen-to-acquire-decode-genetics-a-global-leader-in-human-genetics/ |website=deCODE genetics |access-date=22 February 2022 |date=12 December 2012}}</ref> by {{w|Kári Stefánsson}} and colleagues with the aim of using population genetics studies to identify variations in the human genome associated with common diseases, and to apply these discoveries "to develop novel methods to identify, treat and prevent diseases."<ref>{{cite web |title=Icelandic Genomics Company Identifies Location of Gene for Essential Tremor |url=https://www.decode.com/icelandic-genomics-company-identifies-location-of-gene-for-essential-tremor/ |website=deCODE genetics |access-date=14 March 2022 |date=25 August 1997}}</ref> || {{w|Iceland}}
 
|-
 
|-
−
| 1996 || {{w|Biotechnology}} || Company launch || {{w|Ceres, Inc.}} is founded.<ref>{{cite web |title=Ceres, Inc. |url=https://www.agropages.com/companydirectory/Detail-14587.htm |website=Grainews |access-date=23 February 2022 |language=en |date=23 February 2022}}</ref> A provider of seeds of genetically modified crops used for biofuel production<ref>{{cite journal |last1=Lee |first1=David |last2=Chen |first2=Alice |last3=Nair |first3=Ramesh |title=Genetically Engineered Crops for Biofuel Production: Regulatory Perspectives |journal=Biotechnology and Genetic Engineering Reviews |date=January 2008 |volume=25 |issue=1 |pages=331–362 |doi=10.5661/bger-25-331}}</ref>, in 2016 it would be acquired by Land O'Lakes.<ref>{{cite web |title=Land O’Lakes, Inc. to Acquire Ceres, Inc. in Cash Tender Offer |url=https://www.landolakesinc.com/lolinc/media/Pdf/Press%20Releases/2016/6-17-16.pdf |website=landolakesinc |access-date=6 April 2022}}</ref>
+
| 1996 || {{w|Genetically modified crops}} || Company launch || {{w|Ceres, Inc.}} is founded.<ref>{{cite web |title=Ceres, Inc. |url=https://www.agropages.com/companydirectory/Detail-14587.htm |website=Grainews |access-date=23 February 2022 |language=en |date=23 February 2022}}</ref> Based in {{w|Thousand Oaks, California}}, it is a provider of seeds of genetically modified crops used for biofuel production<ref>{{cite journal |last1=Lee |first1=David |last2=Chen |first2=Alice |last3=Nair |first3=Ramesh |title=Genetically Engineered Crops for Biofuel Production: Regulatory Perspectives |journal=Biotechnology and Genetic Engineering Reviews |date=January 2008 |volume=25 |issue=1 |pages=331–362 |doi=10.5661/bger-25-331}}</ref>, in 2016 it would be acquired by Land O'Lakes.<ref>{{cite web |title=Land O’Lakes, Inc. to Acquire Ceres, Inc. in Cash Tender Offer |url=https://www.landolakesinc.com/lolinc/media/Pdf/Press%20Releases/2016/6-17-16.pdf |website=landolakesinc |access-date=6 April 2022}}</ref>
 
|-
 
|-
−
| 1996 (November) || {{w|Biotechnology}} || Company launch || {{w|Helixmith}} is founded.<ref>{{cite web |title=Helixmith - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/helixmith |website=Crunchbase |access-date=23 February 2022 |language=en}}</ref> Based in {{w|Seoul}}, it develops biopharmaceuticals for untreated diseases. Helixmith has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an {{w|adeno-associated virus}} vector program targeting neuromuscular diseases.<ref>{{cite web |title=LinkedIn Login, Sign in |url=https://www.linkedin.com/company/helixmith/about/ |website=LinkedIn |access-date=18 May 2022}}</ref> || {{w|South Korea}}
+
| 1996 (November) || {{w|Biopharmaceutical}} || Company launch || {{w|Helixmith}} is founded.<ref>{{cite web |title=Helixmith - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/helixmith |website=Crunchbase |access-date=23 February 2022 |language=en}}</ref> Based in {{w|Seoul}}, it develops biopharmaceuticals for untreated diseases. Helixmith has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an {{w|adeno-associated virus}} vector program targeting neuromuscular diseases.<ref>{{cite web |title=LinkedIn Login, Sign in |url=https://www.linkedin.com/company/helixmith/about/ |website=LinkedIn |access-date=18 May 2022}}</ref> || {{w|South Korea}}
 
|-
 
|-
−
| 1996 || {{w|Biotechnology}} || Company launch || {{w|United Therapeutics}} is founded.<ref>{{cite web |title=TYVASO® (treprostinil), an inhaled prostacyclin |url=https://www.tyvaso.com/pah/pah-prostacyclin/united-therapeutics/ |website=www.tyvaso.com |access-date=25 February 2022 |language=en}}</ref> Based in {{w|Silver Spring, Maryland}}, it develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension, and infectious diseases.<ref>{{cite web |title=ShieldSquare Captcha |url=https://www.globaldata.com/company-profile/united-therapeutics-corp/ |website=www.globaldata.com |access-date=18 May 2022 |language=en}}</ref> || {{w|United States}}
+
| 1996 || {{w|Pharmaceutical}} || Company launch || {{w|United Therapeutics}} is founded.<ref>{{cite web |title=TYVASO® (treprostinil), an inhaled prostacyclin |url=https://www.tyvaso.com/pah/pah-prostacyclin/united-therapeutics/ |website=www.tyvaso.com |access-date=25 February 2022 |language=en}}</ref> Based in {{w|Silver Spring, Maryland}}, it develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension, and infectious diseases.<ref>{{cite web |title=ShieldSquare Captcha |url=https://www.globaldata.com/company-profile/united-therapeutics-corp/ |website=www.globaldata.com |access-date=18 May 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1997 || {{w|Radiopharmaceutical}}s, {{w|oncology}} || Company launch || {{w|Algeta}} is founded.<ref>{{cite web |title=Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone Met |url=https://www.fiercebiotech.com/biotech/algeta-signs-800-million-eur560m-global-agreement-bayer-for-development-and |website=Fierce Biotech |access-date=26 February 2022 |language=en |date=3 September 2009}}</ref> It is a Norwegian therapeutics company focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer. Algeta targets metastatic and disseminated tumor types for which there is substantial unmet medical need.<ref>{{cite web |title=Algeta ASA - Oslo, Norway |url=https://www.bionity.com/en/companies/14523/algeta-asa.html#:~:text=Algeta%20is%20a%20Norwegian%20therapeutics,is%20substantial%20unmet%20medical%20need. |website=www.bionity.com |access-date=10 May 2022 |language=en}}</ref> || {{w|Norway}}
 
| 1997 || {{w|Radiopharmaceutical}}s, {{w|oncology}} || Company launch || {{w|Algeta}} is founded.<ref>{{cite web |title=Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone Met |url=https://www.fiercebiotech.com/biotech/algeta-signs-800-million-eur560m-global-agreement-bayer-for-development-and |website=Fierce Biotech |access-date=26 February 2022 |language=en |date=3 September 2009}}</ref> It is a Norwegian therapeutics company focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer. Algeta targets metastatic and disseminated tumor types for which there is substantial unmet medical need.<ref>{{cite web |title=Algeta ASA - Oslo, Norway |url=https://www.bionity.com/en/companies/14523/algeta-asa.html#:~:text=Algeta%20is%20a%20Norwegian%20therapeutics,is%20substantial%20unmet%20medical%20need. |website=www.bionity.com |access-date=10 May 2022 |language=en}}</ref> || {{w|Norway}}
Line 262: Line 245:
 
| 1997 || {{w|Biopharmaceutical}}s, {{w|RNA interference}} || Company launch || {{w|Benitec Biopharma}} is founded.<ref>{{cite web |title=Benitec Biopharma Inc (BNTC) Stock Price & News - Google Finance |url=https://www.google.com/finance/quote/BNTC:NASDAQ?hl=en |website=www.google.com |access-date=3 March 2022 |language=en}}</ref> Based in {{w|Melbourne}}, it focuses on the development of novel genetic medicines.<ref>{{cite web |title=BENITEC BIOPHARMA LIMITED |url=https://benitec.com/wp-content/uploads/2019/09/20180830-Appendix4Eand2018AnnualReport.pdf |website=benitec |access-date=19 May 2022}}</ref> || {{w|Australia}}
 
| 1997 || {{w|Biopharmaceutical}}s, {{w|RNA interference}} || Company launch || {{w|Benitec Biopharma}} is founded.<ref>{{cite web |title=Benitec Biopharma Inc (BNTC) Stock Price & News - Google Finance |url=https://www.google.com/finance/quote/BNTC:NASDAQ?hl=en |website=www.google.com |access-date=3 March 2022 |language=en}}</ref> Based in {{w|Melbourne}}, it focuses on the development of novel genetic medicines.<ref>{{cite web |title=BENITEC BIOPHARMA LIMITED |url=https://benitec.com/wp-content/uploads/2019/09/20180830-Appendix4Eand2018AnnualReport.pdf |website=benitec |access-date=19 May 2022}}</ref> || {{w|Australia}}
 
|-
 
|-
−
| 1997 || {{w|Biotechnology}} || Company launch || {{w|Biolex}} is founded. Focused on expression of difficult-to-synthesize recombinant proteins, it would file for  [[w:Chapter 7, Title 11, United States Code|Chapter 7 bankruptcy]] on July 5, 2012.<ref>{{cite web |title=Biolex Therapeutics files for $38M bankruptcy |url=https://www.bizjournals.com/triangle/blog/2012/07/biolex-therapeutics-files-for-38m.html |website=www.bizjournals.com |access-date=28 January 2022}}</ref> || {{w|United States}}
+
| 1997 || Recombinant proteins || Company launch || {{w|Biolex}} is founded. Focused on expression of difficult-to-synthesize recombinant proteins, it would file for  [[w:Chapter 7, Title 11, United States Code|Chapter 7 bankruptcy]] on July 5, 2012.<ref>{{cite web |title=Biolex Therapeutics files for $38M bankruptcy |url=https://www.bizjournals.com/triangle/blog/2012/07/biolex-therapeutics-files-for-38m.html |website=www.bizjournals.com |access-date=28 January 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1997 (March) || {{w|Biopharmaceutical}}s || Company launch || {{w|BioMarin Pharmaceutical}} is founded.<ref>{{cite web |title=BioMarin Pharmaceutical History: Founding, Timeline, and Milestones |url=https://www.zippia.com/biomarin-pharmaceutical-careers-1531/history/ |website=www.zippia.com |access-date=28 February 2022 |date=27 August 2020}}</ref> It is a biotechnology company that develops and commercializes therapies for individuals with serious lifethreatening rare diseases and medical conditions.<ref>{{cite web |title=Is BioMarin Pharmaceutical (BMRN) Stock a Buy For 2021? |url=https://finance.yahoo.com/news/biomarin-pharmaceutical-bmrn-stock-buy-134244622.html#:~:text=%22BioMarin%20Pharmaceutical%20is%20a%20biotechnology,rare%20diseases%20and%20medical%20conditions. |website=finance.yahoo.com |access-date=13 April 2022}}</ref> || {{w|United States}}
 
| 1997 (March) || {{w|Biopharmaceutical}}s || Company launch || {{w|BioMarin Pharmaceutical}} is founded.<ref>{{cite web |title=BioMarin Pharmaceutical History: Founding, Timeline, and Milestones |url=https://www.zippia.com/biomarin-pharmaceutical-careers-1531/history/ |website=www.zippia.com |access-date=28 February 2022 |date=27 August 2020}}</ref> It is a biotechnology company that develops and commercializes therapies for individuals with serious lifethreatening rare diseases and medical conditions.<ref>{{cite web |title=Is BioMarin Pharmaceutical (BMRN) Stock a Buy For 2021? |url=https://finance.yahoo.com/news/biomarin-pharmaceutical-bmrn-stock-buy-134244622.html#:~:text=%22BioMarin%20Pharmaceutical%20is%20a%20biotechnology,rare%20diseases%20and%20medical%20conditions. |website=finance.yahoo.com |access-date=13 April 2022}}</ref> || {{w|United States}}
Line 281: Line 264:
 
|-
 
|-
 
| 1997 || {{w|Oncology}} || Company launch || {{w|Seagen}} is founded.<ref>{{cite web |title=Seagen Inc. » Ninety Nine |url=https://ninetynine.com/compra-acciones-seagen/ |website=Ninety Nine |access-date=3 March 2022 |language=es}}</ref> Based in {{w|Bothell, Washington}}, it is a global biotechnology company that develops and commercializes transformative cancer therapies.<ref>{{cite web |title=Our Mission, Vision, and Values – Seagen |url=https://www.seagen.com/who-we-are#:~:text=Seagen%20is%20a%20global%20biotechnology%20company%20that%20develops%20and%20commercializes,for%20people%20impacted%20by%20cancer. |website=www.seagen.com |access-date=13 May 2022 |language=en}}</ref> || {{w|United States}}
 
| 1997 || {{w|Oncology}} || Company launch || {{w|Seagen}} is founded.<ref>{{cite web |title=Seagen Inc. » Ninety Nine |url=https://ninetynine.com/compra-acciones-seagen/ |website=Ninety Nine |access-date=3 March 2022 |language=es}}</ref> Based in {{w|Bothell, Washington}}, it is a global biotechnology company that develops and commercializes transformative cancer therapies.<ref>{{cite web |title=Our Mission, Vision, and Values – Seagen |url=https://www.seagen.com/who-we-are#:~:text=Seagen%20is%20a%20global%20biotechnology%20company%20that%20develops%20and%20commercializes,for%20people%20impacted%20by%20cancer. |website=www.seagen.com |access-date=13 May 2022 |language=en}}</ref> || {{w|United States}}
 +
|-
 +
| 1997 (September 15) || || Fund launch || Franklin Biotechnology Discovery Fund Class A ({{w|ticker symbol}} FBDIX) is launched in the United States.<ref>{{cite web |title=Franklin Biotechnology Discovery Fund Class A, FBDIX summary - FT.com |url=https://markets.ft.com/data/funds/tearsheet/summary?s=FBDIX |website=markets.ft.com |access-date=1 July 2022}}</ref> It invests principally in equity securities of biotechnology companies and discovery research firms mainly located in the United States.<ref>{{cite web |title=https://www.franklintempleton.lu/our-funds/price-and-performance/products/4912/Z/franklin-biotechnology-discovery-fund/LU0109394709 |url=https://www.franklintempleton.lu/our-funds/price-and-performance/products/4912/Z/franklin-biotechnology-discovery-fund/LU0109394709 |website=www.franklintempleton.lu |access-date=7 July 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1997 || {{w|Pharmaceutical}}, {{w|biotechnology}} || Company launch || {{w|Actelion}} is founded.<ref>{{cite web |title=Actelion Ltd {{!}} Encyclopedia.com |url=https://www.encyclopedia.com/books/politics-and-business-magazines/actelion-ltd |website=www.encyclopedia.com |access-date=3 March 2022}}</ref> Based in {{w|Allschwil}}, {{w|Switzerland}}, it is a pharmaceuticals and biotechnology company established focusing on the manufacture of drugs that treat rare diseases and orphan diseases.<ref>{{cite web |title=About: Actelion |url=https://dbpedia.org/page/Actelion#:~:text=Actelion%20is%20a%20pharmaceuticals%20and,rare%20diseases%20and%20orphan%20diseases. |website=dbpedia.org |access-date=13 May 2022}}</ref> || {{w|Switzerland}}
 
| 1997 || {{w|Pharmaceutical}}, {{w|biotechnology}} || Company launch || {{w|Actelion}} is founded.<ref>{{cite web |title=Actelion Ltd {{!}} Encyclopedia.com |url=https://www.encyclopedia.com/books/politics-and-business-magazines/actelion-ltd |website=www.encyclopedia.com |access-date=3 March 2022}}</ref> Based in {{w|Allschwil}}, {{w|Switzerland}}, it is a pharmaceuticals and biotechnology company established focusing on the manufacture of drugs that treat rare diseases and orphan diseases.<ref>{{cite web |title=About: Actelion |url=https://dbpedia.org/page/Actelion#:~:text=Actelion%20is%20a%20pharmaceuticals%20and,rare%20diseases%20and%20orphan%20diseases. |website=dbpedia.org |access-date=13 May 2022}}</ref> || {{w|Switzerland}}
Line 302: Line 287:
 
| 1998 || {{w|DNA sequencing}} || Company launch || {{w|Celera Corporation}} is founded.<ref>{{cite web |title=Celera Genomics {{!}} American company {{!}} Britannica |url=https://www.britannica.com/topic/Celera-Genomics |website=www.britannica.com |access-date=3 March 2022 |language=en}}</ref> Based in {{w|Alameda, California}}, it focuses on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries.<ref>{{cite web |title=Form 10-K |url=https://www.sec.gov/Archives/edgar/data/1428156/000119312511070267/d10k.htm |website=www.sec.gov |access-date=17 May 2022}}</ref> || {{w|United States}}
 
| 1998 || {{w|DNA sequencing}} || Company launch || {{w|Celera Corporation}} is founded.<ref>{{cite web |title=Celera Genomics {{!}} American company {{!}} Britannica |url=https://www.britannica.com/topic/Celera-Genomics |website=www.britannica.com |access-date=3 March 2022 |language=en}}</ref> Based in {{w|Alameda, California}}, it focuses on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries.<ref>{{cite web |title=Form 10-K |url=https://www.sec.gov/Archives/edgar/data/1428156/000119312511070267/d10k.htm |website=www.sec.gov |access-date=17 May 2022}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 1998 || {{w|Agricultural biotechnology}} || Company launch || {{w|CropDesign}} is founded. Based in {{w|Ghent}}, {{w|Belgium}}, it is a agricultural biotech company that offers crops like corn and rice to the seed market.<ref>{{cite web |title=CropDesign - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/cropdesign |website=Crunchbase |access-date=3 March 2022 |language=en}}</ref> || {{w|Belgium}}
+
| 1998 || {{w|Agricultural biotechnology}} || Company launch || {{w|CropDesign}} is founded. Based in {{w|Ghent}}, {{w|Belgium}}, it is an agricultural biotechnology company that offers crops like corn and rice to the seed market.<ref>{{cite web |title=CropDesign - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/cropdesign |website=Crunchbase |access-date=3 March 2022 |language=en}}</ref> || {{w|Belgium}}
 
|-
 
|-
 
| 1998 (September 5) || {{w|Vaccine}}s, {{w|antibodies}} || Company launch || {{w|Emergent BioSolutions}} is founded.<ref>{{cite web |title=EMERGENT BioSolutions Inc.: A Lodestone Amongst Pebbles—Addressing Public Health Through Vaccines |url=https://www.nature.com/articles/d42473-020-00390-8 |website=nature.com |access-date=3 March 2022 |language=en}}</ref> Based in {{w|Gaithersburg, Maryland}}, it develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats.<ref name="Emergent Bio">{{cite web |title=Emergent BioSolutions - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/emergent-biosolutions |website=Crunchbase |access-date=6 May 2022 |language=en}}</ref> || {{w|United States}}
 
| 1998 (September 5) || {{w|Vaccine}}s, {{w|antibodies}} || Company launch || {{w|Emergent BioSolutions}} is founded.<ref>{{cite web |title=EMERGENT BioSolutions Inc.: A Lodestone Amongst Pebbles—Addressing Public Health Through Vaccines |url=https://www.nature.com/articles/d42473-020-00390-8 |website=nature.com |access-date=3 March 2022 |language=en}}</ref> Based in {{w|Gaithersburg, Maryland}}, it develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats.<ref name="Emergent Bio">{{cite web |title=Emergent BioSolutions - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/emergent-biosolutions |website=Crunchbase |access-date=6 May 2022 |language=en}}</ref> || {{w|United States}}
Line 332: Line 317:
 
| 1999 || Diagnostics || Background || A diagnostic test is introduced for the quick identification of {{w|bovine spongicorm encephalopathy}} and {{w|Creutzfeldt-Jakob disease}}.<ref name=dhShimasaki/>
 
| 1999 || Diagnostics || Background || A diagnostic test is introduced for the quick identification of {{w|bovine spongicorm encephalopathy}} and {{w|Creutzfeldt-Jakob disease}}.<ref name=dhShimasaki/>
 
|-
 
|-
−
| 1999 || {{w|Biosimilar}}s, {{w|biopharmaceutical}}s || Company launch || {{w|Celltrion}} is founded.<ref>{{cite web |title=091990 {{!}} Celltrion Healthcare Co. Ltd. Stock Overview (S. Korea: KRX) |url=https://www.barrons.com/market-data/stocks/091990?countryCode=kr&mod=quotes |website=Barron's |access-date=3 March 2022 |language=en}}</ref> It is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals.|| {{w|South Korea}}
+
| 1999 || {{w|Biosimilar}}s, {{w|biopharmaceutical}}s || Company launch || {{w|Celltrion}} is founded.<ref>{{cite web |title=091990 {{!}} Celltrion Healthcare Co. Ltd. Stock Overview (S. Korea: KRX) |url=https://www.barrons.com/market-data/stocks/091990?countryCode=kr&mod=quotes |website=Barron's |access-date=3 March 2022 |language=en}}</ref> It is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. || {{w|South Korea}}
 +
|-
 +
| 1999 (June 17) || Pharmaceutical, therapeutics || Notable {{w|IPO}} || {{w|United Therapeutics}} completes its IPO, trading under ticket UTHR on {{w|Nasdaq}}.<ref>{{cite web |title=Stock Information {{!}} United Therapeutics Corporation |url=https://ir.unither.com/stock-info/default.aspx#:~:text=United%20Therapeutics%20made%20its%20initial%20public%20offering%20on%20June%2017%2C%201999. |website=ir.unither.com |access-date=2 June 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 1999 (June 30) || || Fund launch || PGIM Jennison Health Sciences Fund- Class A ({{w|ticker symbol}} PHLAX) is launched in the United States.<ref>{{cite web |title=PGIM Jennison Health Sciences Fund- Class A, PHLAX summary - FT.com |url=https://markets.ft.com/data/funds/tearsheet/summary?s=PHLAX |website=markets.ft.com |access-date=1 July 2022}}</ref> It mostly invests in companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations.<ref>{{cite web |title=PGIM Jennison Health Sciences Fund (PHLAX) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/PHLAX?p=PHLAX&.tsrc=fin-srch |website=finance.yahoo.com |access-date=8 July 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 1999 (July 23) || Developer platform || Notable {{w|IPO}} || {{w|BioMarin Pharmaceutical}} completes its IPO, trading under ticket BMRN on {{w|Nasdaq}}.<ref>{{cite web |title=BioMarin Pharmaceutical - Funding, Financials, Valuation & Investors |url=https://www.crunchbase.com/organization/biomarin-pharmaceutical/company_financials#:~:text=Stock%20Price%20Section-,BioMarin%20Pharmaceutical%20is%20registered%20under%20the%20ticker%20NASDAQ%3ABMRN%20.,its%20Jul%2023%2C%201999%20IPO. |website=Crunchbase |access-date=2 June 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 1999 || {{w|Dietary supplement}}s, food ingredients || Company launch || {{w|ChromaDex}} is founded.<ref>{{cite web |title=About: ChromaDex |url=https://dbpedia.org/page/ChromaDex |website=dbpedia.org |access-date=3 March 2022}}</ref> Based in Los Angeles, California, it is a dietary supplement and food ingredient company.<ref>{{cite web |title=ChromaDex |url=https://www.nutraceuticalsworld.com/buyersguide/profile/chromadex/ |website=Nutraceuticals World |access-date=19 May 2022}}</ref> || {{w|United States}}
 
| 1999 || {{w|Dietary supplement}}s, food ingredients || Company launch || {{w|ChromaDex}} is founded.<ref>{{cite web |title=About: ChromaDex |url=https://dbpedia.org/page/ChromaDex |website=dbpedia.org |access-date=3 March 2022}}</ref> Based in Los Angeles, California, it is a dietary supplement and food ingredient company.<ref>{{cite web |title=ChromaDex |url=https://www.nutraceuticalsworld.com/buyersguide/profile/chromadex/ |website=Nutraceuticals World |access-date=19 May 2022}}</ref> || {{w|United States}}
Line 359: Line 350:
 
|-
 
|-
 
| 2000 || Pharmaceutical<ref>{{cite web |title=GlaxoSmithKline - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/glaxosmithkline |website=Crunchbase |access-date=6 May 2022 |language=en}}</ref> || Company launch || {{w|GlaxoSmithKline}} is founded.<ref>{{cite web |title=GSK today: 2000 – present {{!}} GSK |url=https://www.gsk.com/en-gb/about-us/our-history/gsk-today-2000-present/ |website=www.gsk.com |access-date=4 March 2022}}</ref> Based in {{w|London}}, it is one of the world's largest pharmaceutical companies.<ref>{{cite web |last1=CONTRERAS" |first1="ANDREA MURPHY"," ISABEL |title=The Global 2000 2022 |url=https://www.forbes.com/lists/global2000/?sh=4a0a79485ac0#industry:Pharmaceuticals |website=Forbes |access-date=17 May 2022 |language=en}}</ref> || {{w|United Kingdom}}
 
| 2000 || Pharmaceutical<ref>{{cite web |title=GlaxoSmithKline - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/glaxosmithkline |website=Crunchbase |access-date=6 May 2022 |language=en}}</ref> || Company launch || {{w|GlaxoSmithKline}} is founded.<ref>{{cite web |title=GSK today: 2000 – present {{!}} GSK |url=https://www.gsk.com/en-gb/about-us/our-history/gsk-today-2000-present/ |website=www.gsk.com |access-date=4 March 2022}}</ref> Based in {{w|London}}, it is one of the world's largest pharmaceutical companies.<ref>{{cite web |last1=CONTRERAS" |first1="ANDREA MURPHY"," ISABEL |title=The Global 2000 2022 |url=https://www.forbes.com/lists/global2000/?sh=4a0a79485ac0#industry:Pharmaceuticals |website=Forbes |access-date=17 May 2022 |language=en}}</ref> || {{w|United Kingdom}}
 +
|-
 +
| 2000 (June) || {{w|DNA sequencing}} || Company launch || {{w|454 Life Sciences}} is established.<ref>{{cite web |last1=Margulies |first1=Marcel |title=Genome Sequencing in Open Microfabricated High Density Picoliter Reactors |url=https://www.bionity.com/en/encyclopedia/454_Life_Sciences.html |website=Nature |access-date=4 March 2022 |pages=376&ndash;380 |doi=10.1038/nature03959 |date=15 September 2005}}</ref> Based in {{w|Branford, Connecticut}}, it specializes in high-throughput DNA sequencing using a novel massively parallel sequencing-by-synthesis approach.<ref>{{cite web |last1=Margulies |first1=Marcel |title=Genome Sequencing in Open Microfabricated High Density Picoliter Reactors |url=https://www.bionity.com/en/encyclopedia/454_Life_Sciences.html |website=Nature |access-date=29 March 2022 |pages=376&ndash;380 |doi=10.1038/nature03959 |date=15 September 2005}}</ref> || {{w|United States}}
 +
|-
 +
| 2000 (June) || || Background || Scientists at {{w|Celera Genomics}} and the {{w|Human Genome Project}} complete a rough draft of the {{w|human genome}}.<ref>{{cite web |title=Scientists Complete Rough Draft of Human Genome |url=https://archive.nytimes.com/www.nytimes.com/library/national/science/062600sci-human-genome.html |website=archive.nytimes.com |access-date=8 July 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 2000 (July 28) || {{w|Sequencing}}, {{w|genotyping}}, {{w|gene expression}}, {{w|proteomics}} || Notable {{w|IPO}} || {{w|Illumina, Inc.}} completes its initial public offering, trading as ILMN.<ref>{{cite web |title=Illumina, Inc. - Resources |url=https://investor.illumina.com/resources/default.aspx |website=investor.illumina.com |access-date=2 June 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2000 (October) || {{w|Biopharmaceutical}}s || Company launch || {{w|Renovo plc}} is founded.<ref>{{cite web |title=Renovo; biopharmaceutical product company |url=https://www.ukessays.com/essays/business/renovo.php |website=www.ukessays.com |access-date=4 March 2022 |language=en}}</ref> Focused  in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration,<ref>{{cite web |title=LRMN January 2007 Meeting |url=https://web.archive.org/web/20070928140859/http://www.regenmednetwork.com/archive/january_2007_meeting/january_2007_meeting.html |website=web.archive.org |access-date=7 April 2022 |date=28 September 2007}}</ref> the company would be defunct by May 2011.<ref>{{cite web |last1=Grogan |first1=Kevin |title=Future bleak for Renovo with no workers or products |url=https://www.pharmatimes.com/news/future_bleak_for_renovo_with_no_workers_or_products_980961 |website=PharmaTimes |access-date=7 April 2022 |language=en |date=31 May 2011}}</ref> || {{w|United Kingdom}}
 
| 2000 (October) || {{w|Biopharmaceutical}}s || Company launch || {{w|Renovo plc}} is founded.<ref>{{cite web |title=Renovo; biopharmaceutical product company |url=https://www.ukessays.com/essays/business/renovo.php |website=www.ukessays.com |access-date=4 March 2022 |language=en}}</ref> Focused  in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration,<ref>{{cite web |title=LRMN January 2007 Meeting |url=https://web.archive.org/web/20070928140859/http://www.regenmednetwork.com/archive/january_2007_meeting/january_2007_meeting.html |website=web.archive.org |access-date=7 April 2022 |date=28 September 2007}}</ref> the company would be defunct by May 2011.<ref>{{cite web |last1=Grogan |first1=Kevin |title=Future bleak for Renovo with no workers or products |url=https://www.pharmatimes.com/news/future_bleak_for_renovo_with_no_workers_or_products_980961 |website=PharmaTimes |access-date=7 April 2022 |language=en |date=31 May 2011}}</ref> || {{w|United Kingdom}}
Line 371: Line 368:
 
|-
 
|-
 
| 2000 || {{w|Oncology}} || Company launch || {{w|TopoTarget}} is founded.<ref>{{cite web |title=TopoTarget A/S - Kopenhagen, Denmark |url=https://www.bionity.com/en/companies/14440/topotarget-a-s.html |website=www.bionity.com |access-date=4 March 2022 |language=en}}</ref> It focuses on the discovery and development of drugs and therapies to treat cancer.<ref>{{cite web |title=Topotarget - Headquarter Locations, Competitors, Financials, Employees |url=https://www.cbinsights.com/company/topotarget |website=www.cbinsights.com}}</ref> || {{w|Denmark}}
 
| 2000 || {{w|Oncology}} || Company launch || {{w|TopoTarget}} is founded.<ref>{{cite web |title=TopoTarget A/S - Kopenhagen, Denmark |url=https://www.bionity.com/en/companies/14440/topotarget-a-s.html |website=www.bionity.com |access-date=4 March 2022 |language=en}}</ref> It focuses on the discovery and development of drugs and therapies to treat cancer.<ref>{{cite web |title=Topotarget - Headquarter Locations, Competitors, Financials, Employees |url=https://www.cbinsights.com/company/topotarget |website=www.cbinsights.com}}</ref> || {{w|Denmark}}
−
|-
 
−
| 2000 (June) || {{w|DNA sequencing}} || Company launch || {{w|454 Life Sciences}} is established.<ref>{{cite web |last1=Margulies |first1=Marcel |title=Genome Sequencing in Open Microfabricated High Density Picoliter Reactors |url=https://www.bionity.com/en/encyclopedia/454_Life_Sciences.html |website=Nature |access-date=4 March 2022 |pages=376&ndash;380 |doi=10.1038/nature03959 |date=15 September 2005}}</ref> Based in {{w|Branford, Connecticut}}, it specializes in high-throughput DNA sequencing using a novel massively parallel sequencing-by-synthesis approach.<ref>{{cite web |last1=Margulies |first1=Marcel |title=Genome Sequencing in Open Microfabricated High Density Picoliter Reactors |url=https://www.bionity.com/en/encyclopedia/454_Life_Sciences.html |website=Nature |access-date=29 March 2022 |pages=376&ndash;380 |doi=10.1038/nature03959 |date=15 September 2005}}</ref> || {{w|United States}}
 
 
|-
 
|-
 
| 2000 || || Research || R. Batterham recognizes that the biotechnology industry globally lacks in managers and researchers with appropriate entrepreneurial and commercial skills.<ref>Batterham, R. (2000), ''The Chance to Change'', Chief Scientist of Australia, Canberra, DISR.</ref> ||
 
| 2000 || || Research || R. Batterham recognizes that the biotechnology industry globally lacks in managers and researchers with appropriate entrepreneurial and commercial skills.<ref>Batterham, R. (2000), ''The Chance to Change'', Chief Scientist of Australia, Canberra, DISR.</ref> ||
Line 379: Line 374:
 
|-
 
|-
 
| 2000 || || Industry size || As of date, the biotechnology sector includes more than 4,600 companies around the world, of which more than 600 are publicly held.<ref name="Kaitin"/>
 
| 2000 || || Industry size || As of date, the biotechnology sector includes more than 4,600 companies around the world, of which more than 600 are publicly held.<ref name="Kaitin"/>
 +
|-
 +
| 2000 (December 15) || || Accelerator/incubator launch || The {{w|California Institute for Quantitative Biosciences}} (QB3) is founded as a nonprofit research and technology commercialization institute affiliated with three campuses of the University of California in the {{w|San Francisco Bay Area}}: [[w:UC Berkeley|Berkeley]], [[w:UCSF|San Francisco]], and [[w:UC Santa Cruz|Santa Cruz]]. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.<ref>{{cite web |title=QB3 |url=https://www.crunchbase.com/organization/california-institute-for-quantitative-biosciences |website=crunchbase |access-date=29 June 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 2000 (December 27) || Healthcare || Fund launch || Fidelity Advisor Biotechnology Fund Class A ({{w|ticker symbol}} FBTAX) is launched in the United States.<ref>{{cite web |title=Fidelity Advisor® Biotechnology Fund Class A, FBTAX summary - FT.com |url=https://markets.ft.com/data/funds/tearsheet/summary?s=FBTAX |website=markets.ft.com |access-date=1 July 2022}}</ref> It mostly invests in companies principally engaged in biotechnology, as well as companies that benefit significantly from scientific and technological advances in biotech.<ref>{{cite web |title=Fidelity Advisor Biotechnology Fund Class A (FBTAX) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/FBTAX?p=FBTAX&.tsrc=fin-srch |website=finance.yahoo.com |access-date=8 July 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2001 (January 1) || {{w|Antibodies}} ([[w:Primary antibodies|Primary and secondary]]) || Company launch || {{w|Abgent}} is founded. Based in {{w|San Diego, California}}, it manufactures primary antibodies.<ref>{{cite web |title=Abgent - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/abgent |website=Crunchbase |access-date=4 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2001 (January 1) || {{w|Antibodies}} ([[w:Primary antibodies|Primary and secondary]]) || Company launch || {{w|Abgent}} is founded. Based in {{w|San Diego, California}}, it manufactures primary antibodies.<ref>{{cite web |title=Abgent - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/abgent |website=Crunchbase |access-date=4 March 2022 |language=en}}</ref> || {{w|United States}}
Line 392: Line 391:
 
| 2001 || {{w|Gene targeting}} || Background || The United States FDA approves Gleevec, a genetargeted drug for patients with chronic myeloid leukemia. Gleevec is the first gene-targeted drug to receive FDA approval.<ref name=dhShimasaki/> || {{w|United States}}
 
| 2001 || {{w|Gene targeting}} || Background || The United States FDA approves Gleevec, a genetargeted drug for patients with chronic myeloid leukemia. Gleevec is the first gene-targeted drug to receive FDA approval.<ref name=dhShimasaki/> || {{w|United States}}
 
|-
 
|-
−
| 2001 (November) || {{w|Biotechnology}} || Company launch || {{w|Ablynx}} is founded.<ref>{{cite web |title=Ablynx {{!}} Invest Europe |url=https://www.investeurope.eu/about-private-equity/private-equity-in-action/ablynx/ |website=www.investeurope.euhttps |access-date=28 January 2022}}</ref> Acquired by {{w|Sanofi}} in January 2018 for $4.8 Billion<ref>{{cite web |title=Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion |url=https://fortune.com/2018/01/29/sanofi-ablynx-deal-caplacizumab/ |website=Fortune |access-date=28 January 2022 |language=en}}</ref>, it is engaged in the discovery and development of {{w|nanobodies}}. Ablynx is based in {{w|Ghent}}, {{w|Belgium}}.<ref>{{cite web |last1=Morrison |first1=Chris |title=Nanobody approval gives domain antibodies a boost |url=https://www.nature.com/articles/d41573-019-00104-w |website=Nature Reviews Drug Discovery |access-date=28 January 2022 |pages=485–487 |language=en |doi=10.1038/d41573-019-00104-w |date=12 June 2019}}</ref> || {{w|Belgium}}
+
| 2001 (November) || {{w|Nanomedicine}} || Company launch || {{w|Ablynx}} is founded.<ref>{{cite web |title=Ablynx {{!}} Invest Europe |url=https://www.investeurope.eu/about-private-equity/private-equity-in-action/ablynx/ |website=www.investeurope.euhttps |access-date=28 January 2022}}</ref> Acquired by {{w|Sanofi}} in January 2018 for $4.8 billion<ref>{{cite web |title=Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion |url=https://fortune.com/2018/01/29/sanofi-ablynx-deal-caplacizumab/ |website=Fortune |access-date=28 January 2022 |language=en}}</ref>, it is engaged in the discovery and development of {{w|nanobodies}}. Ablynx is based in {{w|Ghent}}, {{w|Belgium}}.<ref>{{cite web |last1=Morrison |first1=Chris |title=Nanobody approval gives domain antibodies a boost |url=https://www.nature.com/articles/d41573-019-00104-w |website=Nature Reviews Drug Discovery |access-date=28 January 2022 |pages=485–487 |language=en |doi=10.1038/d41573-019-00104-w |date=12 June 2019}}</ref> || {{w|Belgium}}
 
|-
 
|-
 
| 2002 (March 1) || {{w|Immunotherapy}}, {{w|oncology}} || Company launch || {{w|Advaxis}}is established.  It is a development-stage biotechnology company with the focus on developing cancer vaccines that utilize multiple mechanisms of immunity.<ref>{{cite web |title=Advaxis Share Price - ADXS, RNS News, Articles, Quotes, & Charts (NASDAQ:ADXS) |url=https://www.proactiveinvestors.com/NASDAQ:ADXS/Advaxis |website=Proactiveinvestors NA |access-date=20 January 2022 |language=en}}</ref> || {{w|United States}}
 
| 2002 (March 1) || {{w|Immunotherapy}}, {{w|oncology}} || Company launch || {{w|Advaxis}}is established.  It is a development-stage biotechnology company with the focus on developing cancer vaccines that utilize multiple mechanisms of immunity.<ref>{{cite web |title=Advaxis Share Price - ADXS, RNS News, Articles, Quotes, & Charts (NASDAQ:ADXS) |url=https://www.proactiveinvestors.com/NASDAQ:ADXS/Advaxis |website=Proactiveinvestors NA |access-date=20 January 2022 |language=en}}</ref> || {{w|United States}}
Line 414: Line 413:
 
| 2002 || {{w|Genetically modified insect}}s || Company launch || {{w|Oxitec}} is founded.<ref>{{cite web |last1=Welle (www.dw.com) |first1=Deutsche |title=Empresa respaldada por Bill Gates libera miles de mosquitos modificados genéticamente {{!}} DW {{!}} 04.05.2021 |url=https://www.dw.com/es/empresa-respaldada-por-bill-gates-libera-miles-de-mosquitos-modificados-gen%C3%A9ticamente/a-57429225 |website=DW.COM |access-date=5 March 2022 |language=es-ES}}</ref> It is a developer of biological solutions to control pests that transmit disease, destroy crops and harm livestock.<ref>{{cite web |title=Oxitec |url=https://www.weforum.org/organizations/oxitec#:~:text=Oxitec%20is%20a%20leading%20developer,destroy%20crops%20and%20harm%20livestock. |website=World Economic Forum |access-date=27 May 2022 |language=en}}</ref> || {{w|United Kingdom}}
 
| 2002 || {{w|Genetically modified insect}}s || Company launch || {{w|Oxitec}} is founded.<ref>{{cite web |last1=Welle (www.dw.com) |first1=Deutsche |title=Empresa respaldada por Bill Gates libera miles de mosquitos modificados genéticamente {{!}} DW {{!}} 04.05.2021 |url=https://www.dw.com/es/empresa-respaldada-por-bill-gates-libera-miles-de-mosquitos-modificados-gen%C3%A9ticamente/a-57429225 |website=DW.COM |access-date=5 March 2022 |language=es-ES}}</ref> It is a developer of biological solutions to control pests that transmit disease, destroy crops and harm livestock.<ref>{{cite web |title=Oxitec |url=https://www.weforum.org/organizations/oxitec#:~:text=Oxitec%20is%20a%20leading%20developer,destroy%20crops%20and%20harm%20livestock. |website=World Economic Forum |access-date=27 May 2022 |language=en}}</ref> || {{w|United Kingdom}}
 
|-
 
|-
−
| 2002 || || Literature || C. Mark Tang publishes ''The Essential Biotech Investment Guide: How to Invest in the Healthcare Biotechnology & Life Sciences Sector''. ||
+
| 2002 || || Literature || C. Mark Tang publishes ''The Essential Biotech Investment Guide: How to Invest in the Healthcare Biotechnology & Life Sciences Sector''.<ref>{{cite book |last1=Tang |first1=Chilung Mark |title=The Essential Biotech Investment Guide: How to Invest in the Healthcare Biotechnology & Life Sciences Sector |date=2002 |publisher=World Scientific |isbn=978-981-238-139-2 |url=https://books.google.com.ar/books/about/The_Essential_Biotech_Investment_Guide.html?id=EwlJxgm2_dUC&redir_esc=y |language=en}}</ref> || {{w|Singapore}} ({{w|World Scientific}})
 
|-
 
|-
 
| 2002 || RNA-based therapeutics || Company launch  || {{w|Prosensa}} is founded.<ref>{{cite web |title=Prosensa - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/prosensa |website=Crunchbase |access-date=18 February 2022 |language=en}}</ref> It is a biotech company dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.<ref>{{cite web |title=Prosensa - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/prosensa#:~:text=Prosensa%20is%20a%20biotech%20company,based%20on%20RNA%2Dbased%20therapeutics. |website=Crunchbase |access-date=10 May 2022 |language=en}}</ref>  || {{w|Netherlands}}
 
| 2002 || RNA-based therapeutics || Company launch  || {{w|Prosensa}} is founded.<ref>{{cite web |title=Prosensa - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/prosensa |website=Crunchbase |access-date=18 February 2022 |language=en}}</ref> It is a biotech company dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.<ref>{{cite web |title=Prosensa - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/prosensa#:~:text=Prosensa%20is%20a%20biotech%20company,based%20on%20RNA%2Dbased%20therapeutics. |website=Crunchbase |access-date=10 May 2022 |language=en}}</ref>  || {{w|Netherlands}}
Line 424: Line 423:
 
| 2002 || {{w|Cloning}} || Background || {{w|The banteng}}, an endangered species, is cloned for the first time.<ref>{{cite web |last1= |first1= |last2= |first2= |title=Scientists Clone Banteng in Effort to Save Dying Species |url=https://www.latimes.com/archives/la-xpm-2003-apr-08-na-clone8-story.html |website=Los Angeles Times |access-date=20 May 2022 |date=8 April 2003}}</ref><ref name=dhShimasaki/> || {{w|United States}}
 
| 2002 || {{w|Cloning}} || Background || {{w|The banteng}}, an endangered species, is cloned for the first time.<ref>{{cite web |last1= |first1= |last2= |first2= |title=Scientists Clone Banteng in Effort to Save Dying Species |url=https://www.latimes.com/archives/la-xpm-2003-apr-08-na-clone8-story.html |website=Los Angeles Times |access-date=20 May 2022 |date=8 April 2003}}</ref><ref name=dhShimasaki/> || {{w|United States}}
 
|-
 
|-
−
| 2002 || {{w|stem cell}} technology || Company launch || {{w|CellResearch Corporation}} is founded.<ref>{{cite web |title=Overview main |url=https://www.cellresearchcorp.com/work |website=CellResearch Corp |access-date=5 March 2022}}</ref> Based in {{w|Singapore}}, it is a biotechnology company with a primary focus on skin cell and cord lining {{w|stem cell}} research.<ref>{{cite web |title=Stem cell skincare product goes global {{!}} The Straits Times |url=https://www.straitstimes.com/business/stem-cell-skincare-product-goes-global |website=www.straitstimes.com |access-date=10 May 2022 |language=en |date=13 August 2015}}</ref> || {{w|Singapore}}
+
| 2002 || {{w|Stem cell}} technology || Company launch || {{w|CellResearch Corporation}} is founded.<ref>{{cite web |title=Overview main |url=https://www.cellresearchcorp.com/work |website=CellResearch Corp |access-date=5 March 2022}}</ref> Based in {{w|Singapore}}, it is a biotechnology company with a primary focus on skin cell and cord lining {{w|stem cell}} research.<ref>{{cite web |title=Stem cell skincare product goes global {{!}} The Straits Times |url=https://www.straitstimes.com/business/stem-cell-skincare-product-goes-global |website=www.straitstimes.com |access-date=10 May 2022 |language=en |date=13 August 2015}}</ref> || {{w|Singapore}}
 
|-
 
|-
 
| 2002 || {{w|Genomics}} || Company launch || NeoGenomics is founded.<ref>{{cite web |title=The Oncology Laboratory Solution for Managed Care |url=https://neogenomics.com/sites/default/files/2021-07/Managed_Care_Brochure_021720_Final.pdf |website=neogenomics.com |access-date=5 March 2022}}</ref> Based in {{w|Fort Myers, Florida}}, it is a cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers.<ref>{{cite web |title=About {{!}} NeoGenomics Laboratories |url=https://neogenomics.com/about |website=neogenomics.com |access-date=20 May 2022}}</ref> || {{w|United States}}
 
| 2002 || {{w|Genomics}} || Company launch || NeoGenomics is founded.<ref>{{cite web |title=The Oncology Laboratory Solution for Managed Care |url=https://neogenomics.com/sites/default/files/2021-07/Managed_Care_Brochure_021720_Final.pdf |website=neogenomics.com |access-date=5 March 2022}}</ref> Based in {{w|Fort Myers, Florida}}, it is a cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers.<ref>{{cite web |title=About {{!}} NeoGenomics Laboratories |url=https://neogenomics.com/about |website=neogenomics.com |access-date=20 May 2022}}</ref> || {{w|United States}}
Line 434: Line 433:
 
| 2003 (May 24) || || Literature || Richard W. Oliver publishes ''The Biotech Age : The Business of Biotech and How to Profit From It''.<ref>{{cite book |last1=Oliver |first1=Richard L. |title=The Biotech Age : The Business of Biotech and How to Profit From It: The Business of Biotech and How to Profit From It |date=24 March 2003 |publisher=McGraw Hill Professional |isbn=978-0-07-141489-0 |url=https://books.google.com.ar/books/about/The_Biotech_Age.html?id=2u0euFAcOcwC&source=kp_book_description&redir_esc=y |language=en}}</ref>
 
| 2003 (May 24) || || Literature || Richard W. Oliver publishes ''The Biotech Age : The Business of Biotech and How to Profit From It''.<ref>{{cite book |last1=Oliver |first1=Richard L. |title=The Biotech Age : The Business of Biotech and How to Profit From It: The Business of Biotech and How to Profit From It |date=24 March 2003 |publisher=McGraw Hill Professional |isbn=978-0-07-141489-0 |url=https://books.google.com.ar/books/about/The_Biotech_Age.html?id=2u0euFAcOcwC&source=kp_book_description&redir_esc=y |language=en}}</ref>
 
|-
 
|-
−
| 2003 (June) || {{w|Biotechnology}} || Company launch || {{w|Acceleron Pharma}} is founded.<ref>{{cite web |title=Acceleron |url=https://www.sec.gov/Archives/edgar/data/1280600/000104746914000314/a2218028z424b4.htm |website=www.sec.gov |access-date=5 March 2022}}</ref> It is a biotechnology company focused on the discovery, development, and commercialization of novel therapies.<ref>{{cite web |title=Acceleron Pharma Inc (NASDAQ:XLRN) - Share price |url=https://www.youinvest.co.uk/market-research/NASDAQ%3AXLRN#:~:text=Acceleron%20Pharma%20is%20a%20biotechnology,of%20cellular%20growth%20and%20repair. |website=AJ Bell Youinvest |access-date=4 April 2022 |language=English}}</ref> || {{w|United States}}
+
| 2003 (June) || {{w|biopharmaceutical}} || Company launch || {{w|Acceleron Pharma}} is founded.<ref>{{cite web |title=Acceleron |url=https://www.sec.gov/Archives/edgar/data/1280600/000104746914000314/a2218028z424b4.htm |website=www.sec.gov |access-date=5 March 2022}}</ref> It is a biotechnology company focused on the discovery, development, and commercialization of novel therapies.<ref>{{cite web |title=Acceleron Pharma Inc (NASDAQ:XLRN) - Share price |url=https://www.youinvest.co.uk/market-research/NASDAQ%3AXLRN#:~:text=Acceleron%20Pharma%20is%20a%20biotechnology,of%20cellular%20growth%20and%20repair. |website=AJ Bell Youinvest |access-date=4 April 2022 |language=English}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2003 || {{w|Blood test}} || Company launch || {{w|Theranos}} is founded by {{w|Elizabeth Holmes}}. Claiming that it could perform a wildly large number of tests, such as measuring glucose levels and detecting different types of antibodies, the company would later be dissolved and liquidated, with founder indicted for {{w|wire fraud}} and {{w|conspiracy}}.<ref>{{cite web |last1=Pflanzer |first1=Lydia Ramsey |title=The rise and fall of Theranos, the blood-testing startup that went from Silicon Valley darling to facing fraud charges |url=https://www.businessinsider.com/the-history-of-silicon-valley-unicorn-theranos-and-ceo-elizabeth-holmes-2018-5 |website=Business Insider |access-date=6 March 2021}}</ref><ref>{{cite web |title=Theranos: Scandal hit blood-testing firm to shut |url=https://www.bbc.com/news/business-45418615 |website=BBC News |access-date=6 March 2021 |date=5 September 2018}}</ref><ref>{{cite web |title=A Timeline Of Theranos's Troubles |url=https://www.investopedia.com/articles/investing/020116/theranos-fallen-unicorn.asp |website=Investopedia |access-date=5 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2003 || {{w|Blood test}} || Company launch || {{w|Theranos}} is founded by {{w|Elizabeth Holmes}}. Claiming that it could perform a wildly large number of tests, such as measuring glucose levels and detecting different types of antibodies, the company would later be dissolved and liquidated, with founder indicted for {{w|wire fraud}} and {{w|conspiracy}}.<ref>{{cite web |last1=Pflanzer |first1=Lydia Ramsey |title=The rise and fall of Theranos, the blood-testing startup that went from Silicon Valley darling to facing fraud charges |url=https://www.businessinsider.com/the-history-of-silicon-valley-unicorn-theranos-and-ceo-elizabeth-holmes-2018-5 |website=Business Insider |access-date=6 March 2021}}</ref><ref>{{cite web |title=Theranos: Scandal hit blood-testing firm to shut |url=https://www.bbc.com/news/business-45418615 |website=BBC News |access-date=6 March 2021 |date=5 September 2018}}</ref><ref>{{cite web |title=A Timeline Of Theranos's Troubles |url=https://www.investopedia.com/articles/investing/020116/theranos-fallen-unicorn.asp |website=Investopedia |access-date=5 March 2022 |language=en}}</ref> || {{w|United States}}
Line 466: Line 465:
 
| 2003 || Synthetic biotechnology || Company launch || [[w:Amyris (company)|Amyris]] is founded. Based in {{w|Emeryville, California}}, it specializes in creating renewable products focusing on fuels and chemicals.<ref>{{cite web |title=Amyris - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/amyris-biotechnologies |website=Crunchbase |access-date=5 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2003 || Synthetic biotechnology || Company launch || [[w:Amyris (company)|Amyris]] is founded. Based in {{w|Emeryville, California}}, it specializes in creating renewable products focusing on fuels and chemicals.<ref>{{cite web |title=Amyris - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/amyris-biotechnologies |website=Crunchbase |access-date=5 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2003 || {{w|Biotechnology}}, {{w|genetics}}, {{w|health diagnostics}}, {{w|life science}}<ref>{{cite web |title=Helicos BioSciences |url=https://www.crunchbase.com/organization/helicos-biosciences |website=crunchbase.com |access-date=24 January 2022}}</ref> || Company launch || {{w|Helicos Biosciences}} is founded.<ref>{{cite web |title=Helicos BioSciences Files for Chapter 11 Bankruptcy Protection |url=https://www.genomeweb.com/sequencing/helicos-biosciences-files-chapter-11-bankruptcy-protection#.YfRINOpByUk |website=Genomeweb |access-date=28 January 2022 |language=en |date=16 November 2012}}</ref> It is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets.<ref>{{cite web |title=Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis… |url=https://www.flagshippioneering.com/press/helicos-biosciences-announces-sale-helicos-genetic-analysis-system-turku-centre-biotechn#:~:text=Helicos%20BioSciences%20is%20a%20life,drug%20discovery%2C%20and%20diagnostic%20markets. |website=Flagship Pioneering |access-date=4 April 2022}}</ref> || {{w|United States}}
+
| 2003 || {{w|Genetics}}, {{w|health diagnostics}}, {{w|life science}}<ref>{{cite web |title=Helicos BioSciences |url=https://www.crunchbase.com/organization/helicos-biosciences |website=crunchbase.com |access-date=24 January 2022}}</ref> || Company launch || {{w|Helicos Biosciences}} is founded.<ref>{{cite web |title=Helicos BioSciences Files for Chapter 11 Bankruptcy Protection |url=https://www.genomeweb.com/sequencing/helicos-biosciences-files-chapter-11-bankruptcy-protection#.YfRINOpByUk |website=Genomeweb |access-date=28 January 2022 |language=en |date=16 November 2012}}</ref> It is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets.<ref>{{cite web |title=Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis… |url=https://www.flagshippioneering.com/press/helicos-biosciences-announces-sale-helicos-genetic-analysis-system-turku-centre-biotechn#:~:text=Helicos%20BioSciences%20is%20a%20life,drug%20discovery%2C%20and%20diagnostic%20markets. |website=Flagship Pioneering |access-date=4 April 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2004 (January 1) || {{w|Monoclonal antibody therapy}} || Company launch || {{w|Alder Biopharmaceuticals}} is founded.<ref>{{cite web |title=Alder Biopharmaceuticals Inc. Completes Series B Financing; H.I.G. Ventures Leads $16 Million Round |url=https://www.biospace.com/article/releases/alder-biopharmaceuticals-inc-completes-series-b-financing-b-h-i-g-ventures-b-leads-16-million-round-/ |website=BioSpace |access-date=5 March 2022}}</ref> It is a biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies.<ref>{{cite web |title=Jobs with Alder BioPharmaceuticals, Inc. |url=https://www.biospace.com/employer/394719/alder-biopharmaceuticals-inc-/#:~:text=Alder%20BioPharmaceuticals%20is%20a%20clinical,commercialization%20of%20novel%20therapeutic%20antibodies. |website=BioSpace |access-date=4 April 2022}}</ref> || {{w|United States}}
 
| 2004 (January 1) || {{w|Monoclonal antibody therapy}} || Company launch || {{w|Alder Biopharmaceuticals}} is founded.<ref>{{cite web |title=Alder Biopharmaceuticals Inc. Completes Series B Financing; H.I.G. Ventures Leads $16 Million Round |url=https://www.biospace.com/article/releases/alder-biopharmaceuticals-inc-completes-series-b-financing-b-h-i-g-ventures-b-leads-16-million-round-/ |website=BioSpace |access-date=5 March 2022}}</ref> It is a biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies.<ref>{{cite web |title=Jobs with Alder BioPharmaceuticals, Inc. |url=https://www.biospace.com/employer/394719/alder-biopharmaceuticals-inc-/#:~:text=Alder%20BioPharmaceuticals%20is%20a%20clinical,commercialization%20of%20novel%20therapeutic%20antibodies. |website=BioSpace |access-date=4 April 2022}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2004 || {{w|Biotechnology}}, {{w|healthcare}}, {{w|life science}} || Company launch || {{w|3H Biomedical}}<ref>{{cite web |title=3H Biomedical |url=https://www.crunchbase.com/organization/3h-biomedical |website=crunchbase.com |access-date=24 January 2022}}</ref> It supplies more than 270 different types of primary human and animal cell-based products for life science research, drug development, screening of chemicals and biomaterials development.<ref>{{cite web |title=3H Biomedical AB |url=https://www.3hbiomedical.com/ |website=www.3hbiomedical.com |access-date=17 March 2022}}</ref> || {{w|Sweden}}
+
| 2004 || {{w|Healthcare}}, {{w|life science}} || Company launch || {{w|3H Biomedical}}<ref>{{cite web |title=3H Biomedical |url=https://www.crunchbase.com/organization/3h-biomedical |website=crunchbase.com |access-date=24 January 2022}}</ref> It supplies more than 270 different types of primary human and animal cell-based products for life science research, drug development, screening of chemicals and biomaterials development.<ref>{{cite web |title=3H Biomedical AB |url=https://www.3hbiomedical.com/ |website=www.3hbiomedical.com |access-date=17 March 2022}}</ref> || {{w|Sweden}}
 
|-
 
|-
 
| 2004 || Sequencing systems || Company launch || {{w|Pacific Biosciences}} is founded. It designs, develops, and manufactures sequencing systems to resolve genetically complex problems.<ref>{{cite web |title=Pacific Biosciences |url=https://www.crunchbase.com/organization/pacific-biosciences |website=crunchbase.com |access-date=24 January 2022}}</ref> || {{w|United States}}
 
| 2004 || Sequencing systems || Company launch || {{w|Pacific Biosciences}} is founded. It designs, develops, and manufactures sequencing systems to resolve genetically complex problems.<ref>{{cite web |title=Pacific Biosciences |url=https://www.crunchbase.com/organization/pacific-biosciences |website=crunchbase.com |access-date=24 January 2022}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2004 || {{w|Biotechnology}} || Company launch || {{w|Molecular Partners}} is founded by researchers at the {{w|University of Zürich}}, while studying monoclonal antibodies.<ref name=":0">{{cite journal | last1 = Plückthun | first1 = A | year = 2015 | title = Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy | journal = Annu. Rev. Pharmacol. Toxicol. | volume = 55 | issue = 1| pages = 489–511 | doi = 10.1146/annurev-pharmtox-010611-134654 | pmid = 25562645 }}</ref> || {{w|Switzerland}}
+
| 2004 || {{w|Biopharmaceutical}} || Company launch || {{w|Molecular Partners}} is founded by researchers at the {{w|University of Zürich}}, while studying monoclonal antibodies.<ref name=":0">{{cite journal | last1 = Plückthun | first1 = A | year = 2015 | title = Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy | journal = Annu. Rev. Pharmacol. Toxicol. | volume = 55 | issue = 1| pages = 489–511 | doi = 10.1146/annurev-pharmtox-010611-134654 | pmid = 25562645 }}</ref> || {{w|Switzerland}}
 
|-
 
|-
 
| 2004 || Pharmaceutical || Company launch || {{w|Medivation}} is founded.<ref>{{cite web |title=Medivation |url=https://ar.linkedin.com/company/medivation |website=linkedin |access-date=5 March 2022}}</ref> Focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options,<ref>{{cite web |title=Jobs with Medivation, Inc. |url=https://www.biospace.com/employer/545671/medivation-inc-/ |website=BioSpace |access-date=17 March 2022}}</ref> it would be acquired by {{w|Pfizer}} in September 2016.<ref>{{cite web |title=Pfizer Completes Acquisition of Medivation |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_medivation |website=pfizer.com |access-date=17 March 2022}}</ref> || {{w|United States}}  
 
| 2004 || Pharmaceutical || Company launch || {{w|Medivation}} is founded.<ref>{{cite web |title=Medivation |url=https://ar.linkedin.com/company/medivation |website=linkedin |access-date=5 March 2022}}</ref> Focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options,<ref>{{cite web |title=Jobs with Medivation, Inc. |url=https://www.biospace.com/employer/545671/medivation-inc-/ |website=BioSpace |access-date=17 March 2022}}</ref> it would be acquired by {{w|Pfizer}} in September 2016.<ref>{{cite web |title=Pfizer Completes Acquisition of Medivation |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_medivation |website=pfizer.com |access-date=17 March 2022}}</ref> || {{w|United States}}  
 
|-
 
|-
 
| 2004 || {{w|Bioinformatics}} || Company launch || {{w|Genostar}} is founded.<ref>{{cite web |title=About: Genostar |url=https://dbpedia.org/describe/?uri=http%3A%2F%2Fdbpedia.org%2Fresource%2FGenostar |website=dbpedia.org |access-date=28 January 2022}}</ref> Based in {{w|Grenoble}}, {{w|France}}, it is a provider of bioinformatics software, databases and complete data analysis services for microbial research.<ref>{{cite web |title=In-house analysis pipeline for next generation genome sequencing speeds up innovation |url=https://www.mynewsdesk.com/chr-hansen/pressreleases/in-house-analysis-pipeline-for-next-generation-genome-sequencing-speeds-up-innovation-1097447 |website=Mynewsdesk |access-date=28 January 2022 |language=en}}</ref> || {{w|France}}
 
| 2004 || {{w|Bioinformatics}} || Company launch || {{w|Genostar}} is founded.<ref>{{cite web |title=About: Genostar |url=https://dbpedia.org/describe/?uri=http%3A%2F%2Fdbpedia.org%2Fresource%2FGenostar |website=dbpedia.org |access-date=28 January 2022}}</ref> Based in {{w|Grenoble}}, {{w|France}}, it is a provider of bioinformatics software, databases and complete data analysis services for microbial research.<ref>{{cite web |title=In-house analysis pipeline for next generation genome sequencing speeds up innovation |url=https://www.mynewsdesk.com/chr-hansen/pressreleases/in-house-analysis-pipeline-for-next-generation-genome-sequencing-speeds-up-innovation-1097447 |website=Mynewsdesk |access-date=28 January 2022 |language=en}}</ref> || {{w|France}}
 +
|-
 +
| 2004 || || Accelerator/incubator launch || The Portland State University Business Accelerator is founded.<ref>{{cite web |title=Portland State University Business Accelerator |url=https://www.linkedin.com/company/psuaccelerator/about/ |website=linkedin |access-date=29 June 2022}}</ref> This accelerator provides office space and fully-loaded lab facilities.  The dedicated and skilled staff of the accelerator appeals to the region’s top science and technology startups. The startups are also leveraging the affordable co-working space, access to the conference room, monthly Business tycoons meetings and topic-related Lunch & Learns, fundraising and business management.<ref name="Top 15 biotech incubators and accelerators in the US"/> || {{w|United States}}
 
|-
 
|-
 
| 2004 || {{w|Agricultural biotechnology}} || Background || The {{w|Food and Agriculture Organization}} endorses biotech crops, stating biotechnology is a complementary tool to traditional farming methods that can help poor farmers and consumers in developing nations.<ref name=dhShimasaki/> ||
 
| 2004 || {{w|Agricultural biotechnology}} || Background || The {{w|Food and Agriculture Organization}} endorses biotech crops, stating biotechnology is a complementary tool to traditional farming methods that can help poor farmers and consumers in developing nations.<ref name=dhShimasaki/> ||
Line 486: Line 487:
 
| 2004 || || Literature || Bryan Bergeron, Bryan P. Bergeron, and Paul Chan publish ''Biotech Industry: A Global, Economic, and Financing Overview'', which attempts to offer a clear vision of the global biotech market through 2010, including which regions and corporations are best positioned to dominate the market.<ref>{{cite book |last1=Bergeron |first1=Bryan |last2=Bergeron |first2=Bryan P. |last3=Chan |first3=Paul |title=Biotech Industry: A Global, Economic, and Financing Overview |date=30 January 2004 |publisher=Wiley |isbn=978-0-471-46561-4 |url=https://books.google.com.ar/books/about/Biotech_Industry.html?id=XKa2AAAAIAAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
| 2004 || || Literature || Bryan Bergeron, Bryan P. Bergeron, and Paul Chan publish ''Biotech Industry: A Global, Economic, and Financing Overview'', which attempts to offer a clear vision of the global biotech market through 2010, including which regions and corporations are best positioned to dominate the market.<ref>{{cite book |last1=Bergeron |first1=Bryan |last2=Bergeron |first2=Bryan P. |last3=Chan |first3=Paul |title=Biotech Industry: A Global, Economic, and Financing Overview |date=30 January 2004 |publisher=Wiley |isbn=978-0-471-46561-4 |url=https://books.google.com.ar/books/about/Biotech_Industry.html?id=XKa2AAAAIAAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
−
| 2004 || {{w|Biotechnology}} || Company launch || {{w|FlexGen B.V.}} is founded in the {{w|Netherlands}}.<ref>{{cite web |title=FlexGen BV {{!}} FlexGen Closes New Round of Financing {{!}} InvestEgate |url=https://www.investegate.co.uk/articlePrint.aspx?id=20090302171500H4449 |website=www.investegate.co.uk |access-date=28 January 2022}}</ref> A spin-off from {{w|Leiden University Medical Centre}} and Dutch Space (part of {{w|EADS}}), the company would be declared bankrupt on 21 December 2015.<ref>{{cite web |title=Bankruptcy Flexgen Bv in Leiden (F.05/15/975) - FaillissementsDossier.nl |url=https://www.faillissementsdossier.nl/en/bankruptcy/1157821/flexgen-bv.aspx |website=www.faillissementsdossier.nl |access-date=28 January 2022}}</ref> || {{w|Netherlands}}  
+
| 2004 || {{w|Oligonucleotide}}s || Company launch || {{w|FlexGen B.V.}} is founded in the {{w|Netherlands}}.<ref>{{cite web |title=FlexGen BV {{!}} FlexGen Closes New Round of Financing {{!}} InvestEgate |url=https://www.investegate.co.uk/articlePrint.aspx?id=20090302171500H4449 |website=www.investegate.co.uk |access-date=28 January 2022}}</ref> A spin-off from {{w|Leiden University Medical Centre}} and Dutch Space (part of {{w|EADS}}), the company would be declared bankrupt on 21 December 2015.<ref>{{cite web |title=Bankruptcy Flexgen Bv in Leiden (F.05/15/975) - FaillissementsDossier.nl |url=https://www.faillissementsdossier.nl/en/bankruptcy/1157821/flexgen-bv.aspx |website=www.faillissementsdossier.nl |access-date=28 January 2022}}</ref> || {{w|Netherlands}}  
 
|-
 
|-
−
| 2004 || Live sciences || Company launch || {{w|CD Genomics}} is founded.<ref>{{cite web |title=Finally! CD Genomics Has Its Own Blog {{!}} CD Genomics Blog |url=https://www.cd-genomics.com/blog/finally-cd-genomics-has-its-own-blog/ |website=cd-genomics.com |access-date=29 January 2022}}</ref> It specializes in sequencing services, as well as genotyping, library construction, bioinformatics, aptamers, microarray, health diagnostics, mutagenesis analyses and others for the genomics industry.<ref>{{cite web |title=About Us – CD Genomics |url=https://www.cd-genomics.com/about-us.html#:~:text=CD%20Genomics%20is%20a%20world,others%20for%20the%20genomics%20industry. |website=www.cd-genomics.com |access-date=29 January 2022}}</ref> || {{w|United States}}
+
| 2004 || {{w|DNA sequencing}}, {{w|Live science}} || Company launch || {{w|CD Genomics}} is founded.<ref>{{cite web |title=Finally! CD Genomics Has Its Own Blog {{!}} CD Genomics Blog |url=https://www.cd-genomics.com/blog/finally-cd-genomics-has-its-own-blog/ |website=cd-genomics.com |access-date=29 January 2022}}</ref> It specializes in sequencing services, as well as genotyping, library construction, bioinformatics, {{w|aptamer}}s, {{w|microarray}}, health diagnostics, mutagenesis analyses and others for the genomics industry.<ref>{{cite web |title=About Us – CD Genomics |url=https://www.cd-genomics.com/about-us.html#:~:text=CD%20Genomics%20is%20a%20world,others%20for%20the%20genomics%20industry. |website=www.cd-genomics.com |access-date=29 January 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2005 (March) || {{w|Pharmaceutical}}s || Company launch || {{w|Jazz Pharmaceuticals}} is founded.<ref>{{cite web |title=Bloomberg - Are you a robot? |url=https://www.bloomberg.com/profile/person/1393401 |website=www.bloomberg.com |access-date=5 March 2022}}</ref> It focuses on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.<ref>{{cite web |title=Jazz Pharmaceuticals, Inc. Announces Initial Public Offering {{!}} Jazz Pharmaceuticals plc |url=https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-inc-announces-initial-public-offering#:~:text=Jazz%20Pharmaceuticals%20is%20a%20specialty,needs%20in%20neurology%20and%20psychiatry. |website=investor.jazzpharma.com |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
 
| 2005 (March) || {{w|Pharmaceutical}}s || Company launch || {{w|Jazz Pharmaceuticals}} is founded.<ref>{{cite web |title=Bloomberg - Are you a robot? |url=https://www.bloomberg.com/profile/person/1393401 |website=www.bloomberg.com |access-date=5 March 2022}}</ref> It focuses on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.<ref>{{cite web |title=Jazz Pharmaceuticals, Inc. Announces Initial Public Offering {{!}} Jazz Pharmaceuticals plc |url=https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-inc-announces-initial-public-offering#:~:text=Jazz%20Pharmaceuticals%20is%20a%20specialty,needs%20in%20neurology%20and%20psychiatry. |website=investor.jazzpharma.com |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
 +
|-
 +
| 2004 (September 1) || || Fund launch || Rydex Biotechnology Fund Class A ({{w|ticker symbol}} RYBOX) is launched.<ref>{{cite web |title=Rydex Biotechnology Fund Class A, RYBOX summary - FT.com |url=https://markets.ft.com/data/funds/tearsheet/summary?s=RYBOX |website=markets.ft.com |access-date=1 July 2022}}</ref> It mostly invests in biotechnology companies that are traded in the United States.<ref>{{cite web |title=Rydex Biotechnology Fund Class A (RYBOX) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/RYBOX?p=RYBOX&.tsrc=fin-srch |website=finance.yahoo.com |access-date=8 July 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2005 || Biotechnology || Company launch || {{w|Micreos}} is founded. It is a Netherlands-based [[w:Bacteriophage|phage]]- and {{w|endolysin}} technology development company.<ref>{{cite web |title=Scientific Opinion on the evaluation of the safety and efficacy of ListexTM P100 for the removal of Listeria monocytogenes surface contamination of raw fish {{!}} EFSA |url=http://www.efsa.europa.eu/en/efsajournal/pub/2615 |website=www.efsa.europa.eu |access-date=28 January 2022 |language=en}}</ref> Micreos develops {{w|Staphefekt}}, an endolysin that selectively kills ''{{w|Staphylococcus aureus}}'' bacteria.<ref>{{cite web |title=Wayback Machine |url=https://web.archive.org/web/20160919015518/https://www.gladskin.com/Content/Images/uploaded/Pdf/Specific_lysis_of_MSSA_and_MRSA_by_Staphefekt-Herpers_et_al_Abstract_ECCMID_2014-03-1.pdf |website=web.archive.org |access-date=21 March 2022}}</ref> || {{w|Netherlands}}
 
| 2005 || Biotechnology || Company launch || {{w|Micreos}} is founded. It is a Netherlands-based [[w:Bacteriophage|phage]]- and {{w|endolysin}} technology development company.<ref>{{cite web |title=Scientific Opinion on the evaluation of the safety and efficacy of ListexTM P100 for the removal of Listeria monocytogenes surface contamination of raw fish {{!}} EFSA |url=http://www.efsa.europa.eu/en/efsajournal/pub/2615 |website=www.efsa.europa.eu |access-date=28 January 2022 |language=en}}</ref> Micreos develops {{w|Staphefekt}}, an endolysin that selectively kills ''{{w|Staphylococcus aureus}}'' bacteria.<ref>{{cite web |title=Wayback Machine |url=https://web.archive.org/web/20160919015518/https://www.gladskin.com/Content/Images/uploaded/Pdf/Specific_lysis_of_MSSA_and_MRSA_by_Staphefekt-Herpers_et_al_Abstract_ECCMID_2014-03-1.pdf |website=web.archive.org |access-date=21 March 2022}}</ref> || {{w|Netherlands}}
Line 510: Line 513:
 
| 2005 || {{w|Scientific instrument}}s || Company launch || {{w|CovalX}} is founded.<ref>{{cite web |title=Disulfide Bond Mapping Services {{!}} CovalX |url=https://covalx.com/antibody-charact-disulfide-map.php |website=covalx.com |access-date=5 March 2022 |language=en}}</ref> It specializes in protein interaction analysis based on mass spectrometry. CovalX provides epitope mapping, intact mass analysis, protein interactions, protein aggregation, sequencing, disulfide mapping, and other services.<ref>{{cite web |title=CovalX |url=https://craft.co/covalx |website=craft.co |access-date=15 March 2022}}</ref> || {{w|Switzerland}}
 
| 2005 || {{w|Scientific instrument}}s || Company launch || {{w|CovalX}} is founded.<ref>{{cite web |title=Disulfide Bond Mapping Services {{!}} CovalX |url=https://covalx.com/antibody-charact-disulfide-map.php |website=covalx.com |access-date=5 March 2022 |language=en}}</ref> It specializes in protein interaction analysis based on mass spectrometry. CovalX provides epitope mapping, intact mass analysis, protein interactions, protein aggregation, sequencing, disulfide mapping, and other services.<ref>{{cite web |title=CovalX |url=https://craft.co/covalx |website=craft.co |access-date=15 March 2022}}</ref> || {{w|Switzerland}}
 
|-
 
|-
−
| 2005 || {{w|Biotechnology}}, {{w|healthcare}}, {{w|health diagnostics}} || Company launch || {{w|Celsense}} is founded.<ref>{{cite web |title=Celsense, Inc. |url=https://celsense.com/wp-content/uploads/2019/05/Celsense-Whitepaper-IND-Enabling-Data-Sets-May19.pdf |website=celsense.com |access-date=5 March 2022}}</ref> Based in {{w|Pittsburgh, Pennsylvania}}, it is a biotechnology company providing magnetic resonance imaging contrast agents.<ref>{{cite web |title=Celsense - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/celsense |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
+
| 2005 || {{w|Healthcare}}, {{w|health diagnostics}} || Company launch || {{w|Celsense}} is founded.<ref>{{cite web |title=Celsense, Inc. |url=https://celsense.com/wp-content/uploads/2019/05/Celsense-Whitepaper-IND-Enabling-Data-Sets-May19.pdf |website=celsense.com |access-date=5 March 2022}}</ref> Based in {{w|Pittsburgh, Pennsylvania}}, it is a biotechnology company providing magnetic resonance imaging contrast agents.<ref>{{cite web |title=Celsense - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/celsense |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2005 (August 5) || {{w|Biotechnology}}, {{w|diabetes}}, {{w|pharmaceutical}} ||  Company launch || {{w|Avid Radiopharmaceuticals}} is founded. Acquired later by {{w|Eli Lilly}}, it develops molecular imaging agents for detecting and monitoring chronic human diseases.<ref>{{cite web |title=Avid Radiopharmaceuticals - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/avid-radiopharmaceuticals |website=Crunchbase |access-date=5 March 2022 |language=en}}</ref> ||
+
| 2005 (August 5) || {{w|Diabetes}}, {{w|pharmaceutical}} ||  Company launch || {{w|Avid Radiopharmaceuticals}} is founded. Acquired later by {{w|Eli Lilly}}, it develops molecular imaging agents for detecting and monitoring chronic human diseases.<ref>{{cite web |title=Avid Radiopharmaceuticals - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/avid-radiopharmaceuticals |website=Crunchbase |access-date=5 March 2022 |language=en}}</ref> ||
 
|-
 
|-
 
| 2005 || || Business growth || In this year alone, biotech firms participated in 1,400 deals involving billions of dollars.<ref name="Kaitin"/> ||
 
| 2005 || || Business growth || In this year alone, biotech firms participated in 1,400 deals involving billions of dollars.<ref name="Kaitin"/> ||
 +
|-
 +
| 2006 (January 31) || || Fund launch || SPDR S&P Biotech ETF ({{w|ticker symbol}} XBI) is launched in the United States, where it is available as well as in {{w|Mexico}}.<ref>{{cite web |title=SPDR® S&P Biotech ETF, XBI:PCQ:USD summary - FT.com |url=https://markets.ft.com/data/etfs/tearsheet/summary?s=XBI:PCQ:USD |website=markets.ft.com |access-date=1 July 2022}}</ref> It seeks to track the performance of the S&P Biotechnology Select Industry Index.<ref>{{cite web |title=SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/XBI?p=XBI&.tsrc=fin-srch |website=finance.yahoo.com |access-date=8 July 2022}}</ref> ||  {{w|United States}}
 
|-
 
|-
 
| 2006 (March) || {{w|Genomics}} || Company launch || {{w|Complete Genomics}} is founded.<ref>{{cite web |title=Consumer Genomics Startup Genos Research Plans to Let Customers Explore, Share Their Data |url=https://www.genomeweb.com/molecular-diagnostics/consumer-genomics-startup-genos-research-plans-let-customers-explore-share#.YiQwsHpByUk |website=Genomeweb |access-date=6 March 2022 |language=en |date=13 June 2016}}</ref> It is a life sciences company that focuses solely on complete human genome sequencing.<ref>{{cite web |last1=Reid |first1=Clifford |title=Company Profile: Complete Genomics Inc. |url=https://www.futuremedicine.com/doi/10.2217/fon.10.173#:~:text=Complete%20Genomics%20is%20a%20life,the%20ticker%20symbol%20'GNOM'. |website=Future Oncology |access-date=27 March 2022 |pages=219–221 |doi=10.2217/fon.10.173 |date=1 February 2011}}</ref> || {{w|United States}}
 
| 2006 (March) || {{w|Genomics}} || Company launch || {{w|Complete Genomics}} is founded.<ref>{{cite web |title=Consumer Genomics Startup Genos Research Plans to Let Customers Explore, Share Their Data |url=https://www.genomeweb.com/molecular-diagnostics/consumer-genomics-startup-genos-research-plans-let-customers-explore-share#.YiQwsHpByUk |website=Genomeweb |access-date=6 March 2022 |language=en |date=13 June 2016}}</ref> It is a life sciences company that focuses solely on complete human genome sequencing.<ref>{{cite web |last1=Reid |first1=Clifford |title=Company Profile: Complete Genomics Inc. |url=https://www.futuremedicine.com/doi/10.2217/fon.10.173#:~:text=Complete%20Genomics%20is%20a%20life,the%20ticker%20symbol%20'GNOM'. |website=Future Oncology |access-date=27 March 2022 |pages=219–221 |doi=10.2217/fon.10.173 |date=1 February 2011}}</ref> || {{w|United States}}
Line 521: Line 526:
 
|-
 
|-
 
| 2006 || {{w|Laboratory equipment}}, {{w|biotechnology}}, {{w|pharmaceutical}}, {{w|healthcare}} || Company launch || {{w|Thermo Fisher Scientific}} is founded.<ref>{{cite web |title=Thermo Electron and Fisher Scientific to Combine in Industry-Transforming Transaction |url=https://ir.thermofisher.com/investors/news-events/news/news-details/2006/Thermo-Electron-and-Fisher-Scientific-to-Combine-in-Industry-Transforming-Transaction-2006-5-8/default.aspx |website=ir.thermofisher.com |access-date=5 March 2022}}</ref> Based in {{w|Waltham, Massachusetts}}, it manufactures scientific instruments consumables and chemicals.<ref>{{cite web |title=THERMO FISHER SCIENTIFIC INC (TMO) |url=https://www.puentenet.com/cotizaciones/accion/TMO.N |website=www.puentenet.com |access-date=6 April 2022}}</ref> || {{w|United States}}  
 
| 2006 || {{w|Laboratory equipment}}, {{w|biotechnology}}, {{w|pharmaceutical}}, {{w|healthcare}} || Company launch || {{w|Thermo Fisher Scientific}} is founded.<ref>{{cite web |title=Thermo Electron and Fisher Scientific to Combine in Industry-Transforming Transaction |url=https://ir.thermofisher.com/investors/news-events/news/news-details/2006/Thermo-Electron-and-Fisher-Scientific-to-Combine-in-Industry-Transforming-Transaction-2006-5-8/default.aspx |website=ir.thermofisher.com |access-date=5 March 2022}}</ref> Based in {{w|Waltham, Massachusetts}}, it manufactures scientific instruments consumables and chemicals.<ref>{{cite web |title=THERMO FISHER SCIENTIFIC INC (TMO) |url=https://www.puentenet.com/cotizaciones/accion/TMO.N |website=www.puentenet.com |access-date=6 April 2022}}</ref> || {{w|United States}}  
 +
|-
 +
| 2006 || || Accelerator/incubator launch || The Pennsylvania Biotechnology Center (PABC) is founded.<ref>{{cite web |title=Expanding the PABC » Pennsylvania Biotechnology Center |url=https://www.pabiotechbc.org/news-and-events/pabc-expansion/#:~:text=The%20PABC%2C%20which%20opened%20in,have%20operations%20in%20the%20facility. |website=www.pabiotechbc.org |access-date=29 June 2022}}</ref> It is a non-profit life science incubator facility that works "for the building of a global biotechnology centre, to the elevation of local commercial development and creation of jobs, as well as for the education and training of tomorrow’s researchers."<ref name="Top 15 biotech incubators and accelerators in the US"/> || {{w|United States}}
 
|-
 
|-
 
| 2006 || Genetic engineering, polymers || Company launch || {{w|Kraig Biocraft Laboratories}} is founded.<ref>{{cite web |title=KBLB - Kraig Biocraft Laboratories Inc Company Profile - CNNMoney.com |url=https://money.cnn.com/quote/profile/profile.html?symb=KBLB |website=money.cnn.com |access-date=5 March 2022}}</ref> A fully reporting biotechnology company, it develops genetically engineered spider silk based fiber technologies.<ref>{{cite web |title=Kraig Biocraft Laboratories - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/kraig-biocraft-laboratories#:~:text=Kraig%20Biocraft%20is%20a%20fully,spider%20silk%20based%20fiber%20technologies. |website=Crunchbase |access-date=25 March 2022 |language=en}}</ref> || {{w|United States}}  
 
| 2006 || Genetic engineering, polymers || Company launch || {{w|Kraig Biocraft Laboratories}} is founded.<ref>{{cite web |title=KBLB - Kraig Biocraft Laboratories Inc Company Profile - CNNMoney.com |url=https://money.cnn.com/quote/profile/profile.html?symb=KBLB |website=money.cnn.com |access-date=5 March 2022}}</ref> A fully reporting biotechnology company, it develops genetically engineered spider silk based fiber technologies.<ref>{{cite web |title=Kraig Biocraft Laboratories - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/kraig-biocraft-laboratories#:~:text=Kraig%20Biocraft%20is%20a%20fully,spider%20silk%20based%20fiber%20technologies. |website=Crunchbase |access-date=25 March 2022 |language=en}}</ref> || {{w|United States}}  
Line 541: Line 548:
 
|-
 
|-
 
| 2007 || Research reagents || Company launch || {{w|MyBioSource}} is founded.<ref>{{cite web |title=MyBioSource Inc. Scholarship for All Majors |url=https://www.unigo.com/scholarships/high-school-students/scholarships-for-high-school-seniors/mybiosource-inc-scholarship-for-all-majors |website=Unigo.com |access-date=6 March 2022 |language=en |date=18 October 2019}}</ref> It is a biotechnology distribution company that supplies life science products, notably research reagents.<ref>{{cite web |title=MyBioSource |url=https://craft.co/mybiosource |website=craft.co |access-date=6 April 2022}}</ref> || {{w|Canada}}
 
| 2007 || Research reagents || Company launch || {{w|MyBioSource}} is founded.<ref>{{cite web |title=MyBioSource Inc. Scholarship for All Majors |url=https://www.unigo.com/scholarships/high-school-students/scholarships-for-high-school-seniors/mybiosource-inc-scholarship-for-all-majors |website=Unigo.com |access-date=6 March 2022 |language=en |date=18 October 2019}}</ref> It is a biotechnology distribution company that supplies life science products, notably research reagents.<ref>{{cite web |title=MyBioSource |url=https://craft.co/mybiosource |website=craft.co |access-date=6 April 2022}}</ref> || {{w|Canada}}
 +
|-
 +
| 2007 (May 31) || {{w|Healthcare}}, {{w|pharmaceutical}} || Notable {{w|IPO}} || {{w|Jazz Pharmaceuticals}} completes its IPO, trading under ticker JAZZ on {{w|Nasdaq}}.<ref>{{cite web |title=Jazz Pharmaceuticals - Funding, Financials, Valuation & Investors |url=https://www.crunchbase.com/organization/jazz-pharmaceuticals/company_financials |website=Crunchbase |access-date=2 June 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2007 || Pharmaceutical || Background || The United States {{w|FDA}} approves the H5N1 vaccine, the first vaccine approved for {{w|avian flu}}.<ref name=dhShimasaki/> || {{w|United States}}
 
| 2007 || Pharmaceutical || Background || The United States {{w|FDA}} approves the H5N1 vaccine, the first vaccine approved for {{w|avian flu}}.<ref name=dhShimasaki/> || {{w|United States}}
Line 552: Line 561:
 
| 2008 (March 13) || {{w|Vaccines}}, {{w|biopharmaceutical}} || Company launch || {{w|Braasch Biotech}} is founded. Based in {{w|Garretson, South Dakota}}, it is a biopharmaceutical company working exclusively with therapeutic vaccines.<ref>{{cite web |title=Braasch Biotech LLC - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/braasch-biotech-llc |website=Crunchbase |access-date=8 March 2022 |language=en}}</ref> || {{w|United States}}   
 
| 2008 (March 13) || {{w|Vaccines}}, {{w|biopharmaceutical}} || Company launch || {{w|Braasch Biotech}} is founded. Based in {{w|Garretson, South Dakota}}, it is a biopharmaceutical company working exclusively with therapeutic vaccines.<ref>{{cite web |title=Braasch Biotech LLC - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/braasch-biotech-llc |website=Crunchbase |access-date=8 March 2022 |language=en}}</ref> || {{w|United States}}   
 
|-
 
|-
−
| 2008 || {{w|Biotechnology}}, healthcare, medical<ref name="ACT Biotec"/> || Company launch || {{w|ACT Biotech Inc}} is founded.<ref>{{cite web |title=ACT Biotech |url=https://tracxn.com/d/companies/actbiotech.com |website=tracxn.com |access-date=6 March 2022 |language=en}}</ref> Based in {{w|San Francisco}}, {{w|California}}, it is a biopharmaceutical company focused on the development and commercialization of cancer drugs.<ref name="ACT Biotec">{{cite web |title=ACT Biotech - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/act-biotech |website=Crunchbase |access-date=5 May 2022 |language=en}}</ref> || {{w|United States}}
+
| 2008 || Healthcare, medical<ref name="ACT Biotec"/> || Company launch || {{w|ACT Biotech Inc}} is founded.<ref>{{cite web |title=ACT Biotech |url=https://tracxn.com/d/companies/actbiotech.com |website=tracxn.com |access-date=6 March 2022 |language=en}}</ref> Based in {{w|San Francisco}}, {{w|California}}, it is a biopharmaceutical company focused on the development and commercialization of cancer drugs.<ref name="ACT Biotec">{{cite web |title=ACT Biotech - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/act-biotech |website=Crunchbase |access-date=5 May 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2008 || || Literature || Gordon M. Binder and Philip Bashe publish ''Science Lessons: What the Business of Biotech Taught Me about Management''.<ref>{{cite book |last1=Binder |first1=Gordon M. |last2=Bashe |first2=Philip |title=Science Lessons: What the Business of Biotech Taught Me about Management |date=2008 |publisher=Harvard Business Press |isbn=978-1-59139-861-5 |url=https://books.google.com.ar/books/about/Science_Lessons.html?id=sovtAAAAMAAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
| 2008 || || Literature || Gordon M. Binder and Philip Bashe publish ''Science Lessons: What the Business of Biotech Taught Me about Management''.<ref>{{cite book |last1=Binder |first1=Gordon M. |last2=Bashe |first2=Philip |title=Science Lessons: What the Business of Biotech Taught Me about Management |date=2008 |publisher=Harvard Business Press |isbn=978-1-59139-861-5 |url=https://books.google.com.ar/books/about/Science_Lessons.html?id=sovtAAAAMAAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
−
| 2008 || {{w|Biotechnology}}, chemical, greentech<ref name="BioAmbe"/> || Company launch || {{w|BioAmber}} is founded.<ref>{{cite web |title=S-1/A |url=https://www.sec.gov/Archives/edgar/data/1534287/000119312513151231/d442100ds1a.htm |website=www.sec.gov |access-date=6 March 2022}}</ref> Based in {{w|Plymouth, Minnesota}}, it is a sustainable chemicals firm combining biotechnology and chemical catalysis to convert renewable feedstock into chemicals.<ref name="BioAmbe">{{cite web |title=BioAmber - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/bioamber |website=Crunchbase |access-date=10 May 2022 |language=en}}</ref> || {{w|United States}}
+
| 2008 || Chemical, greentech<ref name="BioAmbe"/> || Company launch || {{w|BioAmber}} is founded.<ref>{{cite web |title=S-1/A |url=https://www.sec.gov/Archives/edgar/data/1534287/000119312513151231/d442100ds1a.htm |website=www.sec.gov |access-date=6 March 2022}}</ref> Based in {{w|Plymouth, Minnesota}}, it is a sustainable chemicals firm combining biotechnology and chemical catalysis to convert renewable feedstock into chemicals.<ref name="BioAmbe">{{cite web |title=BioAmber - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/bioamber |website=Crunchbase |access-date=10 May 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2008 || {{w|Immunotherapy}}, [[w:Nucleoside-modified messenger RNA|mRNA-based human therapeutic]] || Company launch || {{w|BioNTech}} (see [[Timeline of BioNTech]]) is founded.<ref>{{cite web |title=La vacuna del covid-19 catapulta al estrellato a los fundadores de BioNTech |url=https://www.france24.com/es/minuto-a-minuto/20201113-la-vacuna-del-covid-19-catapulta-al-estrellato-a-los-fundadores-de-biontech |website=France 24 |access-date=6 March 2022 |date=13 November 2020}}</ref> || {{w|Germany}}
 
| 2008 || {{w|Immunotherapy}}, [[w:Nucleoside-modified messenger RNA|mRNA-based human therapeutic]] || Company launch || {{w|BioNTech}} (see [[Timeline of BioNTech]]) is founded.<ref>{{cite web |title=La vacuna del covid-19 catapulta al estrellato a los fundadores de BioNTech |url=https://www.france24.com/es/minuto-a-minuto/20201113-la-vacuna-del-covid-19-catapulta-al-estrellato-a-los-fundadores-de-biontech |website=France 24 |access-date=6 March 2022 |date=13 November 2020}}</ref> || {{w|Germany}}
Line 562: Line 571:
 
| 2008 || Renewable chemicals || Company launch || {{w|BioTork}} is founded.<ref>{{cite web |title=About: BioTork |url=https://dbpedia.org/page/BioTork |website=dbpedia.org |access-date=6 March 2022}}</ref> It focuses on sustainability through the development of microbial strains and bioconversion processes.<ref>{{cite web |title=BioTork - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/biotork |website=Crunchbase |access-date=24 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2008 || Renewable chemicals || Company launch || {{w|BioTork}} is founded.<ref>{{cite web |title=About: BioTork |url=https://dbpedia.org/page/BioTork |website=dbpedia.org |access-date=6 March 2022}}</ref> It focuses on sustainability through the development of microbial strains and bioconversion processes.<ref>{{cite web |title=BioTork - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/biotork |website=Crunchbase |access-date=24 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2008 || {{w|Biotechnology}}, {{w|healthcare}}, {{w|health diagnostics}}, {{w|hospital}} || Company launch || {{w|Epic Sciences}} is founded. Based in {{w|La Jolla, California}}, it is a diagnostics company engaged in the improvement of cancer management by providing real-time biopsy material to guide personalized medicine.<ref>{{cite web |title=Epic Sciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/epic-sciences |website=Crunchbase |access-date=8 March 2022 |language=en}}</ref> || {{w|United States}}
+
| 2008 || {{w|Healthcare}}, {{w|health diagnostics}}, {{w|hospital}} || Company launch || {{w|Epic Sciences}} is founded. Based in {{w|La Jolla, California}}, it is a diagnostics company engaged in the improvement of cancer management by providing real-time biopsy material to guide personalized medicine.<ref>{{cite web |title=Epic Sciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/epic-sciences |website=Crunchbase |access-date=8 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2008 || {{w|DNA Sequencing}} || Company launch || {{w|Cofactor Genomics}} is founded.<ref>{{cite web |title=Cofactor Genomics awarded $1.5 million grant from NIH |url=https://www.bizjournals.com/stlouis/blog/biznext/2015/07/cofactor-genomics-awarded-1-5-million-grant-from.html |website=www.bizjournals.com |access-date=8 March 2022}}</ref> It focuses in the use of RNA to diagnose disease.<ref>{{cite web |title=Cofactor Genomics is hiring a Computational Scientist (San Francisco, CA) |url=https://www.biostars.org/p/334419/ |website=www.biostars.org |access-date=24 March 2022}}</ref> Based in {{w|San Francisco, California}}, it is a DNA Sequencing company that focuses on the discovery process.<ref>{{cite web |title=COFACTOR GENOMICS |url=https://www.arcturis.com/cofactorgenomics |website=ARCTURIS |access-date=19 May 2022}}</ref> || {{w|United States}}
 
| 2008 || {{w|DNA Sequencing}} || Company launch || {{w|Cofactor Genomics}} is founded.<ref>{{cite web |title=Cofactor Genomics awarded $1.5 million grant from NIH |url=https://www.bizjournals.com/stlouis/blog/biznext/2015/07/cofactor-genomics-awarded-1-5-million-grant-from.html |website=www.bizjournals.com |access-date=8 March 2022}}</ref> It focuses in the use of RNA to diagnose disease.<ref>{{cite web |title=Cofactor Genomics is hiring a Computational Scientist (San Francisco, CA) |url=https://www.biostars.org/p/334419/ |website=www.biostars.org |access-date=24 March 2022}}</ref> Based in {{w|San Francisco, California}}, it is a DNA Sequencing company that focuses on the discovery process.<ref>{{cite web |title=COFACTOR GENOMICS |url=https://www.arcturis.com/cofactorgenomics |website=ARCTURIS |access-date=19 May 2022}}</ref> || {{w|United States}}
Line 576: Line 585:
 
| 2008 || Biotechnology, Human resources, {{w|search engine}} || Company launch || Stemgent is founded.<ref>{{cite web |title=REPROCELL Brand: Stemgent |url=https://www.reprocell.com/en-us/stemgent |website=www.reprocell.com |access-date=8 March 2022 |language=en-us}}</ref> Based in {{w|Cambridge, Massachusetts}}, it is a provider of reagents, services and training for scientists who study cellular reprogramming (iPS cells).<ref>{{cite web |title=Stemgent - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/stemgent#:~:text=Stemgent%20is%20a%20provider%20of,cellular%20reprogramming%20(iPS%20cells). |website=Crunchbase |access-date=24 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2008 || Biotechnology, Human resources, {{w|search engine}} || Company launch || Stemgent is founded.<ref>{{cite web |title=REPROCELL Brand: Stemgent |url=https://www.reprocell.com/en-us/stemgent |website=www.reprocell.com |access-date=8 March 2022 |language=en-us}}</ref> Based in {{w|Cambridge, Massachusetts}}, it is a provider of reagents, services and training for scientists who study cellular reprogramming (iPS cells).<ref>{{cite web |title=Stemgent - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/stemgent#:~:text=Stemgent%20is%20a%20provider%20of,cellular%20reprogramming%20(iPS%20cells). |website=Crunchbase |access-date=24 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2008 || {{w|Biotechnology}}, [[w:Pharmaceutical industry|Pharmaceutical]] || Literature || Martin Austin publishes ''Business Development for the Biotechnology and Pharmaceutical Industry''.<ref>{{cite book |last1=Austin |first1=Mr Martin |title=Business Development for the Biotechnology and Pharmaceutical Industry |date=28 September 2012 |publisher=Gower Publishing, Ltd. |isbn=978-1-4094-5822-7 |url=https://books.google.com.ar/books/about/Business_Development_for_the_Biotechnolo.html?id=cPIKzQjSuOMC&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
+
| 2008 || [[w:Pharmaceutical industry|Pharmaceutical]] || Literature || Martin Austin publishes ''Business Development for the Biotechnology and Pharmaceutical Industry''.<ref>{{cite book |last1=Austin |first1=Mr Martin |title=Business Development for the Biotechnology and Pharmaceutical Industry |date=28 September 2012 |publisher=Gower Publishing, Ltd. |isbn=978-1-4094-5822-7 |url=https://books.google.com.ar/books/about/Business_Development_for_the_Biotechnolo.html?id=cPIKzQjSuOMC&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
 
| 2008 || [[w:Pharmaceutical industry|Pharmaceutical]] || Literature || R. Berry Ira and Robert P. Martin publish ''The Pharmaceutical Regulatory Process''.<ref>{{cite book |last1=Berry |first1=Ira R. |last2=Martin |first2=Robert P. |title=The Pharmaceutical Regulatory Process, Second Edition |date=2 December 2008 |publisher=Taylor & Francis |isbn=978-1-4200-7042-2 |url=https://books.google.com.ar/books?id=jH_KwAEACAAJ&dq=The+Pharmaceutical+Regulatory+Process&hl=en&sa=X&redir_esc=y |language=en}}</ref> ||
 
| 2008 || [[w:Pharmaceutical industry|Pharmaceutical]] || Literature || R. Berry Ira and Robert P. Martin publish ''The Pharmaceutical Regulatory Process''.<ref>{{cite book |last1=Berry |first1=Ira R. |last2=Martin |first2=Robert P. |title=The Pharmaceutical Regulatory Process, Second Edition |date=2 December 2008 |publisher=Taylor & Francis |isbn=978-1-4200-7042-2 |url=https://books.google.com.ar/books?id=jH_KwAEACAAJ&dq=The+Pharmaceutical+Regulatory+Process&hl=en&sa=X&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
−
| 2009 || {{w|Biotechnology}} || Literature || Alexandra Carina Gruber publishes ''Biotech Funding Trends: Insights from Entrepreneurs and Investors''.<ref>{{cite book |last1=Gruber |first1=Alexandra Carina |title=Biotech Funding Trends: Insights from Entrepreneurs and Investors |date=17 February 2009 |publisher=Wiley |isbn=978-3-527-32435-4 |url=https://books.google.com.ar/books?id=sS30wAEACAAJ&dq=Biotech+Funding+Trends:+Insights+from+Entrepreneurs+and+Investors&hl=en&sa=X&redir_esc=y |language=en}}</ref> ||
+
| 2009 || || Literature || Alexandra Carina Gruber publishes ''Biotech Funding Trends: Insights from Entrepreneurs and Investors''.<ref>{{cite book |last1=Gruber |first1=Alexandra Carina |title=Biotech Funding Trends: Insights from Entrepreneurs and Investors |date=17 February 2009 |publisher=Wiley |isbn=978-3-527-32435-4 |url=https://books.google.com.ar/books?id=sS30wAEACAAJ&dq=Biotech+Funding+Trends:+Insights+from+Entrepreneurs+and+Investors&hl=en&sa=X&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
 
| 2009 || {{w|Medical diagnosis}} || Company launch || {{w|OME Care}} is founded.<ref>{{cite web |last1=Ebemidayo |first1=Fiyin |title=Pathway Genomics review - 7 facts you should know [JANUARY 2021] |url=https://nebula.org/blog/pathway-genomics-review/ |website=Nebula Genomics Blog |access-date=8 March 2022 |date=4 January 2021}}</ref> Based in {{w|San Diego, California}}, it is a precision medical diagnostic and home-care company with {{w|mobile application}}s. || {{w|United States}}
 
| 2009 || {{w|Medical diagnosis}} || Company launch || {{w|OME Care}} is founded.<ref>{{cite web |last1=Ebemidayo |first1=Fiyin |title=Pathway Genomics review - 7 facts you should know [JANUARY 2021] |url=https://nebula.org/blog/pathway-genomics-review/ |website=Nebula Genomics Blog |access-date=8 March 2022 |date=4 January 2021}}</ref> Based in {{w|San Diego, California}}, it is a precision medical diagnostic and home-care company with {{w|mobile application}}s. || {{w|United States}}
 
|-
 
|-
−
| 2009 || {{w|Biotechnology}} || Literature || Craig D. Shimasaki publishes ''The Business of Bioscience: What goes into making a Biotechnology Product''.<ref name=dhShimasaki>{{cite book |last1=Shimasaki |first1=Craig |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies |date=8 April 2014 |publisher=Academic Press |isbn=978-0-12-404747-1 |url=https://books.google.com.ar/books/about/Biotechnology_Entrepreneurship.html?id=8AfUAgAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
+
| 2009 || || Literature || Craig D. Shimasaki publishes ''The Business of Bioscience: What goes into making a Biotechnology Product''.<ref name=dhShimasaki>{{cite book |last1=Shimasaki |first1=Craig |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies |date=8 April 2014 |publisher=Academic Press |isbn=978-0-12-404747-1 |url=https://books.google.com.ar/books/about/Biotechnology_Entrepreneurship.html?id=8AfUAgAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
 
| 2009 || {{w|Cancer immunotherapy}} || Company launch || {{w|Kite Pharma}} is founded.<ref>{{cite web |title=Our Focus on Cell Therapy {{!}} Kite Pharma |url=https://www.kitepharma.com/about-us/our-story |website=www.kitepharma.com |access-date=8 March 2022 |language=en}}</ref> It designs and develops immune-based therapies to treat cancer indications.<ref>{{cite web |title=Kite Pharma - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/kite-pharma |website=Crunchbase |access-date=21 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2009 || {{w|Cancer immunotherapy}} || Company launch || {{w|Kite Pharma}} is founded.<ref>{{cite web |title=Our Focus on Cell Therapy {{!}} Kite Pharma |url=https://www.kitepharma.com/about-us/our-story |website=www.kitepharma.com |access-date=8 March 2022 |language=en}}</ref> It designs and develops immune-based therapies to treat cancer indications.<ref>{{cite web |title=Kite Pharma - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/kite-pharma |website=Crunchbase |access-date=21 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2009 || {{w|Cannabis}}-based medicine || Company launch || {{w|Cannabis Science}} is registered and receives its initial Federal Commercial and Government Entity (CAGE) Code clearance. It is one of the only companies in its industry with the ability to work directly with the US Federal Government.<ref>{{cite web |last1=Inc |first1=Cannabis Science |title=Cannabis Science Has US Federal Government Clearance that Changes the Industry, Access to Federal Government Contracts, Supported US Federal Governments Since 2009, Looks for New Federal Policy to Properly Regulate Industry for Patients |url=https://www.globenewswire.com/en/news-release/2018/01/05/1284147/0/en/Cannabis-Science-Has-US-Federal-Government-Clearance-that-Changes-the-Industry-Access-to-Federal-Government-Contracts-Supported-US-Federal-Governments-Since-2009-Looks-for-New-Fede.html |website=GlobeNewswire News Room |access-date=3 March 2022 |language=en |date=5 January 2018}}</ref> || {{w|United States}}
 
| 2009 || {{w|Cannabis}}-based medicine || Company launch || {{w|Cannabis Science}} is registered and receives its initial Federal Commercial and Government Entity (CAGE) Code clearance. It is one of the only companies in its industry with the ability to work directly with the US Federal Government.<ref>{{cite web |last1=Inc |first1=Cannabis Science |title=Cannabis Science Has US Federal Government Clearance that Changes the Industry, Access to Federal Government Contracts, Supported US Federal Governments Since 2009, Looks for New Federal Policy to Properly Regulate Industry for Patients |url=https://www.globenewswire.com/en/news-release/2018/01/05/1284147/0/en/Cannabis-Science-Has-US-Federal-Government-Clearance-that-Changes-the-Industry-Access-to-Federal-Government-Contracts-Supported-US-Federal-Governments-Since-2009-Looks-for-New-Fede.html |website=GlobeNewswire News Room |access-date=3 March 2022 |language=en |date=5 January 2018}}</ref> || {{w|United States}}
 +
|-
 +
| 2009 (July 6) || || Fund launch || Janus Henderson Global Life Sciences Fund Class A ({{w|ticker symbol}} JFNAX) is launched in the United States.<ref>{{cite web |title=Janus Henderson Global Life Sciences Fund Class A, JFNAX summary - FT.com |url=https://markets.ft.com/data/funds/tearsheet/summary?s=JFNAX |website=markets.ft.com |access-date=1 July 2022}}</ref> It mostly invests in companies that the portfolio managers believe have a life science orientation.<ref>{{cite web |title=Janus Henderson Global Life Sciences Fund Class A (JFNAX) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/JFNAX/ |website=finance.yahoo.com |access-date=8 July 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2009 (August 17) || {{w|Biopharmaceutical}}, {{w|pharmaceutical}}, {{w|medical device}}s || Company launch || {{w|Siam Bioscience}} is founded.<ref>{{cite web |title=siambioscience {{!}} Think of success think of siam bio science |url=https://www.siambioscience.com/?lang=en |website=siambioscience.com |access-date=3 March 2022}}</ref> It is a life sciences business focusing on biopharmaceuticals.<ref>{{cite web |title=Siam Bioscience - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/siam-bioscience |website=Crunchbase |access-date=25 March 2022 |language=en}}</ref> || {{w|Thailand}}
 
| 2009 (August 17) || {{w|Biopharmaceutical}}, {{w|pharmaceutical}}, {{w|medical device}}s || Company launch || {{w|Siam Bioscience}} is founded.<ref>{{cite web |title=siambioscience {{!}} Think of success think of siam bio science |url=https://www.siambioscience.com/?lang=en |website=siambioscience.com |access-date=3 March 2022}}</ref> It is a life sciences business focusing on biopharmaceuticals.<ref>{{cite web |title=Siam Bioscience - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/siam-bioscience |website=Crunchbase |access-date=25 March 2022 |language=en}}</ref> || {{w|Thailand}}
 +
|-
 +
| 2009 (September) || {{w|Pharmaceutical}} || Legal || Pfizer is fined $2.3 billion for illegal marketing promoting uses of four of its drugs, including the painkiller Bextra ({{w|Valdecoxib}}),<ref>{{cite web |last1=News |first1=A. B. C. |title=Pfizer fined $2.3 billion for illegal marketing in off-label drug case |url=https://abcnews.go.com/Business/pfizer-fined-23-billion-illegal-marketing-off-label/story?id=8477617 |website=ABC News |access-date=7 June 2022 |language=en}}</ref> after the company promoted Bextra for several uses and dosages that the {{w|FDA}} specifically declined to approve due to safety concerns.<ref>{{cite web |title=Justice Department Announces Largest Health Care Fraud Settlement in Its History |url=https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history |website=www.justice.gov |access-date=7 June 2022 |language=en |date=2 September 2009}}</ref><ref>{{cite web |last1=Harris |first1=Gardiner |title=Pfizer Pays $2.3 Billion to Settle Marketing Case |url=https://www.nytimes.com/2009/09/03/business/03health.html |website=The New York Times |access-date=7 June 2022 |date=2 September 2009}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2010 || {{w|Applied research}}, {{w|R&D}} || Company launch || The {{w|Austrian Centre of Industrial Biotechnology}} is founded.<ref>{{cite web |title=Austrian Centre of Industrial Biotechnology |url=https://ati.ec.europa.eu/technology-centre/austrian-centre-industrial-biotechnology |website=Advanced Technologies for Industry |access-date=8 March 2022 |language=en}}</ref> It is a privately owned non-profit research center specialized on "bridging the gap between basic academic research and experimental industrial development".<ref>{{cite web |title=Austrian Centre of Industrial Biotechnology |url=https://ati.ec.europa.eu/technology-centre/austrian-centre-industrial-biotechnology#:~:text=The%20Austrian%20Centre%20of%20Industrial,research%20and%20experimental%20industrial%20development. |website=Advanced Technologies for Industry |access-date=25 March 2022 |language=en}}</ref> || {{w|Austria}}
 
| 2010 || {{w|Applied research}}, {{w|R&D}} || Company launch || The {{w|Austrian Centre of Industrial Biotechnology}} is founded.<ref>{{cite web |title=Austrian Centre of Industrial Biotechnology |url=https://ati.ec.europa.eu/technology-centre/austrian-centre-industrial-biotechnology |website=Advanced Technologies for Industry |access-date=8 March 2022 |language=en}}</ref> It is a privately owned non-profit research center specialized on "bridging the gap between basic academic research and experimental industrial development".<ref>{{cite web |title=Austrian Centre of Industrial Biotechnology |url=https://ati.ec.europa.eu/technology-centre/austrian-centre-industrial-biotechnology#:~:text=The%20Austrian%20Centre%20of%20Industrial,research%20and%20experimental%20industrial%20development. |website=Advanced Technologies for Industry |access-date=25 March 2022 |language=en}}</ref> || {{w|Austria}}
Line 616: Line 629:
 
| 2011 || Infertility treatment || Company launch || {{w|OvaScience}} is founded.<ref>{{cite web |title=OvaScience - Case - Faculty & Research - Harvard Business School |url=https://www.hbs.edu/faculty/Pages/item.aspx?num=47716 |website=www.hbs.edu |access-date=8 March 2022}}</ref> Based in {{w|Boston, Massachusetts}}, it is a life sciences company focused on the discovery, development and commercialization of treatments for infertility. It would be later acquired by Millendo Therapeutics.<ref>{{cite web |title=OvaScience - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/ovascience |website=Crunchbase |access-date=27 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2011 || Infertility treatment || Company launch || {{w|OvaScience}} is founded.<ref>{{cite web |title=OvaScience - Case - Faculty & Research - Harvard Business School |url=https://www.hbs.edu/faculty/Pages/item.aspx?num=47716 |website=www.hbs.edu |access-date=8 March 2022}}</ref> Based in {{w|Boston, Massachusetts}}, it is a life sciences company focused on the discovery, development and commercialization of treatments for infertility. It would be later acquired by Millendo Therapeutics.<ref>{{cite web |title=OvaScience - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/ovascience |website=Crunchbase |access-date=27 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2011 || {{w|Biotechnology}}, {{w|healthcare}}, {{w|therapeutics}} || Company launch || {{w|Permeon Biologics}} is founded.<ref>{{cite web |title=Permeon Biologics |url=https://www.flagshippioneering.com/companies/permeon-biologics |website=Flagship Pioneering |access-date=8 March 2022}}</ref> Based in {{w|Cambridge, Massachusetts}}, it is a developer of therapeutic drugs.<ref>{{cite web |title=Permeon Biologics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/permeon-biologics |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
+
| 2011 || {{w|Healthcare}}, {{w|therapeutics}} || Company launch || {{w|Permeon Biologics}} is founded.<ref>{{cite web |title=Permeon Biologics |url=https://www.flagshippioneering.com/companies/permeon-biologics |website=Flagship Pioneering |access-date=8 March 2022}}</ref> Based in {{w|Cambridge, Massachusetts}}, it is a developer of therapeutic drugs.<ref>{{cite web |title=Permeon Biologics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/permeon-biologics |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2011 || {{w|Genomics}}, {{w|radiomics}} ||  Company launch || {{w|Sophia Genetics}} is founded.<ref>{{cite web |title=SOPHiA GENETICS |url=https://www.invest-vaud.ch/Portals/4/Files/Portraits/EN_2020/%5BEN%5D_LN_VD_SuccessStory_SophiaGenetics.pdf |website=invest-vaud.ch |access-date=8 March 2022}}</ref> It is a healthcare technology company dedicated to establishing the practice of data driven medicine as the standard of care and for life sciences research.<ref>{{cite web |title=SOPHiA GENETICS |url=https://www.sophiagenetics.com/wp-content/uploads/2021/07/SOPHiA-GENETICS-Quick-Facts.pdf |website=sophiagenetics |access-date=6 April 2022}}</ref> || {{w|Switzerland}}, {{w|United States}}
 
| 2011 || {{w|Genomics}}, {{w|radiomics}} ||  Company launch || {{w|Sophia Genetics}} is founded.<ref>{{cite web |title=SOPHiA GENETICS |url=https://www.invest-vaud.ch/Portals/4/Files/Portraits/EN_2020/%5BEN%5D_LN_VD_SuccessStory_SophiaGenetics.pdf |website=invest-vaud.ch |access-date=8 March 2022}}</ref> It is a healthcare technology company dedicated to establishing the practice of data driven medicine as the standard of care and for life sciences research.<ref>{{cite web |title=SOPHiA GENETICS |url=https://www.sophiagenetics.com/wp-content/uploads/2021/07/SOPHiA-GENETICS-Quick-Facts.pdf |website=sophiagenetics |access-date=6 April 2022}}</ref> || {{w|Switzerland}}, {{w|United States}}
 +
|-
 +
| 2011 || || Accelerator/incubator launch || StartUp Health is launched as a venture capital firm. Based in {{w|San Francisco}}, it seeks to invest in early stage companies operating in the healthcare and technology sectors.<ref>{{cite web |title=StartUp Health Investor Profile: Portfolio & Exits {{!}} PitchBook |url=https://pitchbook.com/profiles/investor/54331-57#:~:text=Founded%20in%202011%2C%20StartUp%20Health,the%20healthcare%20and%20technology%20sectors. |website=pitchbook.com |access-date=29 June 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2011 || {{w|Cellular senescence}} || Company launch || {{w|Unity Biotechnology}} is founded.<ref>{{cite web |title=The Science • Unity Biotechnology |url=https://unitybiotechnology.com/the-science/ |website=Unity Biotechnology • Developing therapeutics to slow, halt, or reverse diseases of aging. |access-date=8 March 2022 |language=en |date=11 April 2018}}</ref> It is a startup biotechnology company that develops drugs which target senescent cells.<ref>{{cite web |title=About: Unity Biotechnology |url=https://dbpedia.org/page/Unity_Biotechnology |website=dbpedia.org |access-date=6 April 2022}}</ref> || {{w|United States}}
 
| 2011 || {{w|Cellular senescence}} || Company launch || {{w|Unity Biotechnology}} is founded.<ref>{{cite web |title=The Science • Unity Biotechnology |url=https://unitybiotechnology.com/the-science/ |website=Unity Biotechnology • Developing therapeutics to slow, halt, or reverse diseases of aging. |access-date=8 March 2022 |language=en |date=11 April 2018}}</ref> It is a startup biotechnology company that develops drugs which target senescent cells.<ref>{{cite web |title=About: Unity Biotechnology |url=https://dbpedia.org/page/Unity_Biotechnology |website=dbpedia.org |access-date=6 April 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2011 (December 18) || Vaccine shipping and storage || Company launch || {{w|Vaxess Technologies}} is founded. Based in {{w|Cambridge, Massachusetts}}, it engages in developing biomedical innovations with a focus on improving access to vaccines.<ref>{{cite web |title=Vaxess Technologies - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/vaxess-technologies |website=Crunchbase |access-date=8 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2011 (December 18) || Vaccine shipping and storage || Company launch || {{w|Vaxess Technologies}} is founded. Based in {{w|Cambridge, Massachusetts}}, it engages in developing biomedical innovations with a focus on improving access to vaccines.<ref>{{cite web |title=Vaxess Technologies - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/vaxess-technologies |website=Crunchbase |access-date=8 March 2022 |language=en}}</ref> || {{w|United States}}
 +
|-
 +
| 2011 (December 20) || || Fund launch || VanEck Biotech ETF ({{w|ticker symbol}} BBH) is launched in the United States, where it is available as well as in {{w|Chile}} and {{w|Mexico}}.<ref>{{cite web |title=VanEck Biotech ETF, BBH:NMQ:USD summary - FT.com |url=https://markets.ft.com/data/etfs/tearsheet/summary?s=BBH:NMQ:USD |website=markets.ft.com |access-date=1 July 2022}}</ref> It invests in common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry.<ref>{{cite web |title=VanEck Biotech ETF (BBH) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/BBH?p=BBH&.tsrc=fin-srch |website=finance.yahoo.com |access-date=8 July 2022}}</ref> || {{w|United States}} 
 +
|-
 +
| 2012 (January) || {{w|Healthcare}} || Accelerator/Incubator launch || JLABS is founded.<ref>{{cite web |title=The JLABS Story: How a Johnson & Johnson Incubator Is Helping Nurture the Next Great Healthcare Breakthroughs |url=https://www.jnj.com/innovation/the-jlabs-story-how-a-johnson-and-johnson-incubator-is-helping-nurture-healthcare-breakthroughs#:~:text=Today%2C%20JLABS%20is%20an%20integral,with%20Richter%20at%20the%20helm. |website=Content Lab U.S. |access-date=29 June 2022 |language=en |date=31 January 2017}}</ref> It is an innovation incubator arm of {{w|Johnson & Johnson}}.<ref>{{cite web |last1=Landi |first1=Heather |title=JLABS executive on the ROI of a 'no-strings-attached' health tech incubator |url=https://www.fiercehealthcare.com/tech/jlabs-executive-roi-a-no-strings-attached-health-tech-incubator |website=Fierce Healthcare |access-date=29 June 2022 |language=en |date=22 May 2019}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2012 (May 2) || || Literature || M. O'Neill and M. M. Hopkins publish ''A Biotech Manager's Handbook: A Practical Guide'', which outlines the state of the biopharmaceutical industry and goes on to explain the importance of planning.<ref>{{cite book |last1=O'Neill |first1=M. |last2=Hopkins |first2=M. M. |title=A Biotech Manager's Handbook: A Practical Guide |date=2 May 2012 |publisher=Elsevier |isbn=978-1-908818-15-7 |url=https://books.google.com.ar/books/about/A_Biotech_Manager_s_Handbook.html?id=EptlAgAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
| 2012 (May 2) || || Literature || M. O'Neill and M. M. Hopkins publish ''A Biotech Manager's Handbook: A Practical Guide'', which outlines the state of the biopharmaceutical industry and goes on to explain the importance of planning.<ref>{{cite book |last1=O'Neill |first1=M. |last2=Hopkins |first2=M. M. |title=A Biotech Manager's Handbook: A Practical Guide |date=2 May 2012 |publisher=Elsevier |isbn=978-1-908818-15-7 |url=https://books.google.com.ar/books/about/A_Biotech_Manager_s_Handbook.html?id=EptlAgAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
Line 629: Line 648:
 
|-
 
|-
 
| 2012 || {{w|Nanotechnology}} || Company launch || {{w|Tecrea}} is founded.<ref>{{cite web |title=Company Information |url=https://www.tecrea.com/company-information/ |website=Tecrea |access-date=9 March 2022 |language=en}}</ref> Based in {{w|London}}, it aims to provide vastly improved cell delivery technology for research and the clinic.<ref>{{cite web |title=Tecrea - a client of LBIC London BioScience Innovation Centre |url=https://www.lbic.com/tecrea-ltd#:~:text=Tecrea%20is%20a%20small%20and,for%20research%20and%20the%20clinic. |website=LBIC {{!}} Life Sciences, Biotechnology, Offices & Labs {{!}} London BioScience Innovation Centre |access-date=10 May 2022}}</ref> Tecrea's nanotechnology-based cell delivery system is used as a non-toxic method of transfection.<ref>{{cite web |title=Home |url=https://www.tecrea.com/ |website=Tecrea |access-date=20 May 2022 |language=en}}</ref> || {{w|United Kingdom}}
 
| 2012 || {{w|Nanotechnology}} || Company launch || {{w|Tecrea}} is founded.<ref>{{cite web |title=Company Information |url=https://www.tecrea.com/company-information/ |website=Tecrea |access-date=9 March 2022 |language=en}}</ref> Based in {{w|London}}, it aims to provide vastly improved cell delivery technology for research and the clinic.<ref>{{cite web |title=Tecrea - a client of LBIC London BioScience Innovation Centre |url=https://www.lbic.com/tecrea-ltd#:~:text=Tecrea%20is%20a%20small%20and,for%20research%20and%20the%20clinic. |website=LBIC {{!}} Life Sciences, Biotechnology, Offices & Labs {{!}} London BioScience Innovation Centre |access-date=10 May 2022}}</ref> Tecrea's nanotechnology-based cell delivery system is used as a non-toxic method of transfection.<ref>{{cite web |title=Home |url=https://www.tecrea.com/ |website=Tecrea |access-date=20 May 2022 |language=en}}</ref> || {{w|United Kingdom}}
 +
|-
 +
| 2012 || || Accelerator/incubator launch || The California Institute for Biomedical Research (Calibr) is founded as a non-profit with the goal to accelerate the translation of basic research to new medicines that address unmet medical needs.<ref>{{cite web |title=California Institute for Biomedical Research (Calibr) |url=https://www.devex.com/organizations/california-institute-for-biomedical-research-calibr-56685#:~:text=The%20California%20Institute%20for%20Biomedical,that%20address%20unmet%20medical%20needs. |website=devex |access-date=29 June 2022}}</ref> Calibr is a division of Scripps Research and situated in the middle of San Diego’s Torrey Pines Mesa biomedical research hub.<ref name="Top 15 biotech incubators and accelerators in the US"/> || {{w|United States}}
 +
|-
 +
| 2012 (July) || {{w|Pharmaceutical}} || Legal || GlaxoSmithKline agrees to plead guilty and pay $3 billion to settle the largest case of healthcare fraud in the United States to date, as the company is charged for unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices.<ref>{{cite web |title=GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data |url=https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report |website=www.justice.gov |access-date=7 June 2022 |language=en |date=2 July 2012}}</ref> || {{w|United States}}
 +
|-
 +
| 2012 (September 20) || || Accelerator/incubator launch || {{w|Massachusetts}}-based non-profit Lab Central is founded as a launchpad for highly prospective life sciences and biotech start-ups.<ref name="Top 15 biotech incubators and accelerators in the US"/> || {{w|United States}}
 
|-
 
|-
 
| 2012 (October 23) || {{w|Bioinformatics}}, plant breeding and phenotyping, {{w|software}} || Company launch || {{w|Computomics}} is founded.<ref>{{cite web |title=Computomics • chemical startup {{!}} HTGF |url=https://www.htgf.de/en/portfolio/htgffamily/computomics-2/ |website=www.htgf.de |access-date=9 March 2022}}</ref> BAsed in {{w|Tübingen}},{{w|Germany}}, it specializes in machine learning, plant research and bioinformatics, using data "to unlock the diversity of biological life".<ref>{{cite web |title=Computomics |url=https://www.basf.com/global/en/who-we-are/organization/group-companies/BASF_Venture-Capital/portfolio/computomics.html#:~:text=Computomics%20is%20a%20team%20of,such%20as%20local%20environmental%20data. |website=www.basf.com |access-date=17 March 2022}}</ref> || {{w|Germany}}
 
| 2012 (October 23) || {{w|Bioinformatics}}, plant breeding and phenotyping, {{w|software}} || Company launch || {{w|Computomics}} is founded.<ref>{{cite web |title=Computomics • chemical startup {{!}} HTGF |url=https://www.htgf.de/en/portfolio/htgffamily/computomics-2/ |website=www.htgf.de |access-date=9 March 2022}}</ref> BAsed in {{w|Tübingen}},{{w|Germany}}, it specializes in machine learning, plant research and bioinformatics, using data "to unlock the diversity of biological life".<ref>{{cite web |title=Computomics |url=https://www.basf.com/global/en/who-we-are/organization/group-companies/BASF_Venture-Capital/portfolio/computomics.html#:~:text=Computomics%20is%20a%20team%20of,such%20as%20local%20environmental%20data. |website=www.basf.com |access-date=17 March 2022}}</ref> || {{w|Germany}}
 +
|-
 +
| 2012 || || Accelerator/incubator launch || StartX Med is founded with the purpose to accelerate the development of high-potential entrepreneurs in the life sciences and medicine through experiential education and collaborative intelligence.<ref>{{cite web |title=StartX Med |url=https://www.linkedin.com/company/startx-med/about/ |website=linkedin |access-date=29 June 2022}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2012 || Protein for animal and fish feed || Company launch || {{w|Calysta}} is founded.<ref>{{cite web |title=Company - Calysta - Innovative and Sustainable Industrial Products |url=https://calysta.com/about-us/ |website=Calysta |access-date=9 March 2022}}</ref> Based in {{w|Menlo Park, California}}, it develops alternative protein ingredients.<ref>{{cite web |title=Adisseo and Calysta joint venture to help feed our future |url=http://www.feedkind.com/adisseo-calysta-joint-venture-help-feed-future/ |website=FeedKind® |access-date=24 March 2022 |date=21 April 2020}}</ref> || {{w|United States}}
 
| 2012 || Protein for animal and fish feed || Company launch || {{w|Calysta}} is founded.<ref>{{cite web |title=Company - Calysta - Innovative and Sustainable Industrial Products |url=https://calysta.com/about-us/ |website=Calysta |access-date=9 March 2022}}</ref> Based in {{w|Menlo Park, California}}, it develops alternative protein ingredients.<ref>{{cite web |title=Adisseo and Calysta joint venture to help feed our future |url=http://www.feedkind.com/adisseo-calysta-joint-venture-help-feed-future/ |website=FeedKind® |access-date=24 March 2022 |date=21 April 2020}}</ref> || {{w|United States}}
Line 640: Line 667:
 
| 2012 || || Literature || Martin Austin publishes ''Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries: The Commercialization of Intellectual Property''.<ref>{{cite book |last1=Austin |first1=Mr Martin |title=Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries: The Commercialization of Intellectual Property |date=28 December 2012 |publisher=Gower Publishing, Ltd. |isbn=978-1-4094-8483-7 |url=https://books.google.com.ar/books/about/Licensing_Selling_and_Finance_in_the_Pha.html?id=awSoxBLg8DIC&source=kp_book_description&redir_esc=y |language=en}}</ref> ||   
 
| 2012 || || Literature || Martin Austin publishes ''Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries: The Commercialization of Intellectual Property''.<ref>{{cite book |last1=Austin |first1=Mr Martin |title=Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries: The Commercialization of Intellectual Property |date=28 December 2012 |publisher=Gower Publishing, Ltd. |isbn=978-1-4094-8483-7 |url=https://books.google.com.ar/books/about/Licensing_Selling_and_Finance_in_the_Pha.html?id=awSoxBLg8DIC&source=kp_book_description&redir_esc=y |language=en}}</ref> ||   
 
|-
 
|-
−
| 2012 || {{w|Biotechnology}} || Literature || Michael O'Neill and Michael Hopkins publish ''A biotech managers handbook: A practical guide''.<ref>{{cite book |last1=O'Neill |first1=M. |last2=Hopkins |first2=M. M. |title=A Biotech Manager's Handbook: A Practical Guide |date=2 May 2012 |publisher=Elsevier |isbn=978-1-908818-15-7 |url=https://books.google.com.ar/books?id=EptlAgAAQBAJ&printsec=frontcover&dq=A+biotech+managers+handbook:+A+practical+guide&hl=en&sa=X&redir_esc=y#v=onepage&q=A%20biotech%20managers%20handbook%3A%20A%20practical%20guide&f=false |language=en}}</ref> ||
+
| 2012 || || Literature || Michael O'Neill and Michael Hopkins publish ''A biotech managers handbook: A practical guide''.<ref>{{cite book |last1=O'Neill |first1=M. |last2=Hopkins |first2=M. M. |title=A Biotech Manager's Handbook: A Practical Guide |date=2 May 2012 |publisher=Elsevier |isbn=978-1-908818-15-7 |url=https://books.google.com.ar/books?id=EptlAgAAQBAJ&printsec=frontcover&dq=A+biotech+managers+handbook:+A+practical+guide&hl=en&sa=X&redir_esc=y#v=onepage&q=A%20biotech%20managers%20handbook%3A%20A%20practical%20guide&f=false |language=en}}</ref> ||
 
|-
 
|-
−
| 2012 || || Literature || ''Biotechnology Entrepreneurship''.<ref>{{cite book |last1=Shimasaki |first1=Craig |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies |date=8 April 2014 |publisher=Academic Press |isbn=978-0-12-404747-1 |url=https://books.google.com.ar/books/about/Biotechnology_Entrepreneurship.html?id=8AfUAgAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
+
| 2013 || {{w|Healthcare}}, {{w|medical therapeutics}}<ref name="Stem Cell Theranostics"/> || Company launch || {{w|Stem Cell Theranostics}} is founded.<ref name="Stem Cell Theranostics">{{cite web |title=Stem Cell Theranostics |url=https://www.crunchbase.com/organization/stem-cell-theranostics |website=crunchbase.com |access-date=21 January 2022}}</ref> It is a precision medicine-focused biotechnology company developing genetically-targeted therapies for heart failure.<ref>{{cite web |title=Stem Cell Theranostics |url=https://www.linkedin.com/company/stem-cell-theranostics |website=linkedin |access-date=27 March 2022}}</ref> || {{w|United States}}
−
|-
 
−
| 2013 || {{w|Biotechnology}}, {{w|healthcare}}, {{w|medical therapeutics}}<ref name="Stem Cell Theranostics"/> || Company launch || {{w|Stem Cell Theranostics}} is founded.<ref name="Stem Cell Theranostics">{{cite web |title=Stem Cell Theranostics |url=https://www.crunchbase.com/organization/stem-cell-theranostics |website=crunchbase.com |access-date=21 January 2022}}</ref> It is a precision medicine-focused biotechnology company developing genetically-targeted therapies for heart failure.<ref>{{cite web |title=Stem Cell Theranostics |url=https://www.linkedin.com/company/stem-cell-theranostics |website=linkedin |access-date=27 March 2022}}</ref> || {{w|United States}}
 
 
|-
 
|-
 
| 2013 || {{w|Biopharmaceutical}}s || Company launch || {{w|AbbVie}} is founded as a spin off from {{w|Abbott Laboratories}}.<ref>{{cite web |title=Our Company |url=https://www.abbvie.com/our-company.html |website=AbbVie {{!}} Pharmaceutical Research & Development |access-date=6 March 2022 |language=en}}</ref> It is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products.<ref>{{cite web |title=AbbVie (ABBV) |url=https://www.forbes.com/companies/abbvie/?sh=6bd4f83b510f |website=Forbes |access-date=6 April 2022 |language=en}}</ref><ref>{{cite web |title=AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/ABBV/ |website=finance.yahoo.com |access-date=6 April 2022}}</ref> || {{w|United States}}
 
| 2013 || {{w|Biopharmaceutical}}s || Company launch || {{w|AbbVie}} is founded as a spin off from {{w|Abbott Laboratories}}.<ref>{{cite web |title=Our Company |url=https://www.abbvie.com/our-company.html |website=AbbVie {{!}} Pharmaceutical Research & Development |access-date=6 March 2022 |language=en}}</ref> It is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products.<ref>{{cite web |title=AbbVie (ABBV) |url=https://www.forbes.com/companies/abbvie/?sh=6bd4f83b510f |website=Forbes |access-date=6 April 2022 |language=en}}</ref><ref>{{cite web |title=AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance |url=https://finance.yahoo.com/quote/ABBV/ |website=finance.yahoo.com |access-date=6 April 2022}}</ref> || {{w|United States}}
Line 654: Line 679:
 
| 2013 || {{w|Pharmaceuticals}} || Company launch || {{w|CoCo Therapeutics}} is founded.<ref>{{cite web |title=Company created to progress experimental Alzheimer's disease therapy |url=https://wellcome.org/news/company-created-progress-experimental-alzheimers-disease-therapy |website=Wellcome |access-date=8 March 2022 |language=en}}</ref> It is a British biotechnology company focussed on the discovery of new drugs for the treatment of {{w|Alzheimer's disease}}.<ref>{{cite web |title=CoCo Therapeutics Ltd Announces the Appointment of Its Clinical and Scientific Advisory Group |url=https://www.biospace.com/article/releases/-b-coco-therapeutics-ltd-b-announces-the-appointment-of-its-clinical-and-scientific-advisory-group-/ |website=BioSpace |access-date=16 March 2022}}</ref> || {{w|United Kingdom}}
 
| 2013 || {{w|Pharmaceuticals}} || Company launch || {{w|CoCo Therapeutics}} is founded.<ref>{{cite web |title=Company created to progress experimental Alzheimer's disease therapy |url=https://wellcome.org/news/company-created-progress-experimental-alzheimers-disease-therapy |website=Wellcome |access-date=8 March 2022 |language=en}}</ref> It is a British biotechnology company focussed on the discovery of new drugs for the treatment of {{w|Alzheimer's disease}}.<ref>{{cite web |title=CoCo Therapeutics Ltd Announces the Appointment of Its Clinical and Scientific Advisory Group |url=https://www.biospace.com/article/releases/-b-coco-therapeutics-ltd-b-announces-the-appointment-of-its-clinical-and-scientific-advisory-group-/ |website=BioSpace |access-date=16 March 2022}}</ref> || {{w|United Kingdom}}
 
|-
 
|-
−
| 2013 || {{w|Biotechnology}} || Company launch || {{w|CRISPR Therapeutics}} is founded.<ref>{{cite web |title=CRISPR Therapeutics |url=https://www.sec.gov/Archives/edgar/data/1674416/000119312516774104/R7.htm |website=www.sec.gov |access-date=10 March 2022}}</ref> It is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary {{w|CRISPR/Cas9}} platform.<ref>{{cite web |title=CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial… |url=http://www.crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-and-max-cyte-expand-clinical-and-commercial-license-agreement-into-oncology#:~:text=CRISPR%20Therapeutics%20is%20a%20leading,directed%20changes%20to%20genomic%20DNA. |website=CRISPR |access-date=6 April 2022 |language=en}}</ref> || {{w|Switzerland}}, {{w|United States}}
+
| 2013 || {{w|CRISPR}} || Company launch || {{w|CRISPR Therapeutics}} is founded.<ref>{{cite web |title=CRISPR Therapeutics |url=https://www.sec.gov/Archives/edgar/data/1674416/000119312516774104/R7.htm |website=www.sec.gov |access-date=10 March 2022}}</ref> It is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary {{w|CRISPR/Cas9}} platform.<ref>{{cite web |title=CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial… |url=http://www.crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-and-max-cyte-expand-clinical-and-commercial-license-agreement-into-oncology#:~:text=CRISPR%20Therapeutics%20is%20a%20leading,directed%20changes%20to%20genomic%20DNA. |website=CRISPR |access-date=6 April 2022 |language=en}}</ref> || {{w|Switzerland}}, {{w|United States}}
 
|-
 
|-
−
| 2013 || {{w|Biotechnology}}, {{w|clinical Trial}}s, {{w|healthcare}}, {{w|medical therapeutics}} || Company launch || {{w|Juno Therapeutics}} is founded. Based in {{w|Seattle, Washington}}, it is a clinical-stage company developing immunotherapies for the treatment of cancer.<ref>{{cite web |title=Juno Therapeutics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/juno-therapeutics |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> || {{w|United States}}
+
| 2013 || {{w|Clinical Trial}}s, {{w|healthcare}}, {{w|medical therapeutics}} || Company launch || {{w|Juno Therapeutics}} is founded. Based in {{w|Seattle, Washington}}, it is a clinical-stage company developing immunotherapies for the treatment of cancer.<ref>{{cite web |title=Juno Therapeutics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/juno-therapeutics |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2013 || {{w|Biotechnology}}, {{w|developer platform}}, {{w|sensor}} || Company launch || {{w|Kaitek}} is founded.<ref>{{cite web |title=Kaitek Labs trae seguridad al consumo mundial de mariscos |url=https://medium.com/innovate4health/kaitek-labs-trae-seguridad-al-consumo-mundial-de-mariscos-aaa25917298c |website=Innovate4Health |access-date=10 March 2022 |language=en |date=3 January 2019}}</ref> It is a Chilean biotech company focused on the development of bacterial sensors for environmental monitoring.<ref>{{cite web |title=Kaitek Labs - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/kaitek-labs |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|Chile}}
+
| 2013 || || Accelerator/incubator launch || MBC BioLabs is founded. Based in San Francisco, it is an important biotech incubator in the Bay Area.<ref>{{cite web |title=MBC BioLabs |url=https://www.crunchbase.com/organization/mbc-biolabs |website=crunchbase |access-date=29 June 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 2013 || {{w|Developer platform}}, {{w|sensor}} || Company launch || {{w|Kaitek}} is founded.<ref>{{cite web |title=Kaitek Labs trae seguridad al consumo mundial de mariscos |url=https://medium.com/innovate4health/kaitek-labs-trae-seguridad-al-consumo-mundial-de-mariscos-aaa25917298c |website=Innovate4Health |access-date=10 March 2022 |language=en |date=3 January 2019}}</ref> It is a Chilean biotech company focused on the development of bacterial sensors for environmental monitoring.<ref>{{cite web |title=Kaitek Labs - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/kaitek-labs |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|Chile}}
 
|-
 
|-
 
| 2013 || {{w|Fitness}}, {{w|healthcare}}, {{w|internet}} || Company launch || {{w|MyGenetics}} is founded. Based in {{w|Novosibirsk}}, {{w|Russia}}, it is an internet-based service that determines nutrition plans, physical activity levels, and body reactions to various products.<ref>{{cite web |title=MyGenetics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/mygenetics |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> || {{w|Russia}}
 
| 2013 || {{w|Fitness}}, {{w|healthcare}}, {{w|internet}} || Company launch || {{w|MyGenetics}} is founded. Based in {{w|Novosibirsk}}, {{w|Russia}}, it is an internet-based service that determines nutrition plans, physical activity levels, and body reactions to various products.<ref>{{cite web |title=MyGenetics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/mygenetics |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> || {{w|Russia}}
Line 664: Line 691:
 
| 2013 || {{w|Alternative medicine}}, {{w|biotechnology}}, cloud data services, {{w|genetics}}, {{w|healthcare}}, {{w|life science}} || Company launch || {{w|NantOmics}} is founded. Based in {{w|Culver City, California}}, it develops cloud-based molecular profiling tools that help guide cancer patients.<ref>{{cite web |title=NantOmics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/nantomics |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> || {{w|United States}}
 
| 2013 || {{w|Alternative medicine}}, {{w|biotechnology}}, cloud data services, {{w|genetics}}, {{w|healthcare}}, {{w|life science}} || Company launch || {{w|NantOmics}} is founded. Based in {{w|Culver City, California}}, it develops cloud-based molecular profiling tools that help guide cancer patients.<ref>{{cite web |title=NantOmics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/nantomics |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2013 || {{w|Biotechnology}}, {{w|pharmaceutical}} || Company launch || {{w|Spark Therapeutics}} is founded.<ref>{{cite web |title=We Are Spark – Spark Therapeutics |url=https://sparktx.com/we-are-spark/ |website=sparktx.com |access-date=10 March 2022}}</ref> It is a US-based gene therapy company that specializes in rare disease medicines.<ref>{{cite web |title=Roche purchase of Spark Therapeutics is given the go ahead in UK |url=https://www.europeanpharmaceuticalreview.com/news/108162/roche-purchase-of-spark-therapeutics-is-given-the-go-ahead-in-uk/ |website=European Pharmaceutical Review |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
+
| 2013 || {{w|Pharmaceutical}} || Company launch || {{w|Spark Therapeutics}} is founded.<ref>{{cite web |title=We Are Spark – Spark Therapeutics |url=https://sparktx.com/we-are-spark/ |website=sparktx.com |access-date=10 March 2022}}</ref> It is a US-based gene therapy company that specializes in rare disease medicines.<ref>{{cite web |title=Roche purchase of Spark Therapeutics is given the go ahead in UK |url=https://www.europeanpharmaceuticalreview.com/news/108162/roche-purchase-of-spark-therapeutics-is-given-the-go-ahead-in-uk/ |website=European Pharmaceutical Review |access-date=6 April 2022 |language=en}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2013 || || Market size || Global sales of biotech products exceed $175 billion in the year, representing about 19 percent of the $950 billion in total prescription product sales worldwide.<ref name="Kaitin"/>
 
| 2013 || || Market size || Global sales of biotech products exceed $175 billion in the year, representing about 19 percent of the $950 billion in total prescription product sales worldwide.<ref name="Kaitin"/>
 
|-
 
|-
−
| 2014 || {{w|Biotechnology}}, {{w|genetics}}, {{w|healthcare}}, personal health<ref name="Veritas Gene">{{cite web |title=Veritas Genetics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/veritas-genetics |website=Crunchbase |access-date=5 May 2022 |language=en}}</ref> || Company launch || {{w|Veritas Genetics}} is founded.<ref>{{cite web |title=For the second year in a row CNBC has placed Veritas Genetics on their Disruptor 50 list |url=https://www.veritasint.com/news/veritasgenetics-top50-disruptivecompanies2019/ |website=Veritas |access-date=10 March 2022 |date=21 May 2019}}</ref> Based in {{w|Danvers, Massachusetts}}, it is a provider of a genetic testing platform intended to empower people to live healthier and longer. It will be later acquired by LetsGetChecked.<ref name="Veritas Gene"/> || {{w|United States}}
+
| 2014 || {{w|Genetics}}, {{w|healthcare}}, personal health<ref name="Veritas Gene">{{cite web |title=Veritas Genetics - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/veritas-genetics |website=Crunchbase |access-date=5 May 2022 |language=en}}</ref> || Company launch || {{w|Veritas Genetics}} is founded.<ref>{{cite web |title=For the second year in a row CNBC has placed Veritas Genetics on their Disruptor 50 list |url=https://www.veritasint.com/news/veritasgenetics-top50-disruptivecompanies2019/ |website=Veritas |access-date=10 March 2022 |date=21 May 2019}}</ref> Based in {{w|Danvers, Massachusetts}}, it is a provider of a genetic testing platform intended to empower people to live healthier and longer. It will be later acquired by LetsGetChecked.<ref name="Veritas Gene"/> || {{w|United States}}
 
|-
 
|-
 
| 2014 (May 10) || || Literature || Richard W. Oliver publishes ''The Coming Biotech Age: The Business of Bio-Materials''.<ref>{{cite book |last1=Wambugu |first1=Florence |last2=Kamanga |first2=Daniel |title=Biotechnology in Africa: Emergence, Initiatives and Future |date=10 May 2014 |publisher=Springer |isbn=978-3-319-04001-1 |url=https://books.google.com.ar/books/about/Biotechnology_in_Africa.html?id=Y1MlBAAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
| 2014 (May 10) || || Literature || Richard W. Oliver publishes ''The Coming Biotech Age: The Business of Bio-Materials''.<ref>{{cite book |last1=Wambugu |first1=Florence |last2=Kamanga |first2=Daniel |title=Biotechnology in Africa: Emergence, Initiatives and Future |date=10 May 2014 |publisher=Springer |isbn=978-3-319-04001-1 |url=https://books.google.com.ar/books/about/Biotechnology_in_Africa.html?id=Y1MlBAAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 +
|-
 +
| 2014 || || Accelerator/incubator launch || The UCSF Rosenman Institute is founded. It is one of the top biotech incubators and accelerators in the United States.<ref name="Top 15 biotech incubators and accelerators in the US">{{cite web |title=Top 15 biotech incubators and accelerators in the US |url=https://www.kolabtree.com/blog/top-15-biotech-incubators-and-accelerators-in-the-us/ |website=The Kolabtree Blog |access-date=29 June 2022 |date=27 April 2021}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2014 (July 15) || {{w|Analytics}}, {{w|big data}} || Company launch || MyGene is founded. Based in {{w|Beijing}}, it a human genome big data analytics platform.<ref>{{cite web |title=MyGene - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/mygene |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|China}}
 
| 2014 (July 15) || {{w|Analytics}}, {{w|big data}} || Company launch || MyGene is founded. Based in {{w|Beijing}}, it a human genome big data analytics platform.<ref>{{cite web |title=MyGene - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/mygene |website=Crunchbase |access-date=6 April 2022 |language=en}}</ref> || {{w|China}}
 
|-
 
|-
−
| 2014 || [[w:Pharmaceutical industry|Pharmaceutical]] || Literature || Jie Jack Li publishes ''Blockbuster Drugs: The Rise and Decline of the Pharmaceutical Industry''.<ref>{{cite book |last1=Li |first1=Jie Jack |title=Blockbuster Drugs: The Rise and Fall of the Pharmaceutical Industry |date=2014 |publisher=OUP USA |isbn=978-0-19-973768-0 |url=https://books.google.com.ar/books/about/Blockbuster_Drugs.html?id=7XH1AQAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
+
| 2014 || [[w:Pharmaceutical industry|Pharmaceutical]] || Literature || Jie Jack Li publishes ''Blockbuster Drugs: The Rise and Decline of the Pharmaceutical Industry'', which attempts to describe stories behind the discovery and development of highly lucrative medicines, while also exploring the tumult the industry faces as the "patent cliff" nears.<ref>{{cite book |last1=Li |first1=Jie Jack |title=Blockbuster Drugs: The Rise and Fall of the Pharmaceutical Industry |date=2014 |publisher=OUP USA |isbn=978-0-19-973768-0 |url=https://books.google.com.ar/books/about/Blockbuster_Drugs.html?id=7XH1AQAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 +
|-
 +
| 2014 (Fall) || || Accelerator/incubator launch || Illumina Accelerator is founded.<ref>{{cite web |title=Illumina Accelerator Genomics Startup Funding |url=https://www.illumina.com/science/accelerator.html#:~:text=Founded%20in%20Fall%202014%20in,synthetic%20biology%2C%20and%20skin%20microbiome. |website=www.illumina.com |access-date=29 June 2022}}</ref> || {{w|United States}}
 +
|-
 +
| 2014 (October 30) || {{w|DNA sequencing}}, {{w|gene editing}}, {{w|CRISPR}}, therapeutics, {{w|agricultural biology}}, {{w|molecular diagnostics}} || Fund launch || ARK Genomic Revolution ETF ({{w|ticker symbol}} ARKG) is launched. It invests in United States listed securities of companies focused on {{w|genomics}}.<ref>{{cite web |title=ARK Genomic Revolution ETF, ARKG:BTQ:USD summary - FT.com |url=https://markets.ft.com/data/etfs/tearsheet/summary?s=ARKG:BTQ:USD |website=markets.ft.com |access-date=1 July 2022}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2014 || || Literature || ''Biotechnology Entrepreneurship: Leading, Managing and Commercializing Innovative Technologies''.<ref>{{cite book |last1=Shimasaki |first1=Craig |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies |date=8 April 2014 |publisher=Academic Press |isbn=978-0-12-404747-1 |url=https://books.google.com.ar/books/about/Biotechnology_Entrepreneurship.html?id=8AfUAgAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
+
| 2014 (November 1) || || Accelerator/incubator launch || IndieBio is launched. Based in {{w|San Francisco}}, it is one of the largest biotech startup accelerator.<ref>{{cite web |title=IndieBio |url=https://www.crunchbase.com/organization/synbio-axlr8r |website=crunchbase |access-date=29 June 2022}}</ref> || {{w|United States}}
 
|-
 
|-
−
| 2014 || {{w|Biotechnology}} || Literature || Craig Shimasaki publishes ''Biotechnology Entrepreneurship. Starting, Managing, and Leading Biotech Companies''.<ref>{{cite book |last1=Shimasaki |first1=Craig |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies |date=8 April 2014 |publisher=Academic Press |isbn=978-0-12-404747-1 |url=https://books.google.com.ar/books?id=8AfUAgAAQBAJ&printsec=frontcover&dq=Biotechnology+Entrepreneurship.+Starting,+Managing,+and+Leading+Biotech+Companies&hl=en&sa=X&ved=2ahUKEwjzzfOb7Lv2AhUXqpUCHUwXChIQ6AF6BAgIEAI#v=onepage&q=Biotechnology%20Entrepreneurship.%20Starting%2C%20Managing%2C%20and%20Leading%20Biotech%20Companies&f=false |language=en}}</ref> ||
+
| 2014 || || Literature || Craig Shimasaki publishes ''Biotechnology Entrepreneurship: Leading, Managing and Commercializing Innovative Technologies'', which attempts to provide a guide to biotechnology enterprise and entrepreneurship.<ref>{{cite book |last1=Shimasaki |first1=Craig |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies |date=8 April 2014 |publisher=Academic Press |isbn=978-0-12-404747-1 |url=https://books.google.com.ar/books/about/Biotechnology_Entrepreneurship.html?id=8AfUAgAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
 
| 2015 || Biotechnology, pharmaceutical || Company launch || Baxalta is founded.<ref>{{cite web |title=Baxalta - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/baxalta |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> It has a portfolio of differentiated therapies that seek to address unmet medical needs across many disease areas like {{w|hemophilia}}, {{w|immunology}} and {{w|oncology}}.<ref>{{cite web |title=EX-99.1 |url=https://www.sec.gov/Archives/edgar/data/1620546/000119312515214952/d829725dex991.htm#:~:text=Baxalta%20is%20a%20global%2C%20innovative,like%20hemophilia%2C%20immunology%20and%20oncology. |website=www.sec.gov |access-date=17 March 2022}}</ref> ||
 
| 2015 || Biotechnology, pharmaceutical || Company launch || Baxalta is founded.<ref>{{cite web |title=Baxalta - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/baxalta |website=Crunchbase |access-date=10 March 2022 |language=en}}</ref> It has a portfolio of differentiated therapies that seek to address unmet medical needs across many disease areas like {{w|hemophilia}}, {{w|immunology}} and {{w|oncology}}.<ref>{{cite web |title=EX-99.1 |url=https://www.sec.gov/Archives/edgar/data/1620546/000119312515214952/d829725dex991.htm#:~:text=Baxalta%20is%20a%20global%2C%20innovative,like%20hemophilia%2C%20immunology%20and%20oncology. |website=www.sec.gov |access-date=17 March 2022}}</ref> ||
Line 712: Line 745:
 
| 2017 (September) || || Literature || Françoise Simon and Glen Giovannetti publish ''Managing Biotechnology: From Science to Market in the Digital Age'', which provides a comprehensive overview of the new business context and marketing models for biotech companies.<ref>{{cite book |last1=Simon |first1=Francoise |last2=Giovannetti |first2=Glen |title=Managing Biotechnology: From Science to Market in the Digital Age |date=16 October 2017 |publisher=John Wiley & Sons |isbn=978-1-119-21617-9 |url=https://books.google.com.ar/books/about/Managing_Biotechnology.html?id=XsEzDwAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
| 2017 (September) || || Literature || Françoise Simon and Glen Giovannetti publish ''Managing Biotechnology: From Science to Market in the Digital Age'', which provides a comprehensive overview of the new business context and marketing models for biotech companies.<ref>{{cite book |last1=Simon |first1=Francoise |last2=Giovannetti |first2=Glen |title=Managing Biotechnology: From Science to Market in the Digital Age |date=16 October 2017 |publisher=John Wiley & Sons |isbn=978-1-119-21617-9 |url=https://books.google.com.ar/books/about/Managing_Biotechnology.html?id=XsEzDwAAQBAJ&source=kp_book_description&redir_esc=y |language=en}}</ref> ||
 
|-
 
|-
−
| 2017 (November 24) || || Literature || Leah Cannon publishes ''How to Start a Life Science Company: A Comprehensive Guide for First-Time Entrepreneurs''.<ref>{{cite book |title=How to Start a Life Science Company: A Comprehensive Guide for First-Time Entrepreneurs |url=https://www.amazon.com/-/es/Leah-Cannon/dp/0648142329/ref=pd_bxgy_img_1/146-5884464-8532267?pd_rd_w=fPVkP&pf_rd_p=6b3eefea-7b16-43e9-bc45-2e332cbf99da&pf_rd_r=MRPJX5MT2075ZR2SZKQK&pd_rd_r=b68c18d8-dfbf-4844-95fa-e293015be170&pd_rd_wg=HCdH7&pd_rd_i=0648142329&psc=1}}</ref>
+
| 2017 (November 24) || || Literature || Leah Cannon publishes ''How to Start a Life Science Company: A Comprehensive Guide for First-Time Entrepreneurs''.<ref>{{cite book |title=How to Start a Life Science Company: A Comprehensive Guide for First-Time Entrepreneurs |url=https://www.amazon.com/-/es/Leah-Cannon/dp/0648142329/ref=pd_bxgy_img_1/146-5884464-8532267?pd_rd_w=fPVkP&pf_rd_p=6b3eefea-7b16-43e9-bc45-2e332cbf99da&pf_rd_r=MRPJX5MT2075ZR2SZKQK&pd_rd_r=b68c18d8-dfbf-4844-95fa-e293015be170&pd_rd_wg=HCdH7&pd_rd_i=0648142329&psc=1}}</ref> ||
 +
|-
 +
| 2018 (March) || {{w|Blood test}} || Legal || {{w|Theranos}}' CEO {{w|Elizabeth Holmes}}, former company president {{w|Sunny Balwani}}, and the company are charged with {{w|fraud}} by the SEC,<ref>{{cite web |last1=Cava |first1=Marco della |title=She was 'the next Steve Jobs.' Now, Theranos founder Elizabeth Holmes is charged with fraud |url=https://www.usatoday.com/story/tech/2018/03/14/theranos-founder-elizabeth-holmes-charged-massive-fraud/424670002/ |website=USA TODAY |access-date=8 July 2022}}</ref> after fraud and conspiracy are revealed, as well as technology that repeatedly failed quality assurance and results sent to real patients that were incorrect.<ref>{{cite web |title=Everything you need to know about the Theranos scandal |url=https://www.panmacmillan.com/blogs/literary/theranos-elizabeth-holmes-john-carreyrou |website=www.panmacmillan.com |access-date=8 July 2022 |language=en}}</ref> Theranos would be defunct by September 2018.<ref>{{cite web |last1=Abelson |first1=Reed |title=Theranos Is Shutting Down |url=https://www.nytimes.com/2018/09/05/health/theranos-shutting-down.html |website=The New York Times |access-date=8 July 2022 |date=5 September 2018}}</ref> || {{w|United States}}
 
|-
 
|-
 
| 2018 || {{w|Gene therapy}} || Company launch || Reborna Biosciences, Inc. is founded.<ref>{{cite web |title=Reborna Biosciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/reborna-biosciences |website=Crunchbase |access-date=14 March 2022 |language=en}}</ref> Based in {{w|Fujisawa}}, {{w|Japan}}, it is a research and development start-up focusing on the field of rare genetic diseases.<ref>{{cite web |title=Reborna Biosciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/reborna-biosciences |website=Crunchbase |access-date=5 April 2022 |language=en}}</ref> || {{w|Japan}}
 
| 2018 || {{w|Gene therapy}} || Company launch || Reborna Biosciences, Inc. is founded.<ref>{{cite web |title=Reborna Biosciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/reborna-biosciences |website=Crunchbase |access-date=14 March 2022 |language=en}}</ref> Based in {{w|Fujisawa}}, {{w|Japan}}, it is a research and development start-up focusing on the field of rare genetic diseases.<ref>{{cite web |title=Reborna Biosciences - Crunchbase Company Profile & Funding |url=https://www.crunchbase.com/organization/reborna-biosciences |website=Crunchbase |access-date=5 April 2022 |language=en}}</ref> || {{w|Japan}}
 
|-
 
|-
−
| 2019 || || Literature || ''Florentina Matei and Daniela Zirra publish Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective''.<ref>{{cite book |last1=Matei |first1=Florentina |last2=Zirra |first2=Daniela |title=Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective |date=16 August 2019 |publisher=Springer |isbn=978-3-030-22141-6 |url=https://books.google.com.ar/books?id=gdCpDwAAQBAJ&printsec=frontcover&dq=to+Biotech+Entrepreneurship:+From+Idea+to+Business:+A+European+Perspective&hl=en&sa=X&redir_esc=y#v=onepage&q=to%20Biotech%20Entrepreneurship%3A%20From%20Idea%20to%20Business%3A%20A%20European%20Perspective&f=false |language=en}}</ref> ||
+
| 2019 || || Literature || Florentina Matei and Daniela Zirra publish ''Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective''.<ref>{{cite book |last1=Matei |first1=Florentina |last2=Zirra |first2=Daniela |title=Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective |date=16 August 2019 |publisher=Springer |isbn=978-3-030-22141-6 |url=https://books.google.com.ar/books?id=gdCpDwAAQBAJ&printsec=frontcover&dq=to+Biotech+Entrepreneurship:+From+Idea+to+Business:+A+European+Perspective&hl=en&sa=X&redir_esc=y#v=onepage&q=to%20Biotech%20Entrepreneurship%3A%20From%20Idea%20to%20Business%3A%20A%20European%20Perspective&f=false |language=en}}</ref> ||
 
|-
 
|-
 
| 2019 || {{w|Genetic testing}} || Company launch || 54gene is founded. Based in {{w|Washington, D.C.}}, it is a healthcare startup that offers a genetics testing platform.<ref>{{cite web |title=54gene |url=https://www.crunchbase.com/organization/54gene |website=crunchbase.com |access-date=24 March 2022}}</ref> || {{w|United States}}
 
| 2019 || {{w|Genetic testing}} || Company launch || 54gene is founded. Based in {{w|Washington, D.C.}}, it is a healthcare startup that offers a genetics testing platform.<ref>{{cite web |title=54gene |url=https://www.crunchbase.com/organization/54gene |website=crunchbase.com |access-date=24 March 2022}}</ref> || {{w|United States}}
Line 722: Line 757:
 
| 2019 || {{w|Metabolic engineering}}, {{w|synthetic biology}} || Company launch || Cysbio is established as a spinout from The Novo Nordisk Foundation Center for Biosustainability, DTU (Technical University of Denmark).<ref>{{cite web |title=Danish biotech company receives 4,4 million EUR from the EU - DTU Biosustain |url=https://www.biosustain.dtu.dk/nyhedsbase/2021/01/danish-biotech-company-receives-44-million-eur-investment-from-the-eu?id=3ddd6179-f4d5-4de8-af01-8396802d9128 |website=biosustain.dtu.dk |access-date=21 January 2022 |language=en}}</ref> Based in {{w|Kongens Lyngby}}, {{w|Denmark}}, it uses advanced metabolic engineering and synthetic biology approaches to construct bacterial cell factories for transforming the production of biochemicals from renewable feedstocks.<ref>{{cite web |title=Cysbio - Building Biology |url=https://cysbio.com/ |website=Cysbio.com |access-date=6 May 2022}}</ref> || {{w|Denmark}}
 
| 2019 || {{w|Metabolic engineering}}, {{w|synthetic biology}} || Company launch || Cysbio is established as a spinout from The Novo Nordisk Foundation Center for Biosustainability, DTU (Technical University of Denmark).<ref>{{cite web |title=Danish biotech company receives 4,4 million EUR from the EU - DTU Biosustain |url=https://www.biosustain.dtu.dk/nyhedsbase/2021/01/danish-biotech-company-receives-44-million-eur-investment-from-the-eu?id=3ddd6179-f4d5-4de8-af01-8396802d9128 |website=biosustain.dtu.dk |access-date=21 January 2022 |language=en}}</ref> Based in {{w|Kongens Lyngby}}, {{w|Denmark}}, it uses advanced metabolic engineering and synthetic biology approaches to construct bacterial cell factories for transforming the production of biochemicals from renewable feedstocks.<ref>{{cite web |title=Cysbio - Building Biology |url=https://cysbio.com/ |website=Cysbio.com |access-date=6 May 2022}}</ref> || {{w|Denmark}}
 
|-
 
|-
−
| 2021 (October) || || || "The top U.S.-based biotechnology firms in terms of market capitalization as of October 2021 were Johnson & Johnson ($425 billion), Roche ($334 billion), Pfizer ($240), and Novo Nordisk ($225)"<ref name="The Basics of Biotec"/>
+
| 2020 (December) || {{w|RNA therapeutics}} || Notable case || [[w:BioNTech|Pfizer–BioNTech]] and {{w|Moderna}} obtain authorization for their mRNA-based {{w|COVID-19 vaccine}}s.<ref>{{cite web |title=WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access |url=https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access |website=www.who.int |access-date=8 July 2022 |language=en}}</ref> ||
 +
|-
 +
| 2021 (October) || || Statistics || As of date, the top U.S.-based biotechnology firms in terms of market capitalization are {{w|Johnson & Johnson}} ($425 billion), {{w|Roche}} ($334 billion), {{w|Pfizer}} ($240 billion), and {{w|Novo Nordisk}} ($225 billion).<ref name="The Basics of Biotec"/> || {{w|United States}}
 +
|-
 +
|}
 +
 
 +
== Numerical and visual data ==
 +
 
 +
=== Google trends ===
 +
The chart shows {{w|Google Trends}} data for Biotechnology, from January 2004 to May 2022, when the screenshot was taken. Data is also ranked by country and displayed on world map.<ref>{{cite web |title=Google Trends |url=https://trends.google.com/trends/explore?date=all&q=%2Fm%2F01ftz |website=Google Trends |access-date=30 May 2022}}</ref>
 +
[[File:Biotechnology google trends.png|thumb|center|800px]]
 +
 
 +
=== Google Ngram viewer ===
 +
The chart shows Google Ngram Viewer data for biotechnology from 1900 to 2019.<ref>{{cite web |title=Google Books Ngram Viewer |url=https://books.google.com/ngrams/graph?content=biotechnology&year_start=1900&year_end=2019&corpus=26&smoothing=3&direct_url=t1%3B%2Cbiotechnology%3B%2Cc0 |website=books.google.com |access-date=30 May 2022 |language=en}}</ref>
 +
 
 +
[[File:Biotechnology ngram.PNG|thumb|center|800px]]
 +
 
 +
=== Google Scholar ===
 +
 
 +
The table and graph below show the evolution of mentions of Biotechnology on Google Scholar as of May 29, 2022
 +
 
 +
{| class="sortable wikitable"
 +
! Year
 +
! N° of mentions
 +
|-
 +
| 1970 || 30,900
 +
|-
 +
| 1975 || 7,120
 +
|-
 +
| 1980 || 27,800
 +
|-
 +
| 1985 || 16,300
 +
|-
 +
| 1990 || 70,500
 +
|-
 +
| 1995 || 99,700
 +
|-
 +
| 2000 || 319,000
 +
|-
 +
| 2005 || 707,000
 +
|-
 +
| 2010 || 1,070,000
 +
|-
 +
| 2015 || 915,000
 +
|-
 +
| 2020 || 248,000
 
|-
 
|-
 
|}
 
|}
 +
 +
[[File:Biotechnology google scholar.PNG|thumb|center|600px]]
 +
 +
=== Wikipedia views ===
 +
 +
The chart below shows pageviews of the English Wikipedia article Biotechnology, from July 2015 to April 2022.<ref>{{cite web |title=Wikipedia Views: results |url=https://wikipediaviews.org/displayviewsformultiplemonths.php?page=Biotechnology&allmonths=allmonths-api&language=en&drilldown=all |website=wikipediaviews.org |access-date=30 May 2022}}</ref>
 +
 +
[[File:Biotechnology WV.png|thumb|center|600px]]
  
 
==Meta information on the timeline==
 
==Meta information on the timeline==
Line 743: Line 831:
 
   
 
   
 
* [https://etfdb.com/etfs/industry/biotechnology/]
 
* [https://etfdb.com/etfs/industry/biotechnology/]
 +
* [https://www.google.com/search?q=Rydex+Biotechnology+Fund&stick=H4sIAAAAAAAAAONgVeLVT9c3NEypsMwqNja3NJJKyswvSU3OyMvPyU-vVMgtLSlNzFFIK81LKT7FyANSW1meVBifYVSFxC03My48xQgxyTgjrbgkp7IMWXVRTi5MOinZzKKsvAoozaWfq29gZFoUb1yJpLaszBCJW2RQkmsA05qcm5SWl1OZB-ebFRYbxhunw_gwP0CNNi4wLkgph0lmmBVVFJYXpCA7qyAdxU_FIEfDXGmakZJhlo3MN0q3hMunpGVUmlea5kG1G5ZlGZhUVWTApNMMDM2SDPOyHjGeY-IWePnjnrDUEaZJa05eY9zLxCXgk59fnJpTGZSak1iSmhKSL6TDxeaaV5JZUinEI8XFxQFyvGFaSZWRCBfEuGyz7OSMFIsCgfkPpjEKtTJycQenloTk--anZKZVCpUJlWAxUxxuJq8UNxcn2MwMQ-NCIXdU3RZCZlycvqm5SalFxf5pQqpcXM75OTmpySWZ-XlC4lKiXML6yXAB_czi4lKgQismDSalQqO4XZemnWOLEPTY_f-_-7xgBykNLUEuNpf83MTMPEH1TP8HV83e22sJc3GEJFbk5-XnVgrmOB3__-_ze3slRU7fkPP1M86_sxecbcX4IN3NzkGCVYFBg8HQcycvw-2frAe0GA4wMjXtW3GIjYODUYDBiImDoYqBZxGrRFBlSmqFghNKMnUDps8JbIwApexr9s8CAAA&lei=ZkO_YqOrPKDd1sQPmdqaiAQ]
  
 
===Timeline update strategy===
 
===Timeline update strategy===

Latest revision as of 18:56, 22 June 2023

This is a timeline of biotechnology companies, attempting to describe mostly the launch in recent decades of a variety of organizations in the field.

Sample questions

The following are some interesting questions that can be answered by reading this timeline:

  • What are the diverse industries and specialties where biotechnology is conducted?
    • Sort the full timeline by Industry/specialty.
    • You will see a large variety of subfields of biotechnology, but mostly related to healthcare.
  • What are some milestones in the history of biotechnology?
    • Sort the full timeline by Event type and look for the rows with value "Background".
    • You will see important scientific developments shaping the field and giving path to business development.
  • What are some notable or sample biotechnology companies having been launched over the last decades?
    • Sort the full timeline by Event type and look for the rows with value "Company launch".
    • You will see the establishment of a number of companies in different industries, all related to biotechnology.
  • What are some notable Initial public offerings?
    • Sort the full timeline by Event type and look for the rows with value "Notable IPO".
    • You will see some notable IPOs by very important companies in the field.
  • What are some notable accelerators and incubators in the biotechnology sector?
    • Sort the full timeline by Event type and look for the rows with value "Accelerator/incubator launch".
    • You will mostly see a number of these organizations launched in the United States.
  • What are some notable or illustrative biotechnology funds?
    • Sort the full timeline by Event type and look for the rows with value "Fund launch".
    • You will see a number of funds launched in the United States.
  • What are some notable studies related to the business of biotechnology?
    • Sort the full timeline by Event type and look for the rows with value "Research".
  • You will see a number of studies by different authors, revealing particular aspects of the biotechnology business.
    • What are some figures illustrating the evoution of the biotechnology industry?
    • Sort the full timeline by Event type and look for the rows with value "Statistics".
  • What are some publications specialized in the business of biotechnology?
    • Sort the full timeline by Event type and look for the rows with value "Literature".
    • You will see a variety of books in the field.
  • What are some other notable events in the history of biotrchnology companies?
    • Sort the full timeline by Event type and look for the rows with value "Notable case".
  • Other events are described under the following types: "Concept development", "Industry size", "Legal", "Market size", and "Statistics".

Big picture

Time period Development summary More data
1950s Early development Biotechnology arguably takes off around this time, spurred by a better understanding in the post-war period of cell function and molecular biology. A major milestone in this decade is the discovery of the 3D structure of DNA.[1]
1960s Field identity creation In this period, biotechnology acquires a single identity.[2] Around the end of the decade, the exceptional developments in electronics initiate a period of exponential growth in biotechnology, particularly in the fields of bioimaging and functional evaluation.[3]
1970s Pioneering work Pioneering work in biotechnology can be traced back to the mid-decade.[4] Technological advances, start altering the production process and facilitate production of specialized products from generalized machinery, particularly in high throughput screening, nuclear magnetic resonance (NMR), polymerase chain reaction, advances in massspectrometry and crystallography.[5] Massive strides in DNA research are conducted.[1]
1980s Business emergence The biotech arena emerges, when molecular biology is introduced in the business world.[6] The evolution of the modern biotech industry as it is known today is considered to begin in this decade, with scientific innovations leading to the commercialization of products.[4] Great advances in biotechnology are made.[7] The development of the first biotech-derived drugs and vaccines to treat diseases such as cancer and hepatitis B are milestones of the 1980s.[1]
1990s Explosive growth This is often seen as the decade of biotechnology.[8] An explosion in understanding the pathophysiology of human diseases leads to the development of many innovative new medicines. Molecular engineering becomes prominent, and the full potential of monoclonal antibodies is finally realized.[4]
2000s Focus toward chronic diseases A notably continued expansion of biotechnology into chronic diseases is experienced, including new biotech products and second or third indications for existing biologic products. An emphasis is put on the commercialization of biotech products for chronic diseases with an immune etiology. Also, this decade can be characterized as the era of acquisitions of biotech companies by big pharmaceutical companies.[4]


Full timeline

Year Industry/specialty (when applicable) Event type Details Location
1951 Background Artificial insemination of livestock is accomplished using frozen semen.[9]
1958 Background DNA is made in a test tube for the first time.[9]
1975 Background German biologist Georges J. F. Köhler and Argentine biochemist César Milstein discover how to make monoclonal antibodies. This scientific event would revolutionize the medical diagnostics and therapeutics industry sectors. For the first time, specific antibodies to various epitopes (targets) could be isolated and produced in significant quantities for applications in medicine.[5] United Kingdom
1975 Research J.M. Utterback and W.J. Abernathy explore the concept of dominant design and suggest that its occurrence may effect innovation in a firm or an industry. A dominant design is a new product synthesized from individual technological innovations introduced independently in prior product variants.[10]
1978 Background Recombinant human insulin is produced for the first time.[9]
1979 Background Human growth hormone is synthesized for the first time.[9]
1979–1981 Research Eighteen official reports across the industrialized world announce that biotechnology would be "the new technological base for our civilization".[2]
1980 Background Following a 20-year mass vaccination effort, smallpox is globally eradicated.[9] Worldwide
1980 Background The Supreme Court of the United States approves the principle of patenting organisms, which allows ExxonMobil to patent an oil-eating microorganism.[9] United States
1981 Background Scientists at Ohio University accomplish the first functioning germline genetic transformation of laboratory mice by microinjection of cloned DNA into the male pronucleus of fertilized mouse eggs at the one-cell stage.[11][9] United States
1982 Background United States FDA approves Eli Lilly's recombinant insulin Humulin, made from Genentech's specially modified bacteria. This is the first drug produced through recombinant DNA technology and among the first genetically engineered products to be available to consumers.[9][12] United States
1982 Research According to Freeman, patents provide some measure of the "effectiveness" of a firm’s research and development.[5]
1982 Background The first recombinant DNA vaccine for livestock is developed.[13][9]
1985 Background The first DNA marker is found linked to cystic fibrosis. The anonymous marker is known as CRI-917.[9][14]
1985 (December 16) Health Fund launch Fidelity Select Biotechnology Portfolio (FBIOX) is launched in the United States.[15] It mostly invests in companies researching, developing, manufacturing, and distributing various biotechnological products, services, and processes and companies that benefit significantly from advances in biotechnology.[16] United States
1986 Recombinant DNA technology Background Recombivax HB is licensed in the United States. It is the first recombinant vaccine for humans, a vaccine for hepatitis B.[17][9] United States
1986 Genetic engineering Background Interferon becomes the first anticancer drug produced through biotechnology[9] , 29 years after the discovery of the drug, when the development of genetic engineering enables the production of large quantities of high-quality interferon.[18]
1987 Research Monitoring aggregate data over a range of US firms including pharmaceutical companies, Griliches et al. find a very strong relationship between research and development expenditures and patent applications, even after controlling for propensity to patent.[5]
1988 Research S. Majoro suggests that a continuous flow of ideas provides the antecedents for innovation within an organization.[19]
1988 Agricultural biotechnology Background The first pest-resistant corn, Bt corn, is produced.[9] The first permit to field-test transgenic crops containing Bt genes is issued to Monsanto for tomato.[20] United States
1990 Research and development Research According to Cohen and Levinthal, investment in Research and development maintains the absorptive capacity of the firm, a critical aspect of intellectual capital.[5]
1990 (January 1) Cell therapy Company launch Lineage Cell Therapeutics is founded.[21] It engages in the development of novel cell therapies for unmet medical needs.[22] United States (Carlsbad, California)
1990 Research American sociologist Howard E. Aldrich makes the observation that a specialty, technology-based, innovation is often linked to entrepreneurship and business foundings.[5][23] United States
1990 Gene therapy Background The first successful gene therapy is performed on a 4-year-old girl suffering from an immune disorder.[9]
1990 Probiotics Company launch BioGaia is founded.[24] Based in Stockholm, it is a probiotics company engaged in microbiome research. It develops and sells probiotic products.[25][26] Sweden
1990 (August 28) Oncology, telomerase activation, cell therapy Company launch Geron Corporation is founded. [27] It researches and develops therapeutic products for cancer.[28] United States (Menlo Park, California)
1990 Biopharmaceuticals Company launch Nektar Therapeutics is founded. [29] Based in San Carlos, California, it focuses on the discovery and development of novel therapies which selectively modulate the immune system to treat cancer, autoimmune disorders, and chronic inflammatory conditions.[30] United States
1991 Aquaculture Company launch AquaBounty Technologies is founded. [31] Its land-based fish farms produce genetically engineered salmon.[32][33] United States (Maynard, Massachusetts)
1991 Pharmaceutical, biotherapeutics Notable IPO Vertex Pharmaceuticals completes its IPO, trading as VRTX on Nasdaq.[34] Based in Boston, it one of the world's biggest biopharma businesses.[35] United States
1991 Oncology, health diagnostics Company launch ARIAD Pharmaceuticals is founded. [36] An oncology company focused on the discovery, development and commercialization of medicines for the cancer patients, it would be acquired by Takeda for US$5.2 billion on January, 2017.[37] United States (Cambridge, Massachusetts)
1991 Healthcare, medical, pharmaceutical Company launch Camurus is founded.[38] It is Swedish science-led biopharmaceutical company which develops and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions.[39] Sweden
1991 (September) Blood transfusion products Company launch Cerus Corporation is founded.[40] Headquartered in Concord, California, it develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry. United States (Concord, California)
1991 (September 17) Healthcare, pharmaceutical Company launch Synthon is founded. [41] Medications made by Synthon include simvastatin (a statin), tamsulosin (an alpha blocker for the symptomatic treatment of benign prostatic hyperplasia), paroxetine (an antidepressant), and fluvoxamine (an antidepressant) Netherlands (Nijmegen)
1991 Healthcare, molecular diagnostics, biotechnology, precision medicine Company launch Myriad Genetics is founded.[42] It is a molecular diagnostic focused on the discovery and commercialization of diagnostic tests for several major diseases, including cancer, rheumatoid arthritis, and diabetes, among others.[43]
1991 Antibodies, genetics Company launch Santa Cruz Biotechnology is founded by Dr. John Stephenson and his wife Brenda Stephenson in Santa Cruz, California.[44].[45] A developer of biological products for medical research,[46][47] it is one of the world’s largest suppliers of antibodies.[48] United States (Santa Cruz, California)
1991 Research Philip Kotler suggests that a continuous flow of ideas provides the antecedents for the development of new products.[49]
1991 (July 16) Biopharmaceutical Notable IPO Alkermes completes its IPO, trading with ticker name ALKS on Nasdaq.[50] Founded in 1987, it is a biopharmaceutical company that focuses on central nervous system.[51] United States
1992 Genetics, medical[52] Company launch Affymetrix is founded as a spin-off from Affymax Research Institute by Stephen Fodor. [53] The company would introduce its first product in 1994, an HIV genotyping chip.[54] Affymetrix is based in Santa Clara, California. United States
1992 Healthcare, pharmaceutical[55] Company launch Angiotech Pharmaceuticals is founded. [56] In 2017, Angiotech would be acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital.[57][58] Canada
1992 Bioinformatics Company launch Applied Maths is founded in Belgium as a bioinformatics company developing software for the biosciences.[59] It would gain worldwide recognition with the software GelCompar, used as a standard tool for the normalization and comparative analysis of electrophoresis patterns (PFGE, AFLP, RAPD, REP-PCR and variants, etc).[60] Belgium
1992 (May) Biopharmaceuticals, biotherapeutics Company launch Cubist Pharmaceuticals is founded. [61] On 8 December 2014, Merck & Co. would acquire Cubist for US$102 per share in cash ($8.4 billion).[62]
1992 Biomedicine Company launch Dendreon is founded.[63] Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.[64] United States
1992 Biotechnology, healthcare, health diagnostics, medical[65] Company launch MorphoSys is founded.[66] Based in Planegg, Germany, it focuses on the research and development of fully human antibodies.[67] Germany
1992 Dairy farming technology Background The United States FDA approves bovine somatotropin for increased milk production in dairy cows.[9] United States
1992 Background The first version of the Oslo Manual is issued, separating innovations into two types: product and process innovations. A product innovation is "the commercialization of a technologically changed product". A process innovation, alternatively, is a "change in the technology of the production of an item [which] may involve new equipment, new management and organization methods, or both".[5] Norway
1992 (September 8) Biopharmaceutical Company launch Shenzhen Kangtai Biological Products is founded. [68] It is a Chinese company that makes vaccines for diseases such as hepatitis B and measles.[69] China
1993 (January 2) Vaccines, soy protein, healthcare Company launch Bionor Pharma is founded. [70] It is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure.[71] Norway
1993 Biomedicine Company launch Applied Spectral Imaging is founded.[72] It is a multinational biomedical company that develops and manufactures microscopy imaging and digital analysis tools for hospitals, service laboratories and research centers.[73] United States
1993 Oligonucleotide-based tools Company launch Biosearch Technologies is founded.[74] It designs, develops, and manufactures custom oligonucleotides and associated reagents for the molecular diagnostics, research and applied markets.[75] United Kingdom
1993 Immunostimulants Background The United States FDA approves Betaseron, the first of several biotech products that have had a major impact on multiple sclerosis treatment.[9]
1993 Vaccines Company launch Shantha Biotechnics is founded.[76] It is one of the first Indian biotechnology companies to create a recombinant product, obtaining World Health Organization (WHO) prequalification for its Hepatitis B vaccine in 2002.[77] By 2013, Sanofi would complete the acquisition of 100% of the company.[78] India
1993 Biopharma, biotechnology, medical pharmaceutical Company launch Millennium Pharmaceuticals is founded [79]. On May 14, 2008, Japanese company Takeda Pharmaceutical would complete its acquisition of Millennium for a deal worth US$8.8 billion. The new subsidiary would finally be renamed Takeda Oncology. United States
1993 Pharming Company launch Ventria Bioscience is founded.[80] It is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system.[81] United States
1993 (November 12) Medical, medical device, pharmaceutical Notable IPO Incyte Corporation completes its IPO, trading under ticker INCY on Nasdaq·[82] It is a hlobal biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics.[83] United States
1994 (January 1) Biopharmaceuticals Company launch Fermentek is founded.[84][85] Based on Jerusalem, it specializes in the research, development, and manufacture of biologically active natural products isolated from microorganisms and other natural sources such as plants and algae.[86] Israel
1994 (February 16) Literature American journalist Barry Werth publishes The Billion-Dollar Molecule, which recounts the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals. The book is notable as an inside look at a biotechnology company, and the stresses and marketing pressures on funding research into drug design.[87] United States
1994 Oncology, immunotherapy, vaccines Company launch Agenus is founded [88]. It develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.[89] United States
1994 Stem-cell therapy Company launch Advanced Cell Technology, Incorporated (ACT) is founded. Renamed to Ocata Therapeutics in November 2014[90], in February 2016 it would be acquired by Astellas for US$379 million.[91] United States
1994 Pharmaceutical Company launch Cinnagen is founded. [92] Based in Tehran, it is a manufacturing company of biotechnology and biopharmaceutical products.[93] Iran
1994 Biotechnology, pharmaceutical Company launch Corixa is founded in Seattle, Washington. [94] Acquired by GlaxoSmithKline in 2005, the company would close in 2016. United States (Seattle, Washington)
1994 biopharmaceutical Company launch ViroPharma is founded. [95] A company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections, it would be purchased by Irish drug manufacturer Shire in 2013, with Shire paying around US$4.2 billion.[96] United States
1994 Genetics, Oncology Background The first breast cancer gene is discovered.[9]
1994 Epidemiology Background The International Commission for the Certification of Polio Eradication declares the Americas as polio-free.[9]
1994 Immunotherapy, oncology Company launch MediGene is founded.[97] Based in Martinsried, German, this company works on the development of immunotherapies to enhance T cell activity against solid cancers.[98] Germany
1994 Monoclonal antibodies, antigens Company launch HyTest Ltd is founded.[99] Based in Turku, Finland, it is a producer of monoclonal antibodies and antigens for the diagnostic industry.[100] Finland
1994 (November) Genomics, oncology Company launch Exelixis is founded. [101] Based in Alameda, California, it is a genomics-based drug discovery company, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. United States
1995 Genomics Company launch Sangamo Therapeutics is founded.[102] It is a genomic medicine company focused on leveraging novel platforms to advance clinical programs.[103] Australia
1995 (May 5) Medical technology Company launch Aclara Biosciences is founded.[104] It develops microfluidic lab-on-a-chip technology.[105] United States
1995 Healthcare, biotechnology Company launch Acorda Therapeutics is founded.[106] Based in Ardsley, New York, it is a biotechnology company that develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. This company manufactures and markets Zanaflex, Ampyra and Qutenza in the United States.[107] United States
1995 Pharmaceuticals, life sciences Company launch Caliper Life Sciences is founded. [108] It is a provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.[109] United States
1995 Accelerator/incubator launch University of Florida's Sid Martin Biotechnology Incubator opens. It is one of the first bio-business incubators in the United States.[110] United States
1995 Molecular medicine Accelerator/incubator launch The Molecular Medicine Research Institute is founded.[111] Based in the Silicon Valley, MMRI is a sovereign, non-profit medical research institute including facilities that are proficient in supporting their efforts in molecular biology, immunology, cell biology.[112] United States
1995 Research According to Brown and Eisenhardt, new product development is critical to the success, survival, growth and renewal of organizations. New products provide a potential source of competitive advantage and allow organizations to diversify, adapt and even re-engineer to match involving markets and technical conditions.[113]
1995 Immunotherapy, Oncology Background Gene therapy, immune-system modulation, and recombinantly produced antibodies enter the clinic for the treatment of cancer.[9]
1995 Diagnostics Company launch Monogram Biosciences is founded.[114] Based in San Francisco, it focuses on the development and commercialization of novel diagnostic technologies to enable individualized patient treatment decisions, and support the discovery and development of new drug and vaccine candidates.[115] United States
1995 Gene editing Company launch Dharmacon is founded by Stephen Scaringe to develop and commercialize a new technology for RNA oligonucleotide synthesis. [116] United States
1995 (December 29) Fund launch T. Rowe Price Health Sciences Fund (ticker symbol PRHSX) is launched in the United States.[117] It invests in companies that research, develop, produce, or distribute of health-related products and services.[118] United States
1996 Genealogy, Genetic genealogy, Online publishing, Software publishing Company launch Ancestry.com is launched.[119] Based in Lehi, Utah, it is the world's largest provider of DNA services.[120] United States
1996 Concept development Persidis describes bioentrepreneurship as the wealth creation derived from the application of the biosciences to the business context. "Bioentrepreneurs look for commercial value in every aspect of technology that they utilize. Innovativeness is vital to the creation of a biotechnology venture while credibility remains the backbone of the bioentrepreneur’s character."[5]
1996 Vaccines, biopharmaceutical Company launch Bharat Biotech is founded.[121] Based in Hyderabad, it has one of the largest pharmaceutical manufacturing plants of its kind in Asia-Pacific. Bharat Biotech specializes in product-oriented research and development leading to the manufacture of vaccines and biotherapeutics with global IPR’s associated to its products.[122] India
1996 Genetic engineering Background The first genetically engineered crop is launched to the market.[9]
1996 Healthcare, medical, therapeutics Notable IPO Alexion Pharmaceuticals completes an initial public offering of 2,530,000 shares of common stock, trading as ALXN on Nasdaq.[123] United States
1996 Genetics Background A gene associated with Parkinson’s disease is discovered by National Institutes of Health scientists, in collaboration with researchers from the UMDNJ-Robert Wood Johnson Medical School and the Istituto de Scienze Neurologiche in Naples, Italy.[124][9] United States, Italy
1996 Genetics Company launch deCODE genetics is founded.[125] by Kári Stefánsson and colleagues with the aim of using population genetics studies to identify variations in the human genome associated with common diseases, and to apply these discoveries "to develop novel methods to identify, treat and prevent diseases."[126] Iceland
1996 Genetically modified crops Company launch Ceres, Inc. is founded.[127] Based in Thousand Oaks, California, it is a provider of seeds of genetically modified crops used for biofuel production[128], in 2016 it would be acquired by Land O'Lakes.[129]
1996 (November) Biopharmaceutical Company launch Helixmith is founded.[130] Based in Seoul, it develops biopharmaceuticals for untreated diseases. Helixmith has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an adeno-associated virus vector program targeting neuromuscular diseases.[131] South Korea
1996 Pharmaceutical Company launch United Therapeutics is founded.[132] Based in Silver Spring, Maryland, it develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension, and infectious diseases.[133] United States
1997 Radiopharmaceuticals, oncology Company launch Algeta is founded.[134] It is a Norwegian therapeutics company focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer. Algeta targets metastatic and disseminated tumor types for which there is substantial unmet medical need.[135] Norway
1997 Research Chaston highlights that successful small firms exhibit a proactive commitment to innovation as a means through which to sustain overall performance.[5]
1997 mRNA therapeutics Company launch Merix Bioscience is founded as the first mRNA company. Based in Durham, North Carolina, in 2004 the company would change its name to Argos Therapeutics as a sign of its evolution.[136] United States
1997 Therapeutics Company launch Arena Pharmaceuticals is founded.[137] It is a biotechnology company targeting G-protein-coupled receptors.[138] United States
1997 Biopharmaceuticals, RNA interference Company launch Benitec Biopharma is founded.[139] Based in Melbourne, it focuses on the development of novel genetic medicines.[140] Australia
1997 Recombinant proteins Company launch Biolex is founded. Focused on expression of difficult-to-synthesize recombinant proteins, it would file for Chapter 7 bankruptcy on July 5, 2012.[141] United States
1997 (March) Biopharmaceuticals Company launch BioMarin Pharmaceutical is founded.[142] It is a biotechnology company that develops and commercializes therapies for individuals with serious lifethreatening rare diseases and medical conditions.[143] United States
1997 (August) Biopharmaceuticals, oncology Company launch GPC Biotech is founded. Based in Martinsried, Germany, it is a biopharmaceutical company focused on the discovery and development of anticancer drugs.[144] Germany
1997 Biotechnology, pharmaceutical[145] Company launch South Korean biotechnology company Macrogen is founded.[146] Based in Seoul, this precision medicine biotechnology company is a global genetic service provider.[147] South Korea
1997 Agricultural biotechnology Company launch Mendel Biotechnology is founded.[148] Based in Hayward, California, it is a plant biotechnology company that develops genetic and chemical solutions for a range of agricultural markets.[149][150] United States
1997 Biotechnology, healthcare, pharmaceutical[151] Company launch Noxxon Pharma is founded.[152] Based in Berlin, Germany, it develops biostable aptamers and substances based on mirror image nucleic acids.[151] Germany
1997 Stem cell research & development Company launch ReNeuron is founded.[153] Based in Surrey, England, it specializes in stem cell research and development.[154] United Kingdom
1997 Cloning Background Dolly the sheep in Scotland becomes the first animal cloned from an adult cell.[9] United Kingdom
1997 Pharmaceutical Company launch Vernalis Research is founded.[155] Based in Cambridge, England, it develops and applies fragment and structure-based methods to drug discovery, and has generated cell active lead compounds and development.[156] United Kingdom
1997 Oncology Company launch Seagen is founded.[157] Based in Bothell, Washington, it is a global biotechnology company that develops and commercializes transformative cancer therapies.[158] United States
1997 (September 15) Fund launch Franklin Biotechnology Discovery Fund Class A (ticker symbol FBDIX) is launched in the United States.[159] It invests principally in equity securities of biotechnology companies and discovery research firms mainly located in the United States.[160] United States
1997 Pharmaceutical, biotechnology Company launch Actelion is founded.[161] Based in Allschwil, Switzerland, it is a pharmaceuticals and biotechnology company established focusing on the manufacture of drugs that treat rare diseases and orphan diseases.[162] Switzerland
1998 Research antibodies, kits and assays for biological research Company launch Abcam is founded.[163] Based in Cambridge, England, it is a global life sciences company providing antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.[164] United Kingdom
1998 Nanotechnology Company launch American Biotech is founded.[165] Based in Alpine, Utah, it is a nano-silver biotech company with the goal of creating a more stable and powerful silver technology for consumer products.[166] United States
1998 Pharmacogenomics, oncology Background The United States FDA approves Herceptin, a pharmacogenomic breast cancer drug for patients whose cancer overexpresses the HER2 receptor.[9] United States
1998 Biotechnology, healthcare, medical pharmaceutical, therapeutics[167] Company launch Array BioPharma is founded.[168] Based in Boulder, Colorado, it is a biopharmaceutical company focused on the development and commercialization of targeted small molecule drugs. Array BioPharma would be later acquired by Pfizer.[167] United States
1998 Concept development Cooper et al. refer portfolio management to the prioritization of a number of new product development projects through the allocation of appropriate resources – capital, labour and materials. They define portfolio management as a tool used to outline the number of new product opportunities presented and the optimal investment mix between risk and return.[5]
1998 Personalized medicine Company launch Avesthagen is founded.[169] Based in Bangalore, it is a life science company focused in the convergence between food, pharma and population genetics leading to Predictive Preventive Personalized Healthcare.[170] India
1998 Agricultural biotechnology Company launch BASF Plant Science is founded.[171] Based in the Research Triangle Park, North Carolina, it is a subsidiary of BASF in which all plant biotechnology activities are consolidated.[172] United States
1998 Pharmaceutical Company launch Biotie Therapies is founded. It is a specialized drug development company focused on the central nervous system and inflammatory diseases.[173] Turkey
1998 DNA sequencing Company launch Celera Corporation is founded.[174] Based in Alameda, California, it focuses on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries.[175] United States
1998 Agricultural biotechnology Company launch CropDesign is founded. Based in Ghent, Belgium, it is an agricultural biotechnology company that offers crops like corn and rice to the seed market.[176] Belgium
1998 (September 5) Vaccines, antibodies Company launch Emergent BioSolutions is founded.[177] Based in Gaithersburg, Maryland, it develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats.[178] United States
1998 Epigenomics, molecular diagnostics, oncology Company launch Epigenomics AG is founded.[179] Based in Berlin, Germany, it is a molecular diagnostics company focused on the development and commercialization of in vitro diagnostic tests for cancer.[180] Germany
1998 Pharmaceuticals Company launch GW Pharmaceuticals is founded.[181] Based in Cambridge,England, in May 2021, it would be acquired by Jazz Pharmaceuticals.[182] United Kingdom
1998 Research Zucker et al. emphasize the impact of intellectual human capital. In their paper based on data from 751 biotechnology companies in the United States and 327 star scientists, they conclude that the growth and diffusion of intellectual human capital was the main determinant of where and when US biotechnology developed.[5]
1998 Research P. Swann and M. Prevezer define a cluster as a large group of firms in related industries at a particular location.[183] In the United States, there are five recognized biotechnology clusters. They are known as BioBay (San Francisco, California), BioBeach (San Francisco, California), GeneTown (Boston, Massachusetts), BioForest (Seattle, Washington; Portland, Oregon; Vancouver, British Columbia), Pharma Country (New York/New Jersey and Pennsylvania) and BioCapital (Maryland/Virginia/ Washington DC).[5] United States
1998 Sequencing, genotyping, gene expression, proteomics Company launch Illumina, Inc. is founded.[184] Based in San Diego, California, it is a provider of sequencing- and array-based solutions for genetic and genomic analysis.[185] United States
1998 Research According to Andrews and Hahn, the more sustainable organizations are likely to be those that are able to continuously collect, archive, retrieve, create, share and leverage information that can be translated into knowledge and wisdom for real-time decision-making.[186]
1999 (January) Agricultural biotechnology Company launch AgBiotechNet is founded.[187] It is a searchable online database of scientific literature on topics related to agricultural biotechnology.
1999 (January 19) Clinical trials, gene therapy Company launch Applied Genetic Technologies Corporation is established.[188] Based in Alachua, Florida, it conducts human clinical trials of adeno-associated virus-based gene therapies for the treatment of rare diseases.[189] United States
1999 (April 6) Pharmaceutical, biotechnology Company launch AstraZeneca is founded through the merger of the Swedish Astra AB and the British Zeneca Group.[190] Since the merger, it would become among the world's largest pharmaceutical companies. AstraZeneca is involved in developing the Oxford-AstraZeneca COVID-19 vaccine.[191] United Kingdom
1999 (September 9) Omics, genome sequencing Company launch BGI Group is founded.[192] Based in Shenzhen, it is a life science group that operates multiple research labs and entities in the field of genomics, healthcare, precision medicine, and more.[193] China
1999 Life Science Company launch Cell Signaling Technology is founded.[194] Based in Danvers, Massachusetts, it develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study the cell signaling pathways that impact human health.[195] United States
1999 Genome engineering, oncology Company launch Cellectis is founded.[196] Based in Paris, it develops adoptive immunotherapies for cancer.[197] France
1999 Diagnostics Background A diagnostic test is introduced for the quick identification of bovine spongicorm encephalopathy and Creutzfeldt-Jakob disease.[9]
1999 Biosimilars, biopharmaceuticals Company launch Celltrion is founded.[198] It is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. South Korea
1999 (June 17) Pharmaceutical, therapeutics Notable IPO United Therapeutics completes its IPO, trading under ticket UTHR on Nasdaq.[199] United States
1999 (June 30) Fund launch PGIM Jennison Health Sciences Fund- Class A (ticker symbol PHLAX) is launched in the United States.[200] It mostly invests in companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations.[201] United States
1999 (July 23) Developer platform Notable IPO BioMarin Pharmaceutical completes its IPO, trading under ticket BMRN on Nasdaq.[202] United States
1999 Dietary supplements, food ingredients Company launch ChromaDex is founded.[203] Based in Los Angeles, California, it is a dietary supplement and food ingredient company.[204] United States
1999 Immunotherapy Company launch EnCor Biotechnology is founded.[205] Based in Gainesville, Florida, it manufactures antibodies to neural and yeast proteins.[206] United States
1999 Immunotherapy, oncology Company launch Genmab is founded.[207] Based in Copenhagen, it is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases.[208] Denmark
1999 Glycobiology Company launch Ludger Limited is founded.[209] Based in Abingdon, Oxfordshire, England, it is a life science company specialized in glycan analysis technology.[210] United Kingdom
1999 Biopharmaceuticals Company launch Sinovac Biotech is founded.[211] Based in Beijing, it is a biopharmaceutical company that develops, manufactures and commercializes vaccines.[212]
1999 Immunology, oncology Company launch Trubion is founded. It is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer.[213] United States
2000 Test/measurement equipment Company launch Arryx is founded.[214] A developer of tools and technology for manipulation and measurement on the micro and nano length scales, in 2006, it would be acquired by Haemonetics.[215] United States
2000 mRNA therapeutics Company launch CureVac is founded.[216] Based in Tübingen, it provides prophylactic and therapeutic application of messenger RNA.[217][218] Germany
2000 Research Baum et al. identify a strong correlation between the number of collaborations for a start-up biotechnology firm and their commercial success. "The presence of well-reputed individuals or teams within or associated with a biotechnology firm will not only facilitate the formation of these linkages, but draw knowledge and resources to a firm through a process we have termed intellectual gravity."[5]
2000 Immunodiagnostics, molecular diagnostics Company launch DiaSorin is founded.[219] A global leader in the laboratory diagnostics market, is specializes in the immunodiagnostics and molecular diagnostics segments.[220] Italy
2000 (April) Genetic testing Company launch Gene by Gene is founded.[221] Based in Houston, it is a genetic testing services provider.[222] United States
2000 Agricultural biotechnology Background Kenya field-tests a virus resistant sweet potato, the country's first biotech crop.[9] Kenya
2000 Pharmaceutical[223] Company launch GlaxoSmithKline is founded.[224] Based in London, it is one of the world's largest pharmaceutical companies.[225] United Kingdom
2000 (June) DNA sequencing Company launch 454 Life Sciences is established.[226] Based in Branford, Connecticut, it specializes in high-throughput DNA sequencing using a novel massively parallel sequencing-by-synthesis approach.[227] United States
2000 (June) Background Scientists at Celera Genomics and the Human Genome Project complete a rough draft of the human genome.[228] United States
2000 (July 28) Sequencing, genotyping, gene expression, proteomics Notable IPO Illumina, Inc. completes its initial public offering, trading as ILMN.[229] United States
2000 (October) Biopharmaceuticals Company launch Renovo plc is founded.[230] Focused in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration,[231] the company would be defunct by May 2011.[232] United Kingdom
2000 Research C.M. Christensen and M. Overdorf describe disruptive innovation as a result of research studies conducted during the information technology boom of the 1990s. Disruptive innovation refers to a new product that does not initially address the needs of customers but becomes disruptive to the organization or industry.[233]
2000 Genetics, diagnostic tests Company launch Rosetta Genomics is founded. It engages in the discovery, development and commercialization of diagnostic tests for personalized medicine.[234] United States
2000 Genomics Company launch Strand Life Sciences is founded.[235] It is a genomics-based research and diagnostics company which aims to address health by decoding the genetic information contained in an individual's genome.[236] India
2000 (November 13) Agriculture, farming Company launch Syngenta is founded.[237] Based in Basel, it is an agriculture company that provides products and solutions to help farmers achieve food security.[238] Switzerland
2000 Oncology Company launch TopoTarget is founded.[239] It focuses on the discovery and development of drugs and therapies to treat cancer.[240] Denmark
2000 Research R. Batterham recognizes that the biotechnology industry globally lacks in managers and researchers with appropriate entrepreneurial and commercial skills.[241]
2000 Research According to Hill and Brennan, the facilitation and development of industry clusters, where the colocation of biotechnology firms or related industries complement each other, compete against each other or share common resources leads to increasing economies of scale.[242]
2000 Industry size As of date, the biotechnology sector includes more than 4,600 companies around the world, of which more than 600 are publicly held.[4]
2000 (December 15) Accelerator/incubator launch The California Institute for Quantitative Biosciences (QB3) is founded as a nonprofit research and technology commercialization institute affiliated with three campuses of the University of California in the San Francisco Bay Area: Berkeley, San Francisco, and Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.[243] United States
2000 (December 27) Healthcare Fund launch Fidelity Advisor Biotechnology Fund Class A (ticker symbol FBTAX) is launched in the United States.[244] It mostly invests in companies principally engaged in biotechnology, as well as companies that benefit significantly from scientific and technological advances in biotech.[245] United States
2001 (January 1) Antibodies (Primary and secondary) Company launch Abgent is founded. Based in San Diego, California, it manufactures primary antibodies.[246] United States
2001 Literature The U.S. National Research Council publishes Opportunities in Biotechnology for Future Army Applications.[247]
2001 Biomedicine, clinical trials Company launch GeoVax is founded.[248] A biomedical company, it develops, manufactures, tests, conducts human trials, licenses, and commercializes human vaccines for diseases caused by HIV and other infectious agents.[249] United States
2001 Peptide synthesis, therapeutics Company launch CPC Scientific is founded. Based in Sunnyvale, California, it helps pharmaceutical and biotechnology companies in synthetic peptide production and therapeutic development.[250] United States
2001 Nano-medicine Company launch Abraxis BioScience is founded.[251] A nano-medicine company developing treatments for critically ill patients, in 2010, it would be acquired by Celgene Corporation.[252] United States
2001 Gene targeting Background The United States FDA approves Gleevec, a genetargeted drug for patients with chronic myeloid leukemia. Gleevec is the first gene-targeted drug to receive FDA approval.[9] United States
2001 (November) Nanomedicine Company launch Ablynx is founded.[253] Acquired by Sanofi in January 2018 for $4.8 billion[254], it is engaged in the discovery and development of nanobodies. Ablynx is based in Ghent, Belgium.[255] Belgium
2002 (March 1) Immunotherapy, oncology Company launch Advaxisis established. It is a development-stage biotechnology company with the focus on developing cancer vaccines that utilize multiple mechanisms of immunity.[256] United States
2002 Research Based largely on financial and economic criteria, Fisken and Rutherford identifiy three different business models in European biotechnology companies. The Product Business Model: originates from the pharmaceutical model where value is added along the activities of the value chain to deliver a final product to market. This is a proven model where most of the top biotechnology companies in the world are classed as product companies. The Platform Business Model: This is a relatively new concept which aims to generate value from the front end of the industry value chain. It is based on the development of research tools or platform technology that can provide a service to another organization or can be licensed for further development along the value chain The Hybrid Business Model: "This business model is a hybrid of the product and platform business model. It generally consists of a platform technology that is able to generate a pipeline of products. This model is an evolution of the platform business model in that it aims to generate value through downstream activities of the biotechnology value chain. The pipeline of products can be developed organically or through additional in-licensing, purchasing exclusive or semi-exclusive access to another’s technology, to enhance product development opportunities. The convergence of the product and platform business model to create a hybrid model provides investors with the benefit of reduced risk and the potential for future revenue growth. This approach will need to become the preferred model for new and existing biotechnology companies to maintain growth and sustainability in the industry."[5]
2002 RNAi Therapeutics Company launch Alnylam Pharmaceuticals is founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke[257][258][259], as a spin-off from the Max Planck Institute for Biophysical Chemistry[260], It is a leader in the study of RNA interference (RNAi) therapeutics.[261] United States
2002 Agricultural biotechnology[262] Company launch Arcadia Biosciences is founded. It develops products such as nitrogen use crops, salt tolerant plants, sunflower oil, and shelf-life produce.[262] United States
2002 Agricultural biotechnology Background The United States Environmental Protection Agency approves the first transgenic rootworm resistant corn.[9] United States
2002 Healthcare, medical, pharmaceutical Company launch Botanix Pharmaceuticals is founded. It is a pharmaceutical company that focuses on the treatment of skin diseases.[263] Australia
2002 Oncology Company launch OBI Pharma, Inc. is founded.[264] Based in Taipei, it engages in the development and licensing of novel therapeutic agents for unmet medical needs against cancer.[265] Taiwan
2002 (June) Bioinformatics Company launch Phalanx Biotech Group is founded.[266] Based in San Diego, California, it develops whole genome microarray, miRNA microarray and hybridization chamber.[267] United States
2002 Health diagnostics. pharmaceuticals Company launch Catalyst Pharmaceuticals is founded.[268] Based in Coral Gables, Florida, it is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs.[269] United States
2002 Genetically modified insects Company launch Oxitec is founded.[270] It is a developer of biological solutions to control pests that transmit disease, destroy crops and harm livestock.[271] United Kingdom
2002 Literature C. Mark Tang publishes The Essential Biotech Investment Guide: How to Invest in the Healthcare Biotechnology & Life Sciences Sector.[272] Singapore (World Scientific)
2002 RNA-based therapeutics Company launch Prosensa is founded.[273] It is a biotech company dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.[274] Netherlands
2002 Industrial enzymes Company launch Codexis is founded.[275] It is a biosciences company applying synthetic chemistry technologies with the purpose to create improved versions of small molecule therapeutics.[276] United States
2002 Bioinformatics Company launch Integromics is founded.[277] It provides bioinformatics software for data management and data analysis in genomics and proteomics. Spain
2002 Cloning Background The banteng, an endangered species, is cloned for the first time.[278][9] United States
2002 Stem cell technology Company launch CellResearch Corporation is founded.[279] Based in Singapore, it is a biotechnology company with a primary focus on skin cell and cord lining stem cell research.[280] Singapore
2002 Genomics Company launch NeoGenomics is founded.[281] Based in Fort Myers, Florida, it is a cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers.[282] United States
2002 Biotechnology Company launch DBV Technologies is founded.[283] It is a global biopharmaceutical company that develops investigational epicutaneous immunotherapy technology to treat patients suffering from life-threatening food allergies and other immunological disorders.[284] France
2002 (August) Plant biotechnology, Molecular farming (plant-made pharmaceuticals) Company launch Guardian Biotechnologies is founded.[285] It is a biotechnology company focused on molecular farming to produce vaccines, diagnostic assay kits, and commercial enzymes.[286] Canada
2003 (May 24) Literature Richard W. Oliver publishes The Biotech Age : The Business of Biotech and How to Profit From It.[287]
2003 (June) biopharmaceutical Company launch Acceleron Pharma is founded.[288] It is a biotechnology company focused on the discovery, development, and commercialization of novel therapies.[289] United States
2003 Blood test Company launch Theranos is founded by Elizabeth Holmes. Claiming that it could perform a wildly large number of tests, such as measuring glucose levels and detecting different types of antibodies, the company would later be dissolved and liquidated, with founder indicted for wire fraud and conspiracy.[290][291][292] United States
2003 Oncology Company launch Cleveland BioLabs is founded.[293] It is a drug discovery and development company that focuses on treatments for cancer, radiation exposure and other areas.[294] United States
2003 Literature Martin Grossmann publishes Entrepreneurship in Biotechnology: Managing for Growth from Start-Up to Initial Public Offering.[295]
2003 Whole genome sequencing Background The Human Genome Project completes sequencing of the human genome.[9]
2003 Pharmaceutical Literature John Abraham and Helen Lawton Smith publish Regulation of the Pharmaceutical Industry.[296]
2003 Gene therapy, oncology Background China grants the world’s first regulatory approval of the gene therapy product, Gendicine, which delivers the p53 gene as a therapy for squamous cell head and neck cancer.[9] China
2003 Plant biotechnology Company launch TerraVia is founded.[297] It is a next-generation food, nutrition and specialty ingredients company focused on algae.[298]
2003 Statistics Ernst and Young estimate that over 50 per cent of Australian biotech firms are generated from public sector research organizations.[5] Australia
2003 Cord blood banking Company launch Crioestaminal is founded.[299] It is a privately held biotechnology company that engages in preservation of stem cells to treat future ailments.[300] Portugal
2003 Research Palacios-Marques and Garrigós-Simón operationalize the intellectual capital construct in terms of a multi-dimensional scale of measurement, subsequently validated by surveying managers from a large number of biotech firms. These researchers conclude that for biotech firms, human capital is the most important component, followed by relational capital, and finally structural capital.[5]
2003 Pharmaceuticals Company launch Nanjing Ange Pharmaceutical is founded.[301] It is a leading manufacturer and supplier of Sunitinib, Lapatinib, Nilotinib, Dasatinib, Gefitinib, Erlotinib, Imatinib, Canertinib and relative pharmaceutical intermediates.[302] China
2003 Literature Martin Grossmann publishes Entrepreneurship in Biotechnology: Managing for Growth from Start-up to Initial Public Offering[303]
2003 Medical device, therapeutics Company launch BioLineRx is founded.[304] Headquartered near Tel Aviv, it is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies.[305] Israel
2003 Gene Synthesis, protein engineering, protein production, bioinformatics, cell line development, leap-in transposases Company launch ATUM is founded.[306] It provides tools for the life sciences, from design and synthesis of optimized DNA to protein production and GMP cell line development.[307] United States
2003 Synthetic biotechnology Company launch Amyris is founded. Based in Emeryville, California, it specializes in creating renewable products focusing on fuels and chemicals.[308] United States
2003 Genetics, health diagnostics, life science[309] Company launch Helicos Biosciences is founded.[310] It is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets.[311] United States
2004 (January 1) Monoclonal antibody therapy Company launch Alder Biopharmaceuticals is founded.[312] It is a biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies.[313] United States
2004 Healthcare, life science Company launch 3H Biomedical[314] It supplies more than 270 different types of primary human and animal cell-based products for life science research, drug development, screening of chemicals and biomaterials development.[315] Sweden
2004 Sequencing systems Company launch Pacific Biosciences is founded. It designs, develops, and manufactures sequencing systems to resolve genetically complex problems.[316] United States
2004 Biopharmaceutical Company launch Molecular Partners is founded by researchers at the University of Zürich, while studying monoclonal antibodies.[317] Switzerland
2004 Pharmaceutical Company launch Medivation is founded.[318] Focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options,[319] it would be acquired by Pfizer in September 2016.[320] United States
2004 Bioinformatics Company launch Genostar is founded.[321] Based in Grenoble, France, it is a provider of bioinformatics software, databases and complete data analysis services for microbial research.[322] France
2004 Accelerator/incubator launch The Portland State University Business Accelerator is founded.[323] This accelerator provides office space and fully-loaded lab facilities. The dedicated and skilled staff of the accelerator appeals to the region’s top science and technology startups. The startups are also leveraging the affordable co-working space, access to the conference room, monthly Business tycoons meetings and topic-related Lunch & Learns, fundraising and business management.[112] United States
2004 Agricultural biotechnology Background The Food and Agriculture Organization endorses biotech crops, stating biotechnology is a complementary tool to traditional farming methods that can help poor farmers and consumers in developing nations.[9]
2004 Pharmaceutical Background The United States FDA approves the first antiangiogenic drug for cancer, Avastin.[9] United States
2004 Literature Bryan Bergeron, Bryan P. Bergeron, and Paul Chan publish Biotech Industry: A Global, Economic, and Financing Overview, which attempts to offer a clear vision of the global biotech market through 2010, including which regions and corporations are best positioned to dominate the market.[324]
2004 Oligonucleotides Company launch FlexGen B.V. is founded in the Netherlands.[325] A spin-off from Leiden University Medical Centre and Dutch Space (part of EADS), the company would be declared bankrupt on 21 December 2015.[326] Netherlands
2004 DNA sequencing, Live science Company launch CD Genomics is founded.[327] It specializes in sequencing services, as well as genotyping, library construction, bioinformatics, aptamers, microarray, health diagnostics, mutagenesis analyses and others for the genomics industry.[328] United States
2005 (March) Pharmaceuticals Company launch Jazz Pharmaceuticals is founded.[329] It focuses on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.[330] United States
2004 (September 1) Fund launch Rydex Biotechnology Fund Class A (ticker symbol RYBOX) is launched.[331] It mostly invests in biotechnology companies that are traded in the United States.[332] United States
2005 Biotechnology Company launch Micreos is founded. It is a Netherlands-based phage- and endolysin technology development company.[333] Micreos develops Staphefekt, an endolysin that selectively kills Staphylococcus aureus bacteria.[334] Netherlands
2005 Biofuel Background The Energy Policy Act of 2005 is passed and signed into law in the United States, authorizing numerous incentives for bioethanol development.[9] United States
2005 Real-time polymerase chain reaction detection kits Company launch Primerdesign is founded.[335] It is a privately held limited company focused on the design, manufacture, validation and supply of dreal-time PCR kits and reagents.[336] United Kingdom
2005 Pharmaceuticals, contract research Company launch Melior Discovery is founded.[337] It is a provider of in vivo pharmacology services.[338] United States
2005 Biomedical engineering Company launch Medicen is founded.[339] It is a French business cluster mainly focused in biomedical engineering.[340] France
2005 Immunotherapy (Tailored Leukapheresis (TLA) treatment) Company launch Immune Therapy Holdings is founded.[341] Headquartered at the Karolinska Institutet and Karolinska University Hospital in Stockholm, it is a Swedish biotechnology R&D holding company primarily focused on its Tailored Leukapheresis (TLA) treatment for immune mediated inflammatory diseases (IMIDs).[342] Sweden
2005 Gene editing Company launch Horizon Discovery is founded.[343] A gene editing and modulation technology company, it allows the biopharmaceutical and clinical diagnostics industries to gain a greater understanding of gene function, identify the genetic drivers behind human disease and develop personalised molecular, cell and gene therapies.[344] United Kingdom
2005 Antbodies, peptide libraries Company launch Creative Biolabs is founded.[345] It focuses on the development of human single domain antibodies as therapeutics and affinity reagents.[346]
2005 Scientific instruments Company launch CovalX is founded.[347] It specializes in protein interaction analysis based on mass spectrometry. CovalX provides epitope mapping, intact mass analysis, protein interactions, protein aggregation, sequencing, disulfide mapping, and other services.[348] Switzerland
2005 Healthcare, health diagnostics Company launch Celsense is founded.[349] Based in Pittsburgh, Pennsylvania, it is a biotechnology company providing magnetic resonance imaging contrast agents.[350] United States
2005 (August 5) Diabetes, pharmaceutical Company launch Avid Radiopharmaceuticals is founded. Acquired later by Eli Lilly, it develops molecular imaging agents for detecting and monitoring chronic human diseases.[351]
2005 Business growth In this year alone, biotech firms participated in 1,400 deals involving billions of dollars.[4]
2006 (January 31) Fund launch SPDR S&P Biotech ETF (ticker symbol XBI) is launched in the United States, where it is available as well as in Mexico.[352] It seeks to track the performance of the S&P Biotechnology Select Industry Index.[353] United States
2006 (March) Genomics Company launch Complete Genomics is founded.[354] It is a life sciences company that focuses solely on complete human genome sequencing.[355] United States
2006 (April) Biotechnology, genetic genealogy Company launch 23andMe is founded.[356] Based in Mountain View, California, it "offers a direct-to-consumer (DTC) genetic testing service based on the use of single-nucleotide polymorphisms (SNPs) to determine ancestry and to identify genetic markers associated with specific diseases and conditions and a few specific causal variants that the company claimed could provide information about their clients’ health and how to improve it".[357] United States
2006 Laboratory equipment, biotechnology, pharmaceutical, healthcare Company launch Thermo Fisher Scientific is founded.[358] Based in Waltham, Massachusetts, it manufactures scientific instruments consumables and chemicals.[359] United States
2006 Accelerator/incubator launch The Pennsylvania Biotechnology Center (PABC) is founded.[360] It is a non-profit life science incubator facility that works "for the building of a global biotechnology centre, to the elevation of local commercial development and creation of jobs, as well as for the education and training of tomorrow’s researchers."[112] United States
2006 Genetic engineering, polymers Company launch Kraig Biocraft Laboratories is founded.[361] A fully reporting biotechnology company, it develops genetically engineered spider silk based fiber technologies.[362] United States
2006 Pharmaceutical Background The United States Department of Agriculture grants Dow AgroSciences the first regulatory approval for a plantmade vaccine.[9] United States
2006 Cell therapy Company launch InGeneron is founded.[363] It is a cell therapy company that aims to enable treatments designed to heal certain chronic conditions using a patient's own regenerative cells processed at the bedside for same-day application.[364] United States
2006 Pharmaceutical Company launch Galena Biopharma is founded.[365] It is a biopharmaceutical company developing targeted oncology treatments.[366] United States
2006 Pharmaceutical Company launch F-star is founded.[367] It is an immuno-oncology company focused in the development of tetravalent mAb2 bispecific antibodies.[368] Austria
2006 Obesity Company launch Gelesis is founded.[369] It develops a novel category of therapies for GI-related chronic diseases.[370] United States
2006 Oncology, pharmaceutical Company launch Beacon Pharmaceuticals is founded.[371] Based in Dhaka, it is an oncology company that manufactures generic drugs, biotech, hi-tech & conventional general products.[372] Bangladesh
2006 Pharmaceutical Background The United States FDA approves Merck & Co. recombinant vaccine Gardasil, the first vaccine developed against human papillomavirus.[9] United States
2006 Gene therapy Company launch Ablitech, Inc. is founded.[373] It specializes delivering gene therapeutics with the potential to stop cancer and most degenerative diseases.[374] United States
2007 Research reagents Company launch MyBioSource is founded.[375] It is a biotechnology distribution company that supplies life science products, notably research reagents.[376] Canada
2007 (May 31) Healthcare, pharmaceutical Notable IPO Jazz Pharmaceuticals completes its IPO, trading under ticker JAZZ on Nasdaq.[377] United States
2007 Pharmaceutical Background The United States FDA approves the H5N1 vaccine, the first vaccine approved for avian flu.[9] United States
2009 Agricultural biotechnology Background The global biotech crop acreage reaches 330 million acres.[9]
2009 Genetic engineering Background The United States FDA approves the first genetically engineered animal for production of a recombinant form of human antithrombin.[9]
2013 Oncology, biopharmaceutical Company launch Iovance Biotherapeutics is founded. Based in New York City, it develops T-cell-based immunotherapy products for the treatment of cancer.[378] United States
2008 (March 13) Vaccines, biopharmaceutical Company launch Braasch Biotech is founded. Based in Garretson, South Dakota, it is a biopharmaceutical company working exclusively with therapeutic vaccines.[379] United States
2008 Healthcare, medical[380] Company launch ACT Biotech Inc is founded.[381] Based in San Francisco, California, it is a biopharmaceutical company focused on the development and commercialization of cancer drugs.[380] United States
2008 Literature Gordon M. Binder and Philip Bashe publish Science Lessons: What the Business of Biotech Taught Me about Management.[382]
2008 Chemical, greentech[383] Company launch BioAmber is founded.[384] Based in Plymouth, Minnesota, it is a sustainable chemicals firm combining biotechnology and chemical catalysis to convert renewable feedstock into chemicals.[383] United States
2008 Immunotherapy, mRNA-based human therapeutic Company launch BioNTech (see Timeline of BioNTech) is founded.[385] Germany
2008 Renewable chemicals Company launch BioTork is founded.[386] It focuses on sustainability through the development of microbial strains and bioconversion processes.[387] United States
2008 Healthcare, health diagnostics, hospital Company launch Epic Sciences is founded. Based in La Jolla, California, it is a diagnostics company engaged in the improvement of cancer management by providing real-time biopsy material to guide personalized medicine.[388] United States
2008 DNA Sequencing Company launch Cofactor Genomics is founded.[389] It focuses in the use of RNA to diagnose disease.[390] Based in San Francisco, California, it is a DNA Sequencing company that focuses on the discovery process.[391] United States
2008 Literature Alexandra Carina Gruber publishes Biotech Funding Trends: Insights from Entrepreneurs and Investors, which seeks to provide a comprehensive overview of current trends in biotech funding.[392]
2008 Immunotherapy Company launch Immunocore is founded.[393] It is a commercial-stage biotechnology company pioneering the development of a novel class of T-cell receptor bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases.[394] United Kingdom
2008 DNA profiling Company launch PooPrints is founded.[395] It is a US company offering a “DNA solution for dog waste”.[396] United States
2008 Protein engineering Company launch SeSaM-Biotech GmbH is founded.[397] It provides enzyme services in form of Directed Enzyme Evolution, also known as protein engineering.[398] Germany
2008 Biotechnology, Human resources, search engine Company launch Stemgent is founded.[399] Based in Cambridge, Massachusetts, it is a provider of reagents, services and training for scientists who study cellular reprogramming (iPS cells).[400] United States
2008 Pharmaceutical Literature Martin Austin publishes Business Development for the Biotechnology and Pharmaceutical Industry.[401]
2008 Pharmaceutical Literature R. Berry Ira and Robert P. Martin publish The Pharmaceutical Regulatory Process.[402]
2009 Literature Alexandra Carina Gruber publishes Biotech Funding Trends: Insights from Entrepreneurs and Investors.[403]
2009 Medical diagnosis Company launch OME Care is founded.[404] Based in San Diego, California, it is a precision medical diagnostic and home-care company with mobile applications. United States
2009 Literature Craig D. Shimasaki publishes The Business of Bioscience: What goes into making a Biotechnology Product.[9]
2009 Cancer immunotherapy Company launch Kite Pharma is founded.[405] It designs and develops immune-based therapies to treat cancer indications.[406] United States
2009 Cannabis-based medicine Company launch Cannabis Science is registered and receives its initial Federal Commercial and Government Entity (CAGE) Code clearance. It is one of the only companies in its industry with the ability to work directly with the US Federal Government.[407] United States
2009 (July 6) Fund launch Janus Henderson Global Life Sciences Fund Class A (ticker symbol JFNAX) is launched in the United States.[408] It mostly invests in companies that the portfolio managers believe have a life science orientation.[409] United States
2009 (August 17) Biopharmaceutical, pharmaceutical, medical devices Company launch Siam Bioscience is founded.[410] It is a life sciences business focusing on biopharmaceuticals.[411] Thailand
2009 (September) Pharmaceutical Legal Pfizer is fined $2.3 billion for illegal marketing promoting uses of four of its drugs, including the painkiller Bextra (Valdecoxib),[412] after the company promoted Bextra for several uses and dosages that the FDA specifically declined to approve due to safety concerns.[413][414] United States
2010 Applied research, R&D Company launch The Austrian Centre of Industrial Biotechnology is founded.[415] It is a privately owned non-profit research center specialized on "bridging the gap between basic academic research and experimental industrial development".[416] Austria
2010 (September) Biomarkers Company launch Abcodia is founded. Based in London, it is an innovative biotech company engaged in the validation and discovery of molecular biomarkers.[417] United Kingdom
2010 (September) mRNA therapeutics Company launch Moderna is founded.[418] Based in Cambridge, Massachusetts, it is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.[419] See Timeline of Moderna. United States
2010 Protein microarray, multiplexing Company launch Ayoxxa Biosystems is founded. Based in Cologne,Germanys[420][421] it is known for developing protein chip capable of detecting at once multiple biomarkers, biomarker signatures (including markers for cancer, allergies, age related macular degeneration AMD, or infectious diseases) from a small biological sample. The protein chip yields large amounts of data, being primarily aimed for use in biomedical research in academia, clinic and industry.[422][423] Germany
2011 Biotechnology, pharmaceutical, therapeutics[424] Company launch Athira Pharma is founded.[425] Based in Seattle, Washington, it is a drug development company that specializes in biotechnology and pharmaceutical.[426] United States
2011 Genomics, data analysis Company launch Personalis is founded. Based in Menlo Park, California, it is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.[427] United States
2011 Biotechnology, genetics, pharmaceutical[428] Company launch Cambrian Genomics is founded.[429] IT is a biotechnology company developing technologies to synthesize DNA.[430] Based in San Francisco, California, it is a biotechnology company which uses a novel, laser based technique to synthesize DNA.[428] United States
2011 Biotechnology, chemical, chemical engineering, technical support[431] Company launch Carbios is founded.[432] Based in Saint-Beauzire, Puy-de-Dôme, France, it is a chemistry company that focuses on discovering and developing enzymatic bioprocesses applied to plastic and textile polymers.[431] France
2011 Literature Sally Smith Hughes publishes Genentech: The Beginnings of Biotech.[433]
2011 Biotechnology, healthcare, health diagnostics[434] Company launch Galecto Biotech is founded.[435] It develops small molecules for the treatment of severe diseases.[436] Based in Copenhagen, it focuses on the development of novel treatments for fibrosis and cancer.[434] Denmark
2011 Biopharmaceutical Company launch GEMoaB Monoclonals is founded.[437] Based in Dresden, it is a biopharmaceutical company with a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development.[438] Germany
2011 Infertility treatment Company launch OvaScience is founded.[439] Based in Boston, Massachusetts, it is a life sciences company focused on the discovery, development and commercialization of treatments for infertility. It would be later acquired by Millendo Therapeutics.[440] United States
2011 Healthcare, therapeutics Company launch Permeon Biologics is founded.[441] Based in Cambridge, Massachusetts, it is a developer of therapeutic drugs.[442] United States
2011 Genomics, radiomics Company launch Sophia Genetics is founded.[443] It is a healthcare technology company dedicated to establishing the practice of data driven medicine as the standard of care and for life sciences research.[444] Switzerland, United States
2011 Accelerator/incubator launch StartUp Health is launched as a venture capital firm. Based in San Francisco, it seeks to invest in early stage companies operating in the healthcare and technology sectors.[445] United States
2011 Cellular senescence Company launch Unity Biotechnology is founded.[446] It is a startup biotechnology company that develops drugs which target senescent cells.[447] United States
2011 (December 18) Vaccine shipping and storage Company launch Vaxess Technologies is founded. Based in Cambridge, Massachusetts, it engages in developing biomedical innovations with a focus on improving access to vaccines.[448] United States
2011 (December 20) Fund launch VanEck Biotech ETF (ticker symbol BBH) is launched in the United States, where it is available as well as in Chile and Mexico.[449] It invests in common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry.[450] United States
2012 (January) Healthcare Accelerator/Incubator launch JLABS is founded.[451] It is an innovation incubator arm of Johnson & Johnson.[452] United States
2012 (May 2) Literature M. O'Neill and M. M. Hopkins publish A Biotech Manager's Handbook: A Practical Guide, which outlines the state of the biopharmaceutical industry and goes on to explain the importance of planning.[453]
2012 Fitness, genetics, healthcare, wellness Company launch uBiome is founded.[454] Based in San Francisco, California, it is a provider of public access to DNA sequencing technology to understand the microbiome.[455] United States
2012 Nanotechnology Company launch Tecrea is founded.[456] Based in London, it aims to provide vastly improved cell delivery technology for research and the clinic.[457] Tecrea's nanotechnology-based cell delivery system is used as a non-toxic method of transfection.[458] United Kingdom
2012 Accelerator/incubator launch The California Institute for Biomedical Research (Calibr) is founded as a non-profit with the goal to accelerate the translation of basic research to new medicines that address unmet medical needs.[459] Calibr is a division of Scripps Research and situated in the middle of San Diego’s Torrey Pines Mesa biomedical research hub.[112] United States
2012 (July) Pharmaceutical Legal GlaxoSmithKline agrees to plead guilty and pay $3 billion to settle the largest case of healthcare fraud in the United States to date, as the company is charged for unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices.[460] United States
2012 (September 20) Accelerator/incubator launch Massachusetts-based non-profit Lab Central is founded as a launchpad for highly prospective life sciences and biotech start-ups.[112] United States
2012 (October 23) Bioinformatics, plant breeding and phenotyping, software Company launch Computomics is founded.[461] BAsed in Tübingen,Germany, it specializes in machine learning, plant research and bioinformatics, using data "to unlock the diversity of biological life".[462] Germany
2012 Accelerator/incubator launch StartX Med is founded with the purpose to accelerate the development of high-potential entrepreneurs in the life sciences and medicine through experiential education and collaborative intelligence.[463] United States
2012 Protein for animal and fish feed Company launch Calysta is founded.[464] Based in Menlo Park, California, it develops alternative protein ingredients.[465] United States
2012 Artemisinin derivatives Company launch ArtemiFlow is founded.[466] Based in Potsdam, Germany}}, it is a technology-based start-up that uses extracts from a plant called Artemisia Annua to treat malaria, cancer, and other diseases.[467] Germany
2012 Biotechnology Genetics Health Care Medical[468] Company launch 10x Genomics is founded.[468] It provides integrated solutions including instruments, consumables and software for analyzing biological systems.[469]
2012 Literature Martin Austin publishes Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries: The Commercialization of Intellectual Property.[470]
2012 Literature Michael O'Neill and Michael Hopkins publish A biotech managers handbook: A practical guide.[471]
2013 Healthcare, medical therapeutics[472] Company launch Stem Cell Theranostics is founded.[472] It is a precision medicine-focused biotechnology company developing genetically-targeted therapies for heart failure.[473] United States
2013 Biopharmaceuticals Company launch AbbVie is founded as a spin off from Abbott Laboratories.[474] It is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products.[475][476] United States
2013 Enzyme based solutions Company launch Barentzymes is founded.[477] Based in Tromsø, Norway, it is a biotech company addressing the need for enzyme based solutions in industrial biotechnology and is focused on the development of new original enzymes from genetic resources.[478] Norway
2013 Biotechnology, Health Diagnostics, Nanotechnology Company launch Bikanta is founded. Based in Berkeley, California, it engages in the introduction of nanodiamond-based technology.[479] United States
2013 Pharmaceuticals Company launch CoCo Therapeutics is founded.[480] It is a British biotechnology company focussed on the discovery of new drugs for the treatment of Alzheimer's disease.[481] United Kingdom
2013 CRISPR Company launch CRISPR Therapeutics is founded.[482] It is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.[483] Switzerland, United States
2013 Clinical Trials, healthcare, medical therapeutics Company launch Juno Therapeutics is founded. Based in Seattle, Washington, it is a clinical-stage company developing immunotherapies for the treatment of cancer.[484] United States
2013 Accelerator/incubator launch MBC BioLabs is founded. Based in San Francisco, it is an important biotech incubator in the Bay Area.[485] United States
2013 Developer platform, sensor Company launch Kaitek is founded.[486] It is a Chilean biotech company focused on the development of bacterial sensors for environmental monitoring.[487] Chile
2013 Fitness, healthcare, internet Company launch MyGenetics is founded. Based in Novosibirsk, Russia, it is an internet-based service that determines nutrition plans, physical activity levels, and body reactions to various products.[488] Russia
2013 Alternative medicine, biotechnology, cloud data services, genetics, healthcare, life science Company launch NantOmics is founded. Based in Culver City, California, it develops cloud-based molecular profiling tools that help guide cancer patients.[489] United States
2013 Pharmaceutical Company launch Spark Therapeutics is founded.[490] It is a US-based gene therapy company that specializes in rare disease medicines.[491] United States
2013 Market size Global sales of biotech products exceed $175 billion in the year, representing about 19 percent of the $950 billion in total prescription product sales worldwide.[4]
2014 Genetics, healthcare, personal health[492] Company launch Veritas Genetics is founded.[493] Based in Danvers, Massachusetts, it is a provider of a genetic testing platform intended to empower people to live healthier and longer. It will be later acquired by LetsGetChecked.[492] United States
2014 (May 10) Literature Richard W. Oliver publishes The Coming Biotech Age: The Business of Bio-Materials.[494]
2014 Accelerator/incubator launch The UCSF Rosenman Institute is founded. It is one of the top biotech incubators and accelerators in the United States.[112] United States
2014 (July 15) Analytics, big data Company launch MyGene is founded. Based in Beijing, it a human genome big data analytics platform.[495] China
2014 Pharmaceutical Literature Jie Jack Li publishes Blockbuster Drugs: The Rise and Decline of the Pharmaceutical Industry, which attempts to describe stories behind the discovery and development of highly lucrative medicines, while also exploring the tumult the industry faces as the "patent cliff" nears.[496]
2014 (Fall) Accelerator/incubator launch Illumina Accelerator is founded.[497] United States
2014 (October 30) DNA sequencing, gene editing, CRISPR, therapeutics, agricultural biology, molecular diagnostics Fund launch ARK Genomic Revolution ETF (ticker symbol ARKG) is launched. It invests in United States listed securities of companies focused on genomics.[498] United States
2014 (November 1) Accelerator/incubator launch IndieBio is launched. Based in San Francisco, it is one of the largest biotech startup accelerator.[499] United States
2014 Literature Craig Shimasaki publishes Biotechnology Entrepreneurship: Leading, Managing and Commercializing Innovative Technologies, which attempts to provide a guide to biotechnology enterprise and entrepreneurship.[500]
2015 Biotechnology, pharmaceutical Company launch Baxalta is founded.[501] It has a portfolio of differentiated therapies that seek to address unmet medical needs across many disease areas like hemophilia, immunology and oncology.[502]
2015 Bioinformatics, biotechnology, genetics, healthcare, therapeutics Company launch BioViva is founded. Based in the Greater Seattle Area, it is committed to creating regenerative medicine to alleviate diseases caused by cellular degeneration and genetic disorders.[503] United States
2015 Genealogical DNA tests Company launch Embark Veterinary is founded.[504] Based in Boston, Massachusetts, it sells canine DNA test to help dog owners better understand their pet's breed and ancestry.[505] United States
2015 Artificial intelligence, genomics Company launch iCarbonX is founded.[506] Based in Shenzhen, it is an artificial intelligence platform for health data company.[507] China
2015 Genomics Company launch Phase Genomics is founded.[508] It is a life sciences innovation and biotechnology company specializing in genome assembly and analysis.[509]
2015 (December 7) Precision health Company launch Verily is founded.[510] It is a subsidiary of Alphabet Inc. focused on life sciences and healthcare.[511] United States
2016 (January 1) Health information technology, big data Company launch RxAll is founded.[512] This company would be the recipient of 2018 CIO Review Most Promising PharmaTech Vendor Award and 2018 Katapult FutureFest's Glstart-up award in Oslo, Norway.[513][514] United States
2016 Hemophilia-focused pharmaceutical Company launch Bioverativ is founded.[515] Based in Waltham, Massachusetts, it focuses on the discovery, research, development and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders.[516] United States
2016 Diagnostic kits Company launch Mylab Discovery Solutions is founded.[517] Based in Lonavla, Maharashtra, it is a molecular biology company focused on developing tests for human diagnostics, food safety, agriculture, and veterinary.[518][519] India
2016 Mental healthcare Company launch Neurovation Labs is founded.[520] It is a biotechnology company that specializes in the diagnostics and treatment of central nervous system (CNS) disorders.[521]
2016 T cell immunotherapy Company launch Vaccitech is founded.[522] A spin-out company from the University of Oxford's Jenner Institute[523], it is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases.[524] United Kingdom
2016 (September) Genealogical DNA test Company launch Living DNA is founded.[525] A DNA testing company, it offers an ancestry that provides a biogeographical ancestry analysis with Y-DNA and mtDNA haplogroup reports combined with autosomal DNA relative matching. The company also offers a wellbeing test which reports on nutrition and fitness.[526]
2016 (November) Consumer electronics, healthcare[527] Company launch Galvani Bioelectronics is founded as a joint venture by GlaxoSmithKline and Verily, with the purpose to create implants that can precisely target nerves to specific organs and can stay inside a patient for the rest of their life.[528] Based in Stevenage, England, it develops ways to treat chronic illnesses by controlling electrical impulses in the body.[527] United Kingdom
2017 Literature Gary Gereffi publishes The pharmaceutical industry and dependency in the Third World.[529]
2017 Biotechnology, healthcare, information technology, software[530] Company launch OmniVis is founded.[531] Based in San Francisco, it focuses on rapid disease detection technology with the ability to reach communities anywhere in the world.[532] United States
2017 (September) Literature Françoise Simon and Glen Giovannetti publish Managing Biotechnology: From Science to Market in the Digital Age, which provides a comprehensive overview of the new business context and marketing models for biotech companies.[533]
2017 (November 24) Literature Leah Cannon publishes How to Start a Life Science Company: A Comprehensive Guide for First-Time Entrepreneurs.[534]
2018 (March) Blood test Legal Theranos' CEO Elizabeth Holmes, former company president Sunny Balwani, and the company are charged with fraud by the SEC,[535] after fraud and conspiracy are revealed, as well as technology that repeatedly failed quality assurance and results sent to real patients that were incorrect.[536] Theranos would be defunct by September 2018.[537] United States
2018 Gene therapy Company launch Reborna Biosciences, Inc. is founded.[538] Based in Fujisawa, Japan, it is a research and development start-up focusing on the field of rare genetic diseases.[539] Japan
2019 Literature Florentina Matei and Daniela Zirra publish Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective.[540]
2019 Genetic testing Company launch 54gene is founded. Based in Washington, D.C., it is a healthcare startup that offers a genetics testing platform.[541] United States
2019 Metabolic engineering, synthetic biology Company launch Cysbio is established as a spinout from The Novo Nordisk Foundation Center for Biosustainability, DTU (Technical University of Denmark).[542] Based in Kongens Lyngby, Denmark, it uses advanced metabolic engineering and synthetic biology approaches to construct bacterial cell factories for transforming the production of biochemicals from renewable feedstocks.[543] Denmark
2020 (December) RNA therapeutics Notable case Pfizer–BioNTech and Moderna obtain authorization for their mRNA-based COVID-19 vaccines.[544]
2021 (October) Statistics As of date, the top U.S.-based biotechnology firms in terms of market capitalization are Johnson & Johnson ($425 billion), Roche ($334 billion), Pfizer ($240 billion), and Novo Nordisk ($225 billion).[1] United States

Numerical and visual data

Google trends

The chart shows Google Trends data for Biotechnology, from January 2004 to May 2022, when the screenshot was taken. Data is also ranked by country and displayed on world map.[545]

Biotechnology google trends.png

Google Ngram viewer

The chart shows Google Ngram Viewer data for biotechnology from 1900 to 2019.[546]

Biotechnology ngram.PNG

Google Scholar

The table and graph below show the evolution of mentions of Biotechnology on Google Scholar as of May 29, 2022

Year N° of mentions
1970 30,900
1975 7,120
1980 27,800
1985 16,300
1990 70,500
1995 99,700
2000 319,000
2005 707,000
2010 1,070,000
2015 915,000
2020 248,000
Biotechnology google scholar.PNG

Wikipedia views

The chart below shows pageviews of the English Wikipedia article Biotechnology, from July 2015 to April 2022.[547]

Biotechnology WV.png

Meta information on the timeline

How the timeline was built

The initial version of the timeline was written by Sebastian.

Funding information for this timeline is available.

Feedback and comments

Feedback for the timeline can be provided at the following places:

  • FIXME

What the timeline is still missing

Timeline update strategy

See also

External links

References

  1. ↑ 1.0 1.1 1.2 1.3 "The Basics of Biotechnology". Investopedia. Retrieved 31 May 2022. 
  2. ↑ 2.0 2.1 Bud, Robert (1991). "Biotechnology in the Twentieth Century". Social Studies of Science. pp. 415–457. Retrieved 31 May 2022. 
  3. ↑ Castellano, C. (1991). "Biotechnology in the 1980s and 1990s: A Brief Survey". Imaging and Computing in Gastroenterology: 110–114. doi:10.1007/978-3-642-75739-6_19. 
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Evens, Ronald; Kaitin, Kenneth (February 2015). "The Evolution Of Biotechnology And Its Impact On Health Care". Health Affairs. 34 (2): 210–219. doi:10.1377/hlthaff.2014.1023. 
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 Hine, Damian; Kapeleris, John (1 January 2006). Innovation and Entrepreneurship in Biotechnology, an International Perspective: Concepts, Theories and Cases. Edward Elgar Publishing. ISBN 978-1-84542-885-3. 
  6. ↑ Rasmussen, Nicolas (15 May 2014). Gene Jockeys: Life Science and the Rise of Biotech Enterprise. JHU Press. ISBN 978-1-4214-1341-9. 
  7. ↑ "The Biotech Revolution - 1980s- The Lab - Australian Broadcasting Corporation's Gateway to Science". www.abc.net.au. Retrieved 31 May 2022. 
  8. ↑ "1990s seen as 'decade of biotechnology'". Baltimore Sun. Retrieved 31 May 2022. 
  9. ↑ 9.00 9.01 9.02 9.03 9.04 9.05 9.06 9.07 9.08 9.09 9.10 9.11 9.12 9.13 9.14 9.15 9.16 9.17 9.18 9.19 9.20 9.21 9.22 9.23 9.24 9.25 9.26 9.27 9.28 9.29 9.30 9.31 9.32 9.33 9.34 9.35 9.36 9.37 9.38 Shimasaki, Craig (8 April 2014). Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. Academic Press. ISBN 978-0-12-404747-1. 
  10. ↑ Utterback, J.M. and W.J. Abernathy (1975), ‘A dynamic model of product and process innovation’, Omega, 3 (6), 639–56.
  11. ↑ Wagner, Thomas E. (1 September 1985). "THE ROLE OF GENE TRANSFER IN ANIMAL AGRICULTURE AND BIOTECHNOLOGY". Canadian Journal of Animal Science. 65 (3): 539–552. doi:10.4141/cjas85-065. 
  12. ↑ "Recombinant DNA and the Birth of Biotech -- Recombinant Drugs". National Museum of American History. Retrieved 24 May 2022. 
  13. ↑ "25years of recombinant DNA vaccine for livestock". www.biospectrumindia.com. Retrieved 24 May 2022. 
  14. ↑ Tsui, Lap-Chee; Dorfman, Ruslan (1 February 2013). "The Cystic Fibrosis Gene: A Molecular Genetic Perspective". Cold Spring Harbor Perspectives in Medicine. 3 (2): a009472. doi:10.1101/cshperspect.a009472. 
  15. ↑ "Fidelity® Select Biotechnology Portfolio, FBIOX summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  16. ↑ "FBIOX - Fidelity ® Select Biotechnology Portfolio | Fidelity Investments". fundresearch.fidelity.com. Retrieved 7 July 2022. 
  17. ↑ "Pinkbook: Hepatitis B | CDC". www.cdc.gov. 17 August 2021. Retrieved 20 May 2022. 
  18. ↑ Wang, Huaiyuan; Hu, Haijun; Zhang, Kangjian (25 April 2017). "Overview of Interferon: Characteristics, signaling and anti-cancer effect". Archives of Biotechnology and Biomedicine. Retrieved 19 May 2022. 
  19. ↑ Majoro, S. (1988), The Creative Gap: Managing Ideas for Profit, London: Longman
  20. ↑ Plants, National Research Council (US) Committee on Genetically Modified Pest-Protected (2000). "Introduction and Background". National Academies Press (US). 
  21. ↑ "Lineage Cell Therapeutics". crunchbase.com. Retrieved 23 January 2022. 
  22. ↑ "Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference". www.businesswire.com. 4 January 2022. Retrieved 23 January 2022. 
  23. ↑ Aldrich, H.E. (1990), ‘Using an ecological perspective to study organisation founding rates’, Entrepreneurship Theory and Practice, 14 (3), 7–24.
  24. ↑ "Biogaia Probiotics - BioGaia's history". biogaia.com. Retrieved 23 January 2022. 
  25. ↑ "About BioGaia". BioGaia. Retrieved 23 January 2022. 
  26. ↑ "BioGaia". crunchbase.com. Retrieved 23 January 2022. 
  27. ↑ Griffith, Victoria. "Geron". Scientific American. Retrieved 9 February 2022. 
  28. ↑ "Geron". crunchbase.com. Retrieved 23 January 2022. 
  29. ↑ Sewell, Dawson; Scherfner, Erin; Jhaveri, Neelam; Gomila, Jude; Manipula, Melanie; Dean, Alex. "Nektar Therapeutics - Wiki". Golden. Retrieved 9 February 2022. 
  30. ↑ "About Us | Nektar Therapeutics". ir.nektar.com. Retrieved 23 January 2022. 
  31. ↑ "Cascadia Capital Provides Intrexon Corporation with Fairness Opinion of AquaBounty Technologies, LLC". Cascadia Capital. Retrieved 9 February 2022. 
  32. ↑ "AquaBounty". linkedin.com. Retrieved 23 January 2022. 
  33. ↑ "AquaBounty Technologies". crunchbase.com. Retrieved 23 January 2022. 
  34. ↑ "Vertex Pharmaceuticals Incorporated | Encyclopedia.com". www.encyclopedia.com. Retrieved 2 June 2022. 
  35. ↑ "Where will Vertex Pharmaceuticals be in 5 years?". www.healthleadersmedia.com. Retrieved 29 June 2022. 
  36. ↑ "ARIAD Pharmaceuticals". Google Arts & Culture (in español). Retrieved 9 February 2022. 
  37. ↑ "ARIAD Pharmaceuticals". crunchbase.com. Retrieved 23 January 2022. 
  38. ↑ "Camurus". crunchbase.com. Retrieved 23 January 2022. 
  39. ↑ "Camurus". linkedin.com. Retrieved 23 January 2022. 
  40. ↑ "Cerus". crunchbase.com. Retrieved 24 January 2022. 
  41. ↑ "Synthon's history". Synthon. Retrieved 9 February 2022. 
  42. ↑ "Myriad Genetics Company History Starting in May 1991". Myriad Genetics, Inc. Retrieved 9 February 2022. 
  43. ↑ "Disease Info". Myriad Genetics. Retrieved 23 March 2022. 
  44. ↑ "Idaho Mountain Express: Biotechnology firm sets up shop in Ketchum - December 3, 2008". 
  45. ↑ "Versatile Alternatives to Santa Cruz Biotechnology Polyclonal Antibodies - MyBioSource". www.mybiosource.com. Retrieved 29 January 2022. 
  46. ↑ "Santa Cruz Biotechnology opens office in Idaho". 
  47. ↑ "Santa Cruz Biotechnology, Inc.: Private Company Information - Bloomberg". 
  48. ↑ "Economic growth pushes SLO County higher in national ranking". 
  49. ↑ Kotler, P. (1991), Marketing Management: Analysis, Planning, Implementation and Control, 7th edn, Englewood Cliffs, NJ: Prentice-Hall.
  50. ↑ "Alkermes PLC (ALKS) Stock Price, Quote & News". Stock Analysis. Retrieved 2 June 2022. 
  51. ↑ "ALKERMES PUBLIC LIMITED COMPANY". investor.alkermes. Retrieved 29 June 2022. 
  52. ↑ "Affymetrix". crunchbase.com. Retrieved 24 January 2022. 
  53. ↑ "Affymetrix". www.bionity.com. Retrieved 9 February 2022. 
  54. ↑ "Affymetrix and bioMérieux Extend Their Agreement on GeneChip® Technology to Breast Cancer Diagnostics". biomerieux.com. Retrieved 2022-01-12. 
  55. ↑ "Angiotech Pharmaceuticals". crunchbase.com. Retrieved 24 January 2022. 
  56. ↑ "Surgical Specialties Corporation (formerly Angiotech) Profile on T-Net". T-Net British Columbia. Retrieved 9 February 2022. 
  57. ↑ Falconer, Kirk (19 December 2016). "Angiotech Pharmaceuticals to be acquired by Vivo, ZQ-led group". PE Hub. Retrieved 25 January 2022. 
  58. ↑ "Angiotech closes acquisition of certain product candidates and technology assets of Haemacure Corporation". newswire.ca. Retrieved 25 January 2022. 
  59. ↑ "Applied Maths - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 24 January 2022. 
  60. ↑ Dijkshoorn, L.; Towner, K. J.; Struelens, M. (10 July 2001). New Approaches for the Generation and Analysis of Microbial Typing Data. Elsevier. ISBN 978-0-08-053748-1. 
  61. ↑ "Working At Cubist Pharmaceuticals: Employee Reviews and Culture". www.zippia.com. 18 May 2020. Retrieved 9 February 2022. 
  62. ↑ "Merck to take on superbugs with Cubist Pharma buy". Reuters. 9 December 2014. Retrieved 24 January 2022. 
  63. ↑ Timmerman, Luke (28 April 2007). "Short-sellers are betting Dendreon won't win FDA's OK". The Seattle Times. Retrieved 29 January 2022. 
  64. ↑ "AUA IMPACT Trial Presentation Summary" (PDF). 
  65. ↑ "MorphoSys - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 May 2022. 
  66. ↑ "Our History | Morphosys de". www.morphosys.com. Retrieved 9 February 2022. 
  67. ↑ "MorphoSys - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 25 January 2022. 
  68. ↑ "Shenzhen Kangtai Biological Products Co., Ltd Company Profile - China | Financials & Key Executives | EMIS". www.emis.com. Retrieved 9 February 2022. 
  69. ↑ Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee; Kristoffersen, Matthew (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. Retrieved 17 May 2022. 
  70. ↑ "Bionor Pharma". www.crunchbase.com. Retrieved 9 February 2022. 
  71. ↑ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 21 March 2022. 
  72. ↑ "Diagnostics tools for pathology, cytogenetic and research laboratories". ASI. Retrieved 9 February 2022. 
  73. ↑ "Working At Applied Spectral Imaging: Employee Reviews and Culture". www.zippia.com. 18 May 2020. Retrieved 21 March 2022. 
  74. ↑ "Biosearch Technologies Licenses Access to New CDC "PDM" H1N1 Signatures". LGC Biosearch Technologies. Retrieved 9 February 2022. 
  75. ↑ "Biosearch Technologies- Chemistry for Genomics and Proteomics". www.gene-quantification.de. Retrieved 23 March 2022. 
  76. ↑ "(PDF) Indian vaccine innovation: The case of Shantha Biotechnics". ResearchGate. Retrieved 9 February 2022. 
  77. ↑ Chakma, Justin; Masum, Hassan; Perampaladas, Kumar; Heys, Jennifer; Singer, Peter A (December 2011). "Indian vaccine innovation: the case of Shantha Biotechnics". Globalization and Health. 7 (1): 9. doi:10.1186/1744-8603-7-9. 
  78. ↑ "Sanofi infusing $122M to complete buy-out of Shantha Biotech and further expansion". Retrieved 25 January 2022. 
  79. ↑ "History of Millennium Pharmaceuticals, Inc. – FundingUniverse". www.fundinguniverse.com. Retrieved 9 February 2022. 
  80. ↑ "Ventria Bioscience". www.crunchbase.com. Retrieved 9 February 2022. 
  81. ↑ "Ventria Bioscience". linkedin. Retrieved 6 April 2022. 
  82. ↑ "Incyte". crunchbase. Retrieved 2 June 2022. 
  83. ↑ "ShieldSquare Captcha". www.globaldata.com. Retrieved 7 July 2022. 
  84. ↑ "Fermentek Biotechnology". il.linkedin.com. Retrieved 18 February 2022. 
  85. ↑ "Fermentek - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 18 February 2022. 
  86. ↑ "Community for Businesses in Latin America and the Caribbean | ConnectAmericas". connectamericas.com. Retrieved 24 March 2022. 
  87. ↑ "The Billion-Dollar Molecule". Wikipedia. 28 November 2020. Retrieved 18 May 2022. 
  88. ↑ "Agenus". www.bizjournals.com. Retrieved 9 February 2022. 
  89. ↑ "Agenus - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 25 January 2022. 
  90. ↑ "Press Releases :: Ocata Therapeutics, Inc. (OCAT)". web.archive.org. 2 April 2015. Retrieved 25 January 2022. 
  91. ↑ Writer, GEN Staff (10 November 2015). "Astellas to acquire Ocata Therapeutics for $379M". GEN - Genetic Engineering and Biotechnology News. Retrieved 25 January 2022. 
  92. ↑ "CinnaGen: Our History". www.cinnagen.com. Retrieved 5 February 2022. 
  93. ↑ "CinnaGen - Headquarter Locations, Competitors, Financials, Employees". www.cbinsights.com. Retrieved 24 March 2022. 
  94. ↑ "Corixa Corporation - company". www.coulterpharm.com. Retrieved 9 February 2022. 
  95. ↑ "ViroPharma's". www.bizjournals.com. Retrieved 9 February 2022. 
  96. ↑ "Shire acquires ViroPharma for $4.2bn". Financier Worldwide. Retrieved 29 January 2022. 
  97. ↑ "Medigene". medigene.com. Retrieved 29 January 2022. 
  98. ↑ "Medigene". medigene.com. Retrieved 29 January 2022. 
  99. ↑ "HyTest". fi.linkedin.com. Retrieved 25 January 2022. 
  100. ↑ "Antibody Manufacturing and Cardiac Marker Production | HyTest Ltd.". hytest.fi. Retrieved 29 January 2022. 
  101. ↑ "Exelixis is On a Mission to Help Cancer Patients Recover Stronger and Live Longer". Exelixis. Retrieved 9 February 2022. 
  102. ↑ Hanel, Meredith; Sewell, Dawson; Faraguna, Carla; Scherfner, Erin; Mariappan, Lax; Gomila, Jude; Otieno, Wyckliffe; Bedia, Marie Gabrielle Laguna-; Mešanović, Mevludin; Jhaveri, Neelam. "Sangamo Therapeutics - Wiki". Golden. Retrieved 9 February 2022. 
  103. ↑ "Overview | Sangamo Therapeutics, Inc.". investor.sangamo.com. Retrieved 25 March 2022. 
  104. ↑ "Aclara Biosciences Company Profile: Acquisition & Investors | PitchBook". pitchbook.com. Retrieved 9 February 2022. 
  105. ↑ "Companies Granted $3 Million to Develop New Microfluidic System". www.bioprocessonline.com. Retrieved 25 March 2022. 
  106. ↑ "Acorda Therapeutics Inc - Investors - Corporate Governance". ir.acorda.com. Retrieved 9 February 2022. 
  107. ↑ "Acorda Therapeutics, Inc. – Cruelty Free Investing". crueltyfreeinvesting.org. Retrieved 6 April 2022. 
  108. ↑ "History of Caliper Life Sciences, Inc. – FundingUniverse". www.fundinguniverse.com. Retrieved 9 February 2022. 
  109. ↑ "Caliper Life Sciences to Acquire Cambridge Research & Instrumentation". Fierce Biotech. 9 December 2010. Retrieved 6 April 2022. 
  110. ↑ "LinkedIn Login, Sign in". LinkedIn. Retrieved 29 June 2022. 
  111. ↑ Colombo, Sharon. "About". Molecular Medicine Research Institute. Retrieved 29 June 2022. 
  112. ↑ 112.0 112.1 112.2 112.3 112.4 112.5 "Top 15 biotech incubators and accelerators in the US". The Kolabtree Blog. 27 April 2021. Retrieved 29 June 2022. 
  113. ↑ Brown, S.L. and K.M. Eisenhardt (1995), ‘Product development: past research, present findings and future directions’, Academy of Management Review, 20 (2), 343–78
  114. ↑ "Monogram Biosciences - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 25 February 2022. 
  115. ↑ "Monogram Biosciences". linkedin. Retrieved 19 May 2022. 
  116. ↑ "Dharmacon". dbpedia.org. Retrieved 9 February 2022. 
  117. ↑ "T. Rowe Price Health Sciences Fund, PRHSX summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  118. ↑ "PRHSX | T Rowe Price Health Sciences Fund Overview". MarketWatch. Retrieved 8 July 2022. 
  119. ↑ "Ancestry celebrates 25 years!". www.ancestry.com. Retrieved 20 February 2022. 
  120. ↑ "Blackstone to acquire Ancestry.com for $4.7 billion". Reuters. 24 August 2020. Retrieved 17 May 2022. 
  121. ↑ "History & Milestones - Bharat Biotech - A Leading Biotech Company". www.bharatbiotech.com. Retrieved 21 February 2022. 
  122. ↑ "Bharat Biotech". devex. Retrieved 6 April 2022. 
  123. ↑ "Alexion Pharmaceuticals". alexion. Retrieved 2 June 2022. 
  124. ↑ "Scientists Locate Parkinson's Gene". Genome.gov. Retrieved 19 May 2022. 
  125. ↑ "Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics". deCODE genetics. 12 December 2012. Retrieved 22 February 2022. 
  126. ↑ "Icelandic Genomics Company Identifies Location of Gene for Essential Tremor". deCODE genetics. 25 August 1997. Retrieved 14 March 2022. 
  127. ↑ "Ceres, Inc.". Grainews. 23 February 2022. Retrieved 23 February 2022. 
  128. ↑ Lee, David; Chen, Alice; Nair, Ramesh (January 2008). "Genetically Engineered Crops for Biofuel Production: Regulatory Perspectives". Biotechnology and Genetic Engineering Reviews. 25 (1): 331–362. doi:10.5661/bger-25-331. 
  129. ↑ "Land O'Lakes, Inc. to Acquire Ceres, Inc. in Cash Tender Offer" (PDF). landolakesinc. Retrieved 6 April 2022. 
  130. ↑ "Helixmith - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 23 February 2022. 
  131. ↑ "LinkedIn Login, Sign in". LinkedIn. Retrieved 18 May 2022. 
  132. ↑ "TYVASO® (treprostinil), an inhaled prostacyclin". www.tyvaso.com. Retrieved 25 February 2022. 
  133. ↑ "ShieldSquare Captcha". www.globaldata.com. Retrieved 18 May 2022. 
  134. ↑ "Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone Met". Fierce Biotech. 3 September 2009. Retrieved 26 February 2022. 
  135. ↑ "Algeta ASA - Oslo, Norway". www.bionity.com. Retrieved 10 May 2022. 
  136. ↑ October 29th, reas Ebertz 15 April 2021 (15 April 2021). "The history of mRNA applications". The DNA Universe BLOG. Retrieved 12 March 2022. 
  137. ↑ "Arena Pharmaceuticals Begins Receptor Drug Discovery Collaboration With Fujisawa | Arena Pharmaceuticals, Inc.". invest.arenapharm.com. Retrieved 26 February 2022. 
  138. ↑ "Is Arena Pharmaceuticals, Inc. (ARNA) Stock About to Get Hot Tuesday?". www.investorsobserver.com. Retrieved 5 April 2022. 
  139. ↑ "Benitec Biopharma Inc (BNTC) Stock Price & News - Google Finance". www.google.com. Retrieved 3 March 2022. 
  140. ↑ "BENITEC BIOPHARMA LIMITED" (PDF). benitec. Retrieved 19 May 2022. 
  141. ↑ "Biolex Therapeutics files for $38M bankruptcy". www.bizjournals.com. Retrieved 28 January 2022. 
  142. ↑ "BioMarin Pharmaceutical History: Founding, Timeline, and Milestones". www.zippia.com. 27 August 2020. Retrieved 28 February 2022. 
  143. ↑ "Is BioMarin Pharmaceutical (BMRN) Stock a Buy For 2021?". finance.yahoo.com. Retrieved 13 April 2022. 
  144. ↑ "GPC Biotech - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 28 February 2022. 
  145. ↑ "Macrogen - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  146. ↑ "About: Macrogen". dbpedia.org. Retrieved 2 March 2022. 
  147. ↑ "Macrogen – Human, animal & plant, microorganism genomic variation through combination of high depth sequencing". Retrieved 2 March 2022. 
  148. ↑ "Mendel Biotechnology" (PDF). aphis.usda.gov. Retrieved 3 March 2022. 
  149. ↑ "Mendel Biotechnology". crunchbase. Retrieved 6 May 2022. 
  150. ↑ "Mendel Biotechnology". crunchbase. Retrieved 6 May 2022. 
  151. ↑ 151.0 151.1 "Noxxon Pharma". crunchbase. Retrieved 6 May 2022. 
  152. ↑ "About: Noxxon Pharma". dbpedia.org. Retrieved 3 March 2022. 
  153. ↑ "ReNeuron Group - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 3 March 2022. 
  154. ↑ Sinden, John D (January 2006). "ReNeuron Group plc". Regenerative Medicine. 1 (1): 143–147. doi:10.2217/17460751.1.1.143. 
  155. ↑ "Vernalis". linkedin.com. Retrieved 3 March 2022. 
  156. ↑ "Vernalis Research". Google Arts & Culture. Retrieved 19 May 2022. 
  157. ↑ "Seagen Inc. » Ninety Nine". Ninety Nine (in español). Retrieved 3 March 2022. 
  158. ↑ "Our Mission, Vision, and Values – Seagen". www.seagen.com. Retrieved 13 May 2022. 
  159. ↑ "Franklin Biotechnology Discovery Fund Class A, FBDIX summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  160. ↑ "https://www.franklintempleton.lu/our-funds/price-and-performance/products/4912/Z/franklin-biotechnology-discovery-fund/LU0109394709". www.franklintempleton.lu. Retrieved 7 July 2022.  External link in |title= (help)
  161. ↑ "Actelion Ltd | Encyclopedia.com". www.encyclopedia.com. Retrieved 3 March 2022. 
  162. ↑ "About: Actelion". dbpedia.org. Retrieved 13 May 2022. 
  163. ↑ "Our journey – Abcam plc". corporate.abcam.com. Retrieved 3 March 2022. 
  164. ↑ "Investors – Abcam plc". corporate.abcam.com. Retrieved 19 May 2022. 
  165. ↑ "American Biotech Labs - Overview, News & Competitors | ZoomInfo.com". ZoomInfo. Retrieved 3 March 2022. 
  166. ↑ "American Biotech Labs, LLC". linkedin. Retrieved 19 May 2022. 
  167. ↑ 167.0 167.1 "Array BioPharma - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  168. ↑ "Array Biopharma Inc.". dnb.com. Retrieved 3 March 2022. 
  169. ↑ "Still lost in transition". Business Today. Retrieved 3 March 2022. 
  170. ↑ "Avesthagen - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 17 May 2022. 
  171. ↑ "SeedQuest - Central information website for the global seed industry". www.seedquest.com. Retrieved 3 March 2022. 
  172. ↑ "Basf Plant Science: Buy Basf Plant Science Online at Low Price in India on Snapdeal". www.snapdeal.com. Retrieved 17 May 2022. 
  173. ↑ "Biotie Therapies - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 3 March 2022. 
  174. ↑ "Celera Genomics | American company | Britannica". www.britannica.com. Retrieved 3 March 2022. 
  175. ↑ "Form 10-K". www.sec.gov. Retrieved 17 May 2022. 
  176. ↑ "CropDesign - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 3 March 2022. 
  177. ↑ "EMERGENT BioSolutions Inc.: A Lodestone Amongst Pebbles—Addressing Public Health Through Vaccines". nature.com. Retrieved 3 March 2022. 
  178. ↑ "Emergent BioSolutions - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  179. ↑ "About us". epigenomics. Retrieved 3 March 2022. 
  180. ↑ "Epigenomics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 17 May 2022. 
  181. ↑ "History & Approach | GW Pharmaceuticals, plc". www.gwpharm.com. Retrieved 3 March 2022. 
  182. ↑ plc, Jazz Pharmaceuticals. "Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc". www.prnewswire.com. Retrieved 19 May 2022. 
  183. ↑ Swann, P. and M. Prevezer (1998), ‘A comparison of the dynamics of industrial clustering in computing and biotechnology’, Research Policy, 25 (7), 1139–58.
  184. ↑ "Opinion: A Study of Illumina's Success". rbj.rady.ucsd.edu. Retrieved 3 March 2022. 
  185. ↑ "Illumina Inc". www.reuters.com. Retrieved 17 May 2022. 
  186. ↑ Andrews, P.P. and J. Hahn (1998), ‘Transforming the value chain into value webs’, Strategy and Leadership, 26 (3), 6–11.
  187. ↑ Nicholson, David (January 2001). "New business models: AgBiotechNet™, a case study". Learned Publishing. 14 (1): 55–59. doi:10.1087/09531510125100287. 
  188. ↑ "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". ir.agtc.com. Retrieved 4 March 2022. 
  189. ↑ "Applied Genetics Technologies Corporation - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 19 May 2022. 
  190. ↑ "Global 500 2009: Industry: - FORTUNE on CNNMoney.com". money.cnn.com. Retrieved 28 January 2022. 
  191. ↑ "A history of AstraZeneca". pharmaphorum.com. 2020-09-18. Retrieved 2021-03-31. 
  192. ↑ "Learn About BGI, Our History and Our Mission to Improve Human Health". www.bgi.com. Retrieved 3 March 2022. 
  193. ↑ "BGI Group - Headquarter Locations, Products, Competitors, Financials, Employees". www.cbinsights.com. Retrieved 17 May 2022. 
  194. ↑ "About Us". Cell Signaling Technology. Retrieved 3 March 2022. 
  195. ↑ "Cell Signaling Technology (CST) – Research Instruments Vietnam Company Limited". rivn.com. Retrieved 27 May 2022. 
  196. ↑ "Our Story | Cellectis". cellectis.com. Retrieved 3 March 2022. 
  197. ↑ "Cellectis - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 21 March 2022. 
  198. ↑ "091990 | Celltrion Healthcare Co. Ltd. Stock Overview (S. Korea: KRX)". Barron's. Retrieved 3 March 2022. 
  199. ↑ "Stock Information | United Therapeutics Corporation". ir.unither.com. Retrieved 2 June 2022. 
  200. ↑ "PGIM Jennison Health Sciences Fund- Class A, PHLAX summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  201. ↑ "PGIM Jennison Health Sciences Fund (PHLAX) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 8 July 2022. 
  202. ↑ "BioMarin Pharmaceutical - Funding, Financials, Valuation & Investors". Crunchbase. Retrieved 2 June 2022. 
  203. ↑ "About: ChromaDex". dbpedia.org. Retrieved 3 March 2022. 
  204. ↑ "ChromaDex". Nutraceuticals World. Retrieved 19 May 2022. 
  205. ↑ "About: EnCor Biotechnology". dbpedia.org. Retrieved 3 March 2022. 
  206. ↑ "About: EnCor Biotechnology". dbpedia.org. Retrieved 19 May 2022. 
  207. ↑ "Our History | Genmab". www.genmab.com. Retrieved 3 March 2022. 
  208. ↑ "Genmab AS Company Profile - Genmab AS Overview". www.linkedin.com. Retrieved 19 May 2022. 
  209. ↑ "Ludger Limited". linkedin.com. Retrieved 3 March 2022. 
  210. ↑ "Ludger Limited". linkedin. Retrieved 19 May 2022. 
  211. ↑ "FORM 20-F/A-5". sec.gov. Retrieved 3 March 2022. 
  212. ↑ "Sinovac Biotech Ltd (SVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile". www.reportlinker.com. Retrieved 19 May 2022. 
  213. ↑ "Trubion Pharmaceuticals - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 3 March 2022. 
  214. ↑ "Arryx - Headquarter Locations, Competitors, Financials, Employees". www.cbinsights.com. Retrieved 3 March 2022. 
  215. ↑ "Arryx, Acquired by Haemonetics Corp. on June 8th, 2006 | Mergr". mergr.com. Retrieved 19 May 2022. 
  216. ↑ "CureVac". finance.yahoo. Retrieved 6 May 2022. 
  217. ↑ "CureVac - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  218. ↑ "CureVac - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  219. ↑ "DiaSorin Inc.". DiaSorin. Retrieved 4 March 2022. 
  220. ↑ "BARDA expands partnership with DiaSorin SpA to develop automated antigen detection assay for acute COVID-19". www.medicalcountermeasures.gov. Retrieved 6 April 2022. 
  221. ↑ "Company". Gene by Gene. Retrieved 4 March 2022. 
  222. ↑ "Gene By Gene Company Profile | Management and Employees List". Datanyze. Retrieved 6 April 2022. 
  223. ↑ "GlaxoSmithKline - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  224. ↑ "GSK today: 2000 – present | GSK". www.gsk.com. Retrieved 4 March 2022. 
  225. ↑ CONTRERAS", "ANDREA MURPHY"," ISABEL. "The Global 2000 2022". Forbes. Retrieved 17 May 2022. 
  226. ↑ Margulies, Marcel (15 September 2005). "Genome Sequencing in Open Microfabricated High Density Picoliter Reactors". Nature. pp. 376–380. doi:10.1038/nature03959. Retrieved 4 March 2022. 
  227. ↑ Margulies, Marcel (15 September 2005). "Genome Sequencing in Open Microfabricated High Density Picoliter Reactors". Nature. pp. 376–380. doi:10.1038/nature03959. Retrieved 29 March 2022. 
  228. ↑ "Scientists Complete Rough Draft of Human Genome". archive.nytimes.com. Retrieved 8 July 2022. 
  229. ↑ "Illumina, Inc. - Resources". investor.illumina.com. Retrieved 2 June 2022. 
  230. ↑ "Renovo; biopharmaceutical product company". www.ukessays.com. Retrieved 4 March 2022. 
  231. ↑ "LRMN January 2007 Meeting". web.archive.org. 28 September 2007. Retrieved 7 April 2022. 
  232. ↑ Grogan, Kevin (31 May 2011). "Future bleak for Renovo with no workers or products". PharmaTimes. Retrieved 7 April 2022. 
  233. ↑ Christensen, C.M. and M. Overdorf (2000), ‘Meeting the challenge of disruptive change’, Harvard Business Review, 78 (2), March, 66.
  234. ↑ "Rosetta Genomics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 4 March 2022. 
  235. ↑ "Strand Life Sciences". ar.linkedin.com. Retrieved 4 March 2022. 
  236. ↑ "Strand Life Sciences". strandls.com. Retrieved 21 March 2022. 
  237. ↑ "Today marks a major milestone for us: 20 years since the founding of Syngenta.". Syngenta. Retrieved 4 March 2022. 
  238. ↑ "Syngenta - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 4 April 2022. 
  239. ↑ "TopoTarget A/S - Kopenhagen, Denmark". www.bionity.com. Retrieved 4 March 2022. 
  240. ↑ "Topotarget - Headquarter Locations, Competitors, Financials, Employees". www.cbinsights.com. 
  241. ↑ Batterham, R. (2000), The Chance to Change, Chief Scientist of Australia, Canberra, DISR.
  242. ↑ Hill, E.W. and J.F. Brennan (2000), ‘A methodology for identifying the drivers of industrial clusters: the foundation of regional competitive advantage’, Economic Development Quarterly, 14 (1), 65–96.
  243. ↑ "QB3". crunchbase. Retrieved 29 June 2022. 
  244. ↑ "Fidelity Advisor® Biotechnology Fund Class A, FBTAX summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  245. ↑ "Fidelity Advisor Biotechnology Fund Class A (FBTAX) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 8 July 2022. 
  246. ↑ "Abgent - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 4 March 2022. 
  247. ↑ Council, National Research; Sciences, Division on Engineering and Physical; Technology, Board on Army Science and; Applications, Committee on Opportunities in Biotechnology for Future Army (11 July 2001). Opportunities in Biotechnology for Future Army Applications. National Academies Press. ISBN 978-0-309-07555-8. 
  248. ↑ "Exhibit 99.1". www.sec.gov. Retrieved 5 March 2022. 
  249. ↑ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 5 April 2022. 
  250. ↑ "CPC Scientific - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 March 2022. 
  251. ↑ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 5 March 2022. 
  252. ↑ Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
  253. ↑ "Ablynx | Invest Europe". www.investeurope.euhttps. Retrieved 28 January 2022. 
  254. ↑ "Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion". Fortune. Retrieved 28 January 2022. 
  255. ↑ Morrison, Chris (12 June 2019). "Nanobody approval gives domain antibodies a boost". Nature Reviews Drug Discovery. pp. 485–487. doi:10.1038/d41573-019-00104-w. Retrieved 28 January 2022. 
  256. ↑ "Advaxis Share Price - ADXS, RNS News, Articles, Quotes, & Charts (NASDAQ:ADXS)". Proactiveinvestors NA. Retrieved 20 January 2022. 
  257. ↑ "Alnylam Pharmaceuticals (ALNY)". Forbes. Retrieved 20 January 2022. 
  258. ↑ "Cambridge bio-startup Alnylam files for IPO". www.bizjournals.com. Retrieved 20 January 2022. 
  259. ↑ "ALNYLAM PHARMACEUTICALS INC". www.sec.gov. Retrieved 20 January 2022. 
  260. ↑ "50 years of technology transfer for the Max Planck Society". www.mpg.de. Retrieved 20 January 2022. 
  261. ↑ "Alnylam Pharmaceuticals, Inc.". nasdaq.com. Retrieved 20 January 2022. 
  262. ↑ 262.0 262.1 "Arcadia Biosciences Inc". www.bloomberg.com. Retrieved 20 January 2022. 
  263. ↑ "Botanix Pharmaceuticals - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 March 2022. 
  264. ↑ "OBI Pharma, Inc". linkedin.com. Retrieved 5 March 2022. 
  265. ↑ "4174 | OBI Pharma Inc. Stock Price & News". WSJ. Retrieved 19 May 2022. 
  266. ↑ "Company - Phalanx Biotech - Life Science Research Lab". Phalanx Bio. Retrieved 5 March 2022. 
  267. ↑ "Phalanx Biotech - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 27 May 2022. 
  268. ↑ "About Catalyst: Our History". catalystpharma.com. Retrieved 5 March 2022. 
  269. ↑ "Catalyst Pharmaceuticals Partners - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 27 May 2022. 
  270. ↑ Welle (www.dw.com), Deutsche. "Empresa respaldada por Bill Gates libera miles de mosquitos modificados genéticamente | DW | 04.05.2021". DW.COM (in español). Retrieved 5 March 2022. 
  271. ↑ "Oxitec". World Economic Forum. Retrieved 27 May 2022. 
  272. ↑ Tang, Chilung Mark (2002). The Essential Biotech Investment Guide: How to Invest in the Healthcare Biotechnology & Life Sciences Sector. World Scientific. ISBN 978-981-238-139-2. 
  273. ↑ "Prosensa - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 18 February 2022. 
  274. ↑ "Prosensa - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 May 2022. 
  275. ↑ "Codexis, Inc. Raises $37 Million In Series D Private Financing; Total To Be Raised Up To $40 Million". BioSpace. Retrieved 4 March 2022. 
  276. ↑ "Codexis - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 25 March 2022. 
  277. ↑ "Integromics". linkedin.com. Retrieved 5 March 2022. 
  278. ↑ "Scientists Clone Banteng in Effort to Save Dying Species". Los Angeles Times. 8 April 2003. Retrieved 20 May 2022. 
  279. ↑ "Overview main". CellResearch Corp. Retrieved 5 March 2022. 
  280. ↑ "Stem cell skincare product goes global | The Straits Times". www.straitstimes.com. 13 August 2015. Retrieved 10 May 2022. 
  281. ↑ "The Oncology Laboratory Solution for Managed Care" (PDF). neogenomics.com. Retrieved 5 March 2022. 
  282. ↑ "About | NeoGenomics Laboratories". neogenomics.com. Retrieved 20 May 2022. 
  283. ↑ "DBV Technologies". paganresearch.io. Retrieved 5 March 2022. 
  284. ↑ "2021 Exhibit - DBV Technologies". Pennsylvania Allergy & Asthma Society. Retrieved 27 March 2022. 
  285. ↑ "Guardian Biotechnologies - definition - Encyclo". www.encyclo.co.uk. Retrieved 5 March 2022. 
  286. ↑ "Guardian Biotechnologies - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 April 2022. 
  287. ↑ Oliver, Richard L. (24 March 2003). The Biotech Age : The Business of Biotech and How to Profit From It: The Business of Biotech and How to Profit From It. McGraw Hill Professional. ISBN 978-0-07-141489-0. 
  288. ↑ "Acceleron". www.sec.gov. Retrieved 5 March 2022. 
  289. ↑ "Acceleron Pharma Inc (NASDAQ:XLRN) - Share price". AJ Bell Youinvest. Retrieved 4 April 2022. 
  290. ↑ Pflanzer, Lydia Ramsey. "The rise and fall of Theranos, the blood-testing startup that went from Silicon Valley darling to facing fraud charges". Business Insider. Retrieved 6 March 2021. 
  291. ↑ "Theranos: Scandal hit blood-testing firm to shut". BBC News. 5 September 2018. Retrieved 6 March 2021. 
  292. ↑ "A Timeline Of Theranos's Troubles". Investopedia. Retrieved 5 March 2022. 
  293. ↑ "Cleveland BioLabs, Inc." (PDF). publications.budget.ny.gov. Retrieved 5 March 2022. 
  294. ↑ "Cleveland BioLabs inks Chinese deal". www.bizjournals.com. Retrieved 4 April 2022. 
  295. ↑ Grossmann, Martin (11 March 2003). Entrepreneurship in Biotechnology: Managing for Growth from Start-up to Initial Public Offering ; with 24 Tables. Springer Science & Business Media. ISBN 978-3-7908-0033-3. 
  296. ↑ Abraham, J.; Smith, H. Lawton; Smith, Helen Lawton (10 June 2003). Regulation of the Pharmaceutical Industry. Springer. ISBN 978-0-230-37259-7. 
  297. ↑ "TerraVia". cen.acs.org. Retrieved 5 March 2022. 
  298. ↑ "TerraVia's Protein-Rich Whole Algae is Emerging as a Top Plant-based Protein Source Across the Grocery Store". www.businesswire.com. 15 September 2016. Retrieved 4 April 2022. 
  299. ↑ "Crioestaminal inaugura Unidade de Produção de Medicamentos de Terapia Celular". Crioestaminal (in português). 15 June 2020. Retrieved 5 March 2022. 
  300. ↑ "Crioestaminal - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 May 2022. 
  301. ↑ "Nanjing Ange Pharmaceutical Co., Ltd. in Nanjing, Jiangsu, China - Company Profile". www.tradeindia.com. Retrieved 5 March 2022. 
  302. ↑ "dasatinib Supplier - Nanjing Ange Pharmaceutical Co., Ltd.". www.worldofchemicals.com. Retrieved 4 April 2022. 
  303. ↑ Grossmann, Martin (11 March 2003). Entrepreneurship in Biotechnology: Managing for Growth from Start-up to Initial Public Offering ; with 24 Tables. Springer Science & Business Media. ISBN 978-3-7908-0033-3. 
  304. ↑ "BioLineRx, Ltd. - Jerusalem, Israel". www.bionity.com. Retrieved 5 March 2022. 
  305. ↑ "BioLineRx | BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease Therapeutics". ir.biolinerx.com. Retrieved 4 April 2022. 
  306. ↑ "DNA2.0, Inc. Becomes ATUM". www.prnewswire.com. Retrieved 5 March 2022. 
  307. ↑ "Tools & Solutions for the Life Sciences - ATUM". www.atum.bio. Retrieved 4 April 2022. 
  308. ↑ "Amyris - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 March 2022. 
  309. ↑ "Helicos BioSciences". crunchbase.com. Retrieved 24 January 2022. 
  310. ↑ "Helicos BioSciences Files for Chapter 11 Bankruptcy Protection". Genomeweb. 16 November 2012. Retrieved 28 January 2022. 
  311. ↑ "Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis…". Flagship Pioneering. Retrieved 4 April 2022. 
  312. ↑ "Alder Biopharmaceuticals Inc. Completes Series B Financing; H.I.G. Ventures Leads $16 Million Round". BioSpace. Retrieved 5 March 2022. 
  313. ↑ "Jobs with Alder BioPharmaceuticals, Inc.". BioSpace. Retrieved 4 April 2022. 
  314. ↑ "3H Biomedical". crunchbase.com. Retrieved 24 January 2022. 
  315. ↑ "3H Biomedical AB". www.3hbiomedical.com. Retrieved 17 March 2022. 
  316. ↑ "Pacific Biosciences". crunchbase.com. Retrieved 24 January 2022. 
  317. ↑ Plückthun, A (2015). "Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy". Annu. Rev. Pharmacol. Toxicol. 55 (1): 489–511. PMID 25562645. doi:10.1146/annurev-pharmtox-010611-134654. 
  318. ↑ "Medivation". linkedin. Retrieved 5 March 2022. 
  319. ↑ "Jobs with Medivation, Inc.". BioSpace. Retrieved 17 March 2022. 
  320. ↑ "Pfizer Completes Acquisition of Medivation". pfizer.com. Retrieved 17 March 2022. 
  321. ↑ "About: Genostar". dbpedia.org. Retrieved 28 January 2022. 
  322. ↑ "In-house analysis pipeline for next generation genome sequencing speeds up innovation". Mynewsdesk. Retrieved 28 January 2022. 
  323. ↑ "Portland State University Business Accelerator". linkedin. Retrieved 29 June 2022. 
  324. ↑ Bergeron, Bryan; Bergeron, Bryan P.; Chan, Paul (30 January 2004). Biotech Industry: A Global, Economic, and Financing Overview. Wiley. ISBN 978-0-471-46561-4. 
  325. ↑ "FlexGen BV | FlexGen Closes New Round of Financing | InvestEgate". www.investegate.co.uk. Retrieved 28 January 2022. 
  326. ↑ "Bankruptcy Flexgen Bv in Leiden (F.05/15/975) - FaillissementsDossier.nl". www.faillissementsdossier.nl. Retrieved 28 January 2022. 
  327. ↑ "Finally! CD Genomics Has Its Own Blog | CD Genomics Blog". cd-genomics.com. Retrieved 29 January 2022. 
  328. ↑ "About Us – CD Genomics". www.cd-genomics.com. Retrieved 29 January 2022. 
  329. ↑ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 5 March 2022. 
  330. ↑ "Jazz Pharmaceuticals, Inc. Announces Initial Public Offering | Jazz Pharmaceuticals plc". investor.jazzpharma.com. Retrieved 6 April 2022. 
  331. ↑ "Rydex Biotechnology Fund Class A, RYBOX summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  332. ↑ "Rydex Biotechnology Fund Class A (RYBOX) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 8 July 2022. 
  333. ↑ "Scientific Opinion on the evaluation of the safety and efficacy of ListexTM P100 for the removal of Listeria monocytogenes surface contamination of raw fish | EFSA". www.efsa.europa.eu. Retrieved 28 January 2022. 
  334. ↑ "Wayback Machine" (PDF). web.archive.org. Retrieved 21 March 2022. 
  335. ↑ "About Primerdesign : The best custom qPCR assay development service in the World". www.primerdesign.co.uk. Retrieved 4 March 2022. 
  336. ↑ "nanoScript 2 Press Release". www.primerdesign.co.uk. Retrieved 27 March 2022. 
  337. ↑ "About Us". Melior Discovery. Retrieved 4 March 2022. 
  338. ↑ "About Us". Melior Discovery. Retrieved 27 March 2022. 
  339. ↑ "MEDICEN PARIS REGION | European Cluster Collaboration Platform". clustercollaboration.eu. Retrieved 4 March 2022. 
  340. ↑ "Présentation des pôles de compétitivité | entreprises.gouv.fr". www.entreprises.gouv.fr. Retrieved 10 May 2022. 
  341. ↑ "GRID - Global Research Identifier Database". www.grid.ac. Retrieved 4 March 2022. 
  342. ↑ "Success Story: Immune Therapy Holdings". web.archive.org. 23 March 2014. Retrieved 20 May 2022. 
  343. ↑ "Horizon Discovery - Email & Phone of top management contacts". www.easyleadz.com. Retrieved 5 March 2022. 
  344. ↑ "Horizon Discovery". LSEG. Retrieved 10 May 2022. 
  345. ↑ "Finally! Creative Biolabs Starts Its Blog – Creative Biolabs Blog". creative-biolabs.com. Retrieved 5 March 2022. 
  346. ↑ "Peer-reviewed Publications - Creative Biolabs". www.creative-biolabs.com. Retrieved 6 April 2022. 
  347. ↑ "Disulfide Bond Mapping Services | CovalX". covalx.com. Retrieved 5 March 2022. 
  348. ↑ "CovalX". craft.co. Retrieved 15 March 2022. 
  349. ↑ "Celsense, Inc." (PDF). celsense.com. Retrieved 5 March 2022. 
  350. ↑ "Celsense - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 April 2022. 
  351. ↑ "Avid Radiopharmaceuticals - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 March 2022. 
  352. ↑ "SPDR® S&P Biotech ETF, XBI:PCQ:USD summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  353. ↑ "SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 8 July 2022. 
  354. ↑ "Consumer Genomics Startup Genos Research Plans to Let Customers Explore, Share Their Data". Genomeweb. 13 June 2016. Retrieved 6 March 2022. 
  355. ↑ Reid, Clifford (1 February 2011). "Company Profile: Complete Genomics Inc.". Future Oncology. pp. 219–221. doi:10.2217/fon.10.173. Retrieved 27 March 2022. 
  356. ↑ Farr, Christina (22 May 2018). "23andMe founder Anne Wojcicki is leading a DNA revolution by going directly to consumers". CNBC. Retrieved 5 March 2022. 
  357. ↑ Stoeklé, Henri-Corto; Mamzer-Bruneel, Marie-France; Vogt, Guillaume; Hervé, Christian (31 March 2016). "23andMe: a new two-sided data-banking market model". BMC Medical Ethics. p. 19. doi:10.1186/s12910-016-0101-9. Retrieved 6 April 2022. 
  358. ↑ "Thermo Electron and Fisher Scientific to Combine in Industry-Transforming Transaction". ir.thermofisher.com. Retrieved 5 March 2022. 
  359. ↑ "THERMO FISHER SCIENTIFIC INC (TMO)". www.puentenet.com. Retrieved 6 April 2022. 
  360. ↑ "Expanding the PABC » Pennsylvania Biotechnology Center". www.pabiotechbc.org. Retrieved 29 June 2022. 
  361. ↑ "KBLB - Kraig Biocraft Laboratories Inc Company Profile - CNNMoney.com". money.cnn.com. Retrieved 5 March 2022. 
  362. ↑ "Kraig Biocraft Laboratories - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 25 March 2022. 
  363. ↑ "Company Profile". InGeneron. Retrieved 5 March 2022. 
  364. ↑ "Company Profile". InGeneron. Retrieved 25 March 2022. 
  365. ↑ Reed, Hughes Hubbard & (5 March 2022). "Firm Helps Sellas Defeat Investors' Securities Fraud Suit". Hughes Hubbard & Reed. Retrieved 5 March 2022. 
  366. ↑ "Orexo sells Abstral® in the United States to Galena Biopharma, Inc." (PDF). cision. Retrieved 27 March 2022. 
  367. ↑ "Transformative bispecific antibody technology" (PDF). media.nature.com. Retrieved 5 March 2022. 
  368. ↑ "Investor Relations | F-star Therapeutics, Inc.". investors.f-star.com. Retrieved 6 April 2022. 
  369. ↑ "Gelesis" (PDF). gelesis.com. Retrieved 5 March 2022. 
  370. ↑ "Gelesis". gelesis.com. Retrieved 6 April 2022. 
  371. ↑ "About Us". Beacon Pharmaceuticals Limited. Retrieved 5 March 2022. 
  372. ↑ "Beacon Pharmaceuticals - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 April 2022. 
  373. ↑ "Ablitech, Inc.". news.cision.com. Retrieved 6 March 2022. 
  374. ↑ "ABLITECH, INC." (PDF). wbtshowcase. Retrieved 6 April 2022. 
  375. ↑ "MyBioSource Inc. Scholarship for All Majors". Unigo.com. 18 October 2019. Retrieved 6 March 2022. 
  376. ↑ "MyBioSource". craft.co. Retrieved 6 April 2022. 
  377. ↑ "Jazz Pharmaceuticals - Funding, Financials, Valuation & Investors". Crunchbase. Retrieved 2 June 2022. 
  378. ↑ "Iovance Biotherapeutics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 March 2022. 
  379. ↑ "Braasch Biotech LLC - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 8 March 2022. 
  380. ↑ 380.0 380.1 "ACT Biotech - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 May 2022. 
  381. ↑ "ACT Biotech". tracxn.com. Retrieved 6 March 2022. 
  382. ↑ Binder, Gordon M.; Bashe, Philip (2008). Science Lessons: What the Business of Biotech Taught Me about Management. Harvard Business Press. ISBN 978-1-59139-861-5. 
  383. ↑ 383.0 383.1 "BioAmber - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 May 2022. 
  384. ↑ "S-1/A". www.sec.gov. Retrieved 6 March 2022. 
  385. ↑ "La vacuna del covid-19 catapulta al estrellato a los fundadores de BioNTech". France 24. 13 November 2020. Retrieved 6 March 2022. 
  386. ↑ "About: BioTork". dbpedia.org. Retrieved 6 March 2022. 
  387. ↑ "BioTork - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 24 March 2022. 
  388. ↑ "Epic Sciences - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 8 March 2022. 
  389. ↑ "Cofactor Genomics awarded $1.5 million grant from NIH". www.bizjournals.com. Retrieved 8 March 2022. 
  390. ↑ "Cofactor Genomics is hiring a Computational Scientist (San Francisco, CA)". www.biostars.org. Retrieved 24 March 2022. 
  391. ↑ "COFACTOR GENOMICS". ARCTURIS. Retrieved 19 May 2022. 
  392. ↑ Gruber, Alexandra Carina (17 December 2008). Biotech Funding Trends: Insights from Entrepreneurs and Investors. Wiley. ISBN 978-3-527-62274-0. 
  393. ↑ "MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies". astrazeneca.com. Retrieved 8 March 2022. 
  394. ↑ Limited, Immunocore Holdings (3 March 2022). "Immunocore Reports Full Year 2021 Financial Results and Provides Business Update". GlobeNewswire News Room. Retrieved 24 March 2022. 
  395. ↑ Wells, Jane (19 December 2018). "This company brings in $7 million a year testing dog poop DNA to catch non-scoopers". CNBC. Retrieved 8 March 2022. 
  396. ↑ "Feedback: Are we dog-walking into a surveillance state?". New Scientist. Retrieved 24 March 2022. 
  397. ↑ "SeSaM-Biotech GmbH – R&D – Oxytrain". oxytrain.eu. Retrieved 8 March 2022. 
  398. ↑ "Enzyme Evolution | A competitive edge for your enzymes". SeSaM-Biotech. Retrieved 24 March 2022. 
  399. ↑ "REPROCELL Brand: Stemgent". www.reprocell.com. Retrieved 8 March 2022. 
  400. ↑ "Stemgent - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 24 March 2022. 
  401. ↑ Austin, Mr Martin (28 September 2012). Business Development for the Biotechnology and Pharmaceutical Industry. Gower Publishing, Ltd. ISBN 978-1-4094-5822-7. 
  402. ↑ Berry, Ira R.; Martin, Robert P. (2 December 2008). The Pharmaceutical Regulatory Process, Second Edition. Taylor & Francis. ISBN 978-1-4200-7042-2. 
  403. ↑ Gruber, Alexandra Carina (17 February 2009). Biotech Funding Trends: Insights from Entrepreneurs and Investors. Wiley. ISBN 978-3-527-32435-4. 
  404. ↑ Ebemidayo, Fiyin (4 January 2021). "Pathway Genomics review - 7 facts you should know [JANUARY 2021]". Nebula Genomics Blog. Retrieved 8 March 2022. 
  405. ↑ "Our Focus on Cell Therapy | Kite Pharma". www.kitepharma.com. Retrieved 8 March 2022. 
  406. ↑ "Kite Pharma - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 21 March 2022. 
  407. ↑ Inc, Cannabis Science (5 January 2018). "Cannabis Science Has US Federal Government Clearance that Changes the Industry, Access to Federal Government Contracts, Supported US Federal Governments Since 2009, Looks for New Federal Policy to Properly Regulate Industry for Patients". GlobeNewswire News Room. Retrieved 3 March 2022. 
  408. ↑ "Janus Henderson Global Life Sciences Fund Class A, JFNAX summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  409. ↑ "Janus Henderson Global Life Sciences Fund Class A (JFNAX) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 8 July 2022. 
  410. ↑ "siambioscience | Think of success think of siam bio science". siambioscience.com. Retrieved 3 March 2022. 
  411. ↑ "Siam Bioscience - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 25 March 2022. 
  412. ↑ News, A. B. C. "Pfizer fined $2.3 billion for illegal marketing in off-label drug case". ABC News. Retrieved 7 June 2022. 
  413. ↑ "Justice Department Announces Largest Health Care Fraud Settlement in Its History". www.justice.gov. 2 September 2009. Retrieved 7 June 2022. 
  414. ↑ Harris, Gardiner (2 September 2009). "Pfizer Pays $2.3 Billion to Settle Marketing Case". The New York Times. Retrieved 7 June 2022. 
  415. ↑ "Austrian Centre of Industrial Biotechnology". Advanced Technologies for Industry. Retrieved 8 March 2022. 
  416. ↑ "Austrian Centre of Industrial Biotechnology". Advanced Technologies for Industry. Retrieved 25 March 2022. 
  417. ↑ "Abcodia - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 8 March 2022. 
  418. ↑ "Company History and Information: mRNA Science - Moderna". www.modernatx.com. Retrieved 8 March 2022. 
  419. ↑ "Moderna Therapeutics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 May 2022. 
  420. ↑ "AYOXXA - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 May 2022. 
  421. ↑ "Ayoxxa". www.nus.edu.sg. Retrieved 8 March 2022. 
  422. ↑ "Singapore luxury apartment sales double in 2021; GCB deal value soars to new high". www.businesstimes.com.sg. Retrieved 14 March 2022. 
  423. ↑ "Market Entry: Where to Start-Up?". INSEAD Knowledge. 30 June 2014. Retrieved 14 March 2022. 
  424. ↑ "Athira Pharma - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  425. ↑ "Athira Pharma raises $204M in IPO, reaching 'big milestone' in fight against Alzheimer's and other diseases". GeekWire. 18 September 2020. Retrieved 8 March 2022. 
  426. ↑ "Quattromed HTI Laborid". baltcap. Retrieved 27 March 2022. 
  427. ↑ "Company". Personalis. Retrieved 20 May 2022. 
  428. ↑ 428.0 428.1 "Cambrian Genomics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  429. ↑ "Cambrian Genomics". tracxn.com. Retrieved 8 March 2022. 
  430. ↑ He, Tianchang; Sewell, Dawson; Manipula, Melanie; Scherfner, Erin; Suter, Will; Singh, Arjun; Abhishek, Gautam; Carruthers, Harley; Alaimo, Katrina-Kay; Gomila, Jude. "Cambrian Genomics - Wiki". Golden. 
  431. ↑ 431.0 431.1 "Carbios - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 27 March 2022. 
  432. ↑ "Carbios - Innovating for a true circular economy in plastics". Carbios (in français). Retrieved 8 March 2022. 
  433. ↑ Hughes, Sally Smith (21 September 2011). Genentech: The Beginnings of Biotech. University of Chicago Press. ISBN 978-0-226-35920-5. 
  434. ↑ 434.0 434.1 "Galecto". crunchbase. Retrieved 10 May 2022. 
  435. ↑ "Galecto Biotech Initiates Clinical Phase I/IIa trial in IPF – Galecto, Inc.". galecto.com. Retrieved 8 March 2022. 
  436. ↑ "Galecto develops galectin modulators | Case Study". Edinburgh Bioquarter. 3 December 2020. Retrieved 27 March 2022. 
  437. ↑ "GEMoaB: next-generation immunotherapies for hard-to-treat cancers". nature.com. Retrieved 8 March 2022. 
  438. ↑ "BACHMANN HEADQUARTERS GERMANY - Ray Capaldi Consultancy". www.raymondcapaldi.com.au. Retrieved 6 April 2022. 
  439. ↑ "OvaScience - Case - Faculty & Research - Harvard Business School". www.hbs.edu. Retrieved 8 March 2022. 
  440. ↑ "OvaScience - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 27 March 2022. 
  441. ↑ "Permeon Biologics". Flagship Pioneering. Retrieved 8 March 2022. 
  442. ↑ "Permeon Biologics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 April 2022. 
  443. ↑ "SOPHiA GENETICS" (PDF). invest-vaud.ch. Retrieved 8 March 2022. 
  444. ↑ "SOPHiA GENETICS" (PDF). sophiagenetics. Retrieved 6 April 2022. 
  445. ↑ "StartUp Health Investor Profile: Portfolio & Exits | PitchBook". pitchbook.com. Retrieved 29 June 2022. 
  446. ↑ "The Science • Unity Biotechnology". Unity Biotechnology • Developing therapeutics to slow, halt, or reverse diseases of aging. 11 April 2018. Retrieved 8 March 2022. 
  447. ↑ "About: Unity Biotechnology". dbpedia.org. Retrieved 6 April 2022. 
  448. ↑ "Vaxess Technologies - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 8 March 2022. 
  449. ↑ "VanEck Biotech ETF, BBH:NMQ:USD summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  450. ↑ "VanEck Biotech ETF (BBH) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 8 July 2022. 
  451. ↑ "The JLABS Story: How a Johnson & Johnson Incubator Is Helping Nurture the Next Great Healthcare Breakthroughs". Content Lab U.S. 31 January 2017. Retrieved 29 June 2022. 
  452. ↑ Landi, Heather (22 May 2019). "JLABS executive on the ROI of a 'no-strings-attached' health tech incubator". Fierce Healthcare. Retrieved 29 June 2022. 
  453. ↑ O'Neill, M.; Hopkins, M. M. (2 May 2012). A Biotech Manager's Handbook: A Practical Guide. Elsevier. ISBN 978-1-908818-15-7. 
  454. ↑ "uBiome Co-Founders Charged With Federal Securities, Health Care Fraud Conspiracies". www.justice.gov. 18 March 2021. Retrieved 9 March 2022. 
  455. ↑ "uBiome - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 April 2022. 
  456. ↑ "Company Information". Tecrea. Retrieved 9 March 2022. 
  457. ↑ "Tecrea - a client of LBIC London BioScience Innovation Centre". LBIC | Life Sciences, Biotechnology, Offices & Labs | London BioScience Innovation Centre. Retrieved 10 May 2022. 
  458. ↑ "Home". Tecrea. Retrieved 20 May 2022. 
  459. ↑ "California Institute for Biomedical Research (Calibr)". devex. Retrieved 29 June 2022. 
  460. ↑ "GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data". www.justice.gov. 2 July 2012. Retrieved 7 June 2022. 
  461. ↑ "Computomics • chemical startup | HTGF". www.htgf.de. Retrieved 9 March 2022. 
  462. ↑ "Computomics". www.basf.com. Retrieved 17 March 2022. 
  463. ↑ "StartX Med". linkedin. Retrieved 29 June 2022. 
  464. ↑ "Company - Calysta - Innovative and Sustainable Industrial Products". Calysta. Retrieved 9 March 2022. 
  465. ↑ "Adisseo and Calysta joint venture to help feed our future". FeedKind®. 21 April 2020. Retrieved 24 March 2022. 
  466. ↑ "Team". Artemiflow. Retrieved 9 March 2022. 
  467. ↑ Day, Lincoln (22 November 2021). "Three Kentucky Agtech Companies That Should Be on Your Radar". Middle Tech. Retrieved 24 March 2022. 
  468. ↑ 468.0 468.1 "10X Genomics". crunchbase.com. Retrieved 21 January 2022. 
  469. ↑ "Merck and 10x Genomics Launch Powerful New Option for CRISPR Research". sigmaaldrich. Retrieved 6 April 2022. 
  470. ↑ Austin, Mr Martin (28 December 2012). Licensing, Selling and Finance in the Pharmaceutical and Healthcare Industries: The Commercialization of Intellectual Property. Gower Publishing, Ltd. ISBN 978-1-4094-8483-7. 
  471. ↑ O'Neill, M.; Hopkins, M. M. (2 May 2012). A Biotech Manager's Handbook: A Practical Guide. Elsevier. ISBN 978-1-908818-15-7. 
  472. ↑ 472.0 472.1 "Stem Cell Theranostics". crunchbase.com. Retrieved 21 January 2022. 
  473. ↑ "Stem Cell Theranostics". linkedin. Retrieved 27 March 2022. 
  474. ↑ "Our Company". AbbVie | Pharmaceutical Research & Development. Retrieved 6 March 2022. 
  475. ↑ "AbbVie (ABBV)". Forbes. Retrieved 6 April 2022. 
  476. ↑ "AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 6 April 2022. 
  477. ↑ "About Barentzymes". Barentzymes. Retrieved 6 March 2022. 
  478. ↑ "Barentzymes – enzyme based solutions | Biotech 365". biotech-365.com. Retrieved 6 April 2022. 
  479. ↑ "Bikanta - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 8 March 2022. 
  480. ↑ "Company created to progress experimental Alzheimer's disease therapy". Wellcome. Retrieved 8 March 2022. 
  481. ↑ "CoCo Therapeutics Ltd Announces the Appointment of Its Clinical and Scientific Advisory Group". BioSpace. Retrieved 16 March 2022. 
  482. ↑ "CRISPR Therapeutics". www.sec.gov. Retrieved 10 March 2022. 
  483. ↑ "CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial…". CRISPR. Retrieved 6 April 2022. 
  484. ↑ "Juno Therapeutics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 March 2022. 
  485. ↑ "MBC BioLabs". crunchbase. Retrieved 29 June 2022. 
  486. ↑ "Kaitek Labs trae seguridad al consumo mundial de mariscos". Innovate4Health. 3 January 2019. Retrieved 10 March 2022. 
  487. ↑ "Kaitek Labs - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 April 2022. 
  488. ↑ "MyGenetics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 March 2022. 
  489. ↑ "NantOmics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 March 2022. 
  490. ↑ "We Are Spark – Spark Therapeutics". sparktx.com. Retrieved 10 March 2022. 
  491. ↑ "Roche purchase of Spark Therapeutics is given the go ahead in UK". European Pharmaceutical Review. Retrieved 6 April 2022. 
  492. ↑ 492.0 492.1 "Veritas Genetics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 May 2022. 
  493. ↑ "For the second year in a row CNBC has placed Veritas Genetics on their Disruptor 50 list". Veritas. 21 May 2019. Retrieved 10 March 2022. 
  494. ↑ Wambugu, Florence; Kamanga, Daniel (10 May 2014). Biotechnology in Africa: Emergence, Initiatives and Future. Springer. ISBN 978-3-319-04001-1. 
  495. ↑ "MyGene - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 April 2022. 
  496. ↑ Li, Jie Jack (2014). Blockbuster Drugs: The Rise and Fall of the Pharmaceutical Industry. OUP USA. ISBN 978-0-19-973768-0. 
  497. ↑ "Illumina Accelerator Genomics Startup Funding". www.illumina.com. Retrieved 29 June 2022. 
  498. ↑ "ARK Genomic Revolution ETF, ARKG:BTQ:USD summary - FT.com". markets.ft.com. Retrieved 1 July 2022. 
  499. ↑ "IndieBio". crunchbase. Retrieved 29 June 2022. 
  500. ↑ Shimasaki, Craig (8 April 2014). Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. Academic Press. ISBN 978-0-12-404747-1. 
  501. ↑ "Baxalta - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 March 2022. 
  502. ↑ "EX-99.1". www.sec.gov. Retrieved 17 March 2022. 
  503. ↑ "BioViva USA - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 10 March 2022. 
  504. ↑ "EMBARK" (PDF). front.embarkvet.com. Retrieved 10 March 2022. 
  505. ↑ "Embark Veterinary". Inc.com. Retrieved 5 April 2022. 
  506. ↑ "Our Difference - iCarbonX". www.icarbonx.com. Retrieved 10 March 2022. 
  507. ↑ "iCarbonX - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 27 March 2022. 
  508. ↑ "Blog". Phase Genomics. Retrieved 12 March 2022. 
  509. ↑ "Phase Genomics Case Study". 1Strategy. Retrieved 27 March 2022. 
  510. ↑ "Former Google life sciences unit renames itself Verily". Reuters. 7 December 2015. Retrieved 12 March 2022. 
  511. ↑ "Announcing Coefficient, a Verily subsidiary focused on employer stop-loss and backed by Swiss Re Corporate Solutions | Swiss Re". corporatesolutions.swissre.com. Retrieved 27 March 2022. 
  512. ↑ Aremo, Oreoluwa (31 August 2021). "RxAll is Building a Trusted Marketplace for Certified Medicines in Africa". Future Africa. Retrieved 13 March 2022. 
  513. ↑ thetechtribune (2020-03-19). "Amy Kao of RxAll". The Tech Tribune. Retrieved 13 March 2022. 
  514. ↑ "RxAll: The Unsung Heroes Combating Counterfeit Medicine". pharma-life-sciences.cioreview.com. Retrieved 13 March 2022. 
  515. ↑ "Bioverativ - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 13 March 2022. 
  516. ↑ "Bioverativ Inc.". www.sec.gov. Retrieved 24 March 2022. 
  517. ↑ "Mylab Discovery Solutions Pvt. Ltd.". in.linkedin.com. Retrieved 13 March 2022. 
  518. ↑ "Mylab Discovery Solutions". Twitter. Retrieved 24 March 2022. 
  519. ↑ "Mylab Discovery Solutions - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 May 2022. 
  520. ↑ "Neurovation Labs - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 13 March 2022. 
  521. ↑ "Neurovation Labs". craft.co. Retrieved 24 March 2022. 
  522. ↑ Fernández, Clara Rodríguez (16 January 2018). "Young Oxford Biotech Raises €22.5M to Develop a Universal Flu Vaccine". Labiotech.eu. Retrieved 13 March 2022. 
  523. ↑ "Vaccitech - Creating ways to treat and prevent disease.". Vaccitech. Retrieved 24 March 2022. 
  524. ↑ "Vaccitech". linkedin. Retrieved 24 March 2022. 
  525. ↑ "Living DNA: David Nicholson and Hannah Morden". Startups.co.uk. 30 November 2016. Retrieved 13 March 2022. 
  526. ↑ "Living DNA - ISOGG Wiki". isogg.org. Retrieved 5 April 2022. 
  527. ↑ 527.0 527.1 "Galvani Bioelectronics - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  528. ↑ Kuchler, Hannah (27 January 2022). "GSK kicks off trials of pioneering 'bioelectronic' disease treatment". Financial Times. Retrieved 13 March 2022. 
  529. ↑ "The Pharmaceutical Industry and Dependency in the Third World av Gary Gereffi (Häftad)". Bokus.com (in svenska). Retrieved 5 April 2022. 
  530. ↑ "OmniVis - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 6 May 2022. 
  531. ↑ "Team". OmniVis. Retrieved 13 March 2022. 
  532. ↑ "OmniVis awarded National Science Foundation Grant". OmniVis. Retrieved 5 April 2022. 
  533. ↑ Simon, Francoise; Giovannetti, Glen (16 October 2017). Managing Biotechnology: From Science to Market in the Digital Age. John Wiley & Sons. ISBN 978-1-119-21617-9. 
  534. ↑ How to Start a Life Science Company: A Comprehensive Guide for First-Time Entrepreneurs. 
  535. ↑ Cava, Marco della. "She was 'the next Steve Jobs.' Now, Theranos founder Elizabeth Holmes is charged with fraud". USA TODAY. Retrieved 8 July 2022. 
  536. ↑ "Everything you need to know about the Theranos scandal". www.panmacmillan.com. Retrieved 8 July 2022. 
  537. ↑ Abelson, Reed (5 September 2018). "Theranos Is Shutting Down". The New York Times. Retrieved 8 July 2022. 
  538. ↑ "Reborna Biosciences - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 14 March 2022. 
  539. ↑ "Reborna Biosciences - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 5 April 2022. 
  540. ↑ Matei, Florentina; Zirra, Daniela (16 August 2019). Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective. Springer. ISBN 978-3-030-22141-6. 
  541. ↑ "54gene". crunchbase.com. Retrieved 24 March 2022. 
  542. ↑ "Danish biotech company receives 4,4 million EUR from the EU - DTU Biosustain". biosustain.dtu.dk. Retrieved 21 January 2022. 
  543. ↑ "Cysbio - Building Biology". Cysbio.com. Retrieved 6 May 2022. 
  544. ↑ "WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access". www.who.int. Retrieved 8 July 2022. 
  545. ↑ "Google Trends". Google Trends. Retrieved 30 May 2022. 
  546. ↑ "Google Books Ngram Viewer". books.google.com. Retrieved 30 May 2022. 
  547. ↑ "Wikipedia Views: results". wikipediaviews.org. Retrieved 30 May 2022. 
Retrieved from "http://timelines.issarice.com/index.php?title=Timeline_of_biotechnology_companies&oldid=74673"